Spirocyclic compounds as modulators of KRAS and uses thereof

Abstract

Disclosed herein are compounds useful for the inhibition of KRAS G12D, G12V, G12A, G12S, G12R, G13D, Q61H, Q61L, Q61R or G12C. The compounds have a general Formula (I): (I) or pharmaceutically acceptable salts thereof, wherein the variables of Formula (I) are as defined herein. Also provided herein are pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a KRAS G12D, G12V, G12A, G12S, G12R, G13D, Q61H, Q61L, Q61R or G12C disorder.

Description

[0001] This application claims the benefit of U.S. Provisional Patent Application No. 63 / 565,476, filed March 14, 2024, and U.S. Provisional Patent Application No. 63 / 645,612, filed May 10, 2024, each of which is incorporated by reference in its entirety. FIELD

[0002] The present disclosure provides compounds having activity as inhibitors of mutant KRAS proteins. This disclosure also provides pharmaceutical compositions comprising the compounds, uses and methods of treating certain disorders, such as cancer, including but not limited to non-small cell lung cancer, colorectal cancer, pancreatic cancer, appendiceal cancer, endometrial cancer, esophageal cancer, cancer of unknown primary, ampullary cancer, gastric cancer, small bowel cancer, sinonasal cancer, bile duct cancer, or melanoma. BACKGROUND

[0003] From its identification as one of the first human oncogenes in 1982 (Der et al.. 1982), KRAS (the Kirsten rat sarcoma viral oncogene homologue) has been the focus of extensive academic and industrial research, as a key node in the MAPK signal transduction pathway , as a transforming factor in a network of parallel effector pathways (e.g., PI3K / AKT) (Vojtek et al., 1998) and as a potential target for anti-cancer agents (Malumbres et al., 2003). Despite progress in die development of inhibitors of upstream and downstream nodes in the MAPK padiway (e.g., EGFR (Sridhar et al., 2003), BRAF (Holderfield et al., 2014) and MEK (Caunt et al.. 2015), the KRAS protein has historically proven resistant to direct inhibition.

[0004] KRAS is a G-protein that couples extracellular mitogenic signaling to intracellular, pro-proliferative responses. KRAS sen es as an intracellular “on / off’ switch. Mitogen stimulation induces the binding of GTP to KRAS, bringing about a conformational change which enables the interaction of KRAS with downstream effector proteins, leading to cellular proliferation. Normally, pro-proliferative signaling is regulated by the action of GTPase-activating proteins (GAPs), which return KRAS to its GDP-bound, non-proliferative state. Mutations in KRAS impair the regulated cycling of KRAS between these GDP- and GTP-bound states, leading to the accumulation of the GTP-bound active state and dysregulated cellular proliferation (Simanshu et al., 2017).

[0005] Attempts to develop inhibitors of mutated KRAS proteins have historically been thwarted by the absence of druggable pockets on the surface of the protein (Cox et al., 2014). In 2013, Shokat and colleagues identified covalent inhibitors of a common (O’Bryan, 2019) oncogenic mutant of KRAS, KRAS G12C, which bound to a previously unrecognized allosteric pocket on GDP-KRAS G12C and prevented its subsequent activation (Ostream et al., 2013). This discover}' brought about significant new efforts in the KRAS inhibitor research, which have recently culminated in the entry of KRAS inhibitors in human clinical trials.

[0006] While some progress has been made on KRAS G12C inhibitors, there is a continued interest and effort to develop inhibitors of KRAS, particularly inhibitors of other KRAS such as KRAS G12D, G12V, G12A, G12S, G12R, G13D, Q61H, Q61L, Q61R or G12C. Thus, there is a need to develop new inhibitors for KRAS G12D, G12V, G12A, G12S, G12R, G13D, Q61H, Q61L, Q61R or G12C for the treatment of disorders, such as cancer. SUMMARY

[0007] One aspect of the disclosure provides a compound of Formula (I): u i5!—(RW% or a pharmaceutically acceptable salt thereof, wherein; X is -CH2- or -O- Z is C-H. C-halogen, C-CN. C-Ci-4 alkyl, C-Ci-4 haloalkyl, C-C1-4 alkoxy, C-C1-4 haloalkoxy, C-C3-7 cycloalkyl or N; Q is CH. C-halogen, C-C1.4 alkyl, C-C1.4 haloalkyl or N; B is a C3-7 cycloalkyl or 3-7 membered heterocycloalkyl; n is 0, 1 or 2; m is 0. 1 or 2; p is 0, 1 or 2; q is 0, 1 or 2; each Rx independently is hydroxyl, halogen, oxo, cyano, -N(RZ)2, C1-4 alkyl. C1.4 deuteroalkyl, C1.4 alkoxy, C1.4 haloalkyl, C1.4 haloalkoxy, C1.4 hydroxyalkylene, 5-7 membered heteroaryl, -S(O)2-Ci-4alkyl, -8(0)2^% -C(O)RZ, -C(O)ORZ, -QOMR^, -Ci-4 alkylene-C(O)-Ci. 4alkyl, -Ci-4 alkylene-C(0)N(Rz)2, Cm alkylene-S(O)2-Ci-4alkyl, or -S-Ci.4alkyl; 0             0            0 or L2 is a bond, Cm alkylene, -O-Ci-e alkylene, -S-Ci-e alkylene. NRZ, O or S, wherein each Cie alkylene. -O-Cm alkylene and -S-Cm alkylene chain is substituted with 0-2 occurrences of R2; R1 is hydrogen, hydroxyl, Ce-io aryl, 5-10 membered heteroaryl, C3-8 cycloalkyl or 4-15 membered heterocycloalkyl, wherein each aryl, heteroaryl, cycloalkyl or heterocycloalkyl is substituted with 0-3 occurrences of R3; each R2 independently is halogen, deuterium, hy droxyl or Ci-4 alkyl; wherein two geminal R2 groups, together with die atom to which they are attached form a spiro-C v- cycloalkyl group substituted with 0-2 occurrences of Rw; or wherein two adjacent R2 groups, together with the atoms to which they are attached form a fused-Cs-? cycloalkyd group substituted with 0-2 occurrences of Rw; R4 is hydrogen, hydroxyl, halogen, Ci-4 alkyl, Ci-4 alkoxy, Ci-4 lialoalkyl, C2-4 alkenyl, C2-4 alkynyl. C3-7 cycloalkyl or cyano: each R5 independently is halogen, cyano, oxo, -T-Ry, hydroxyl. -N(RZ)2, Cm alkyl, Cm haloalkyl. Cm alkoxy or -O-C2-4 alkynyl; each R6aR6bandR6c independently is hydrogen, halogen, hydroxyl, cyano, -N / R2^, -C(O)RZ, -C(O)ORZ, Cm alkyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, C2-4 alkynyl or C3-6 cycloalkyl or R6a and R6b, together with the atom to which they are attached form a fused C3-7 cycloalkyl; R6d is hydrogen, -C(O)-Ci-8 alkyl or -C(O)-OCi-g alkyl; T is Cm alkylene, -S(O)2-, -C(O)-, -C1-4 alkylene-C(O)-, C1-4 alkylene-S(0)2- or -S-; each Rw independently is Cm alkyl. Cm alkoxy, -C(0)-Cm alkyl, -C(0)-0-Cm alkyl, halogen, hydroxyl or Cm haloalkyl; R- is halogen, Cm alkyl, Cm haloalkyl, hydroxyl, cyano or -N(RZ)2; and each Rz independently is hydrogen or Cm alkyl.

[0008] Another aspect of the disclosure provides a pharmacal composition comprising a compound or salt of Formula (I) and a pharmaceutically acceptable excipient.

[0009] Yet another aspect of the disclosure provides method of treating cancer in a subject in need of treatment, tire method comprising administering to the subject a therapeutically effective amount of the compound or salt of Formula (I) or a pharmaceutical composition comprising the compound or salt of Formula (I).

[0010] Still another aspect of the disclosure provides a compound or salt of Formula (I) for use as a medicament. Another aspect of the disclosure provides a compound or salt disclosed herein, or the pharmaceutical composition disclosed herein for use in the treatment of cancer.

[0011] Yet another aspect of the disclosure provides a compound or salt of Formula (I), or the pharmaceutical composition comprising a compound or salt of Formula (I), for the manufacture of a medicament for the treatment of cancer. Another aspect of the disclosure provides the use of a compound or salt disclosed herein, or the pharmaceutical composition of the disclosure, wherein the cancer is non-small cell lung cancer, colorectal cancer, pancreatic cancer, appendiceal cancer, endometrial cancer, esophageal cancer, cancer of unknown primary, ampullary cancer, gastric cancer, small bowel cancer, sinonasal cancer, bile duct cancer, or melanoma, or any combination of the foregoing. In some cases, the cancer is non-small cell lung cancer, colorectal cancer, pancreatic cancer, appendiceal cancer, endometrial cancer, esophageal cancer, cancer of unknown primary', ampullary cancer, gastric cancer, small bowel cancer, sinonasal cancer, bile duct cancer, or melanoma.

[0012] Further aspects and advantages will be apparent to those of ordinary skill in the art from a review of the following detailed description. The description hereafter includes specific cases, embodiments, and examples with the understanding that the disclosure is illustrative and is not intended to limit the embodiments of the present disclosure to the specific cases, embodiments, and examples described herein. DETAILED DESCRIPTION |0013|   Disclosed herein are compounds having activity as inhibitors of KRAS such as KRAS G12D, G12V. G12A, G12S, G12R. G13D, Q61H. Q61L, Q61R or G12C, pharmaceutical compositions comprising the compounds, and uses and methods of treating disorders, such as cancer (e.g.. non-small cell lung cancer, colorectal cancer, pancreatic cancer, appendiceal cancer, endometrial cancer, esophageal cancer, cancer of unknown primary’, ampullary cancer, gastric cancer, small bowel cancer, sinonasal cancer, bile duct cancer, or melanoma), with the compounds and pharmaceutical composition described herein. DEFINITIONS

[0014] The following definitions are provided to assist in understanding the scope of this disclosure. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of ordinary skill in the art to which this disclosure belongs.

[0015] The term “alkyd” refers to a saturated straight chain hydrocarbon or saturated branched chain hydrocarbon containing the indicated number of carbon atoms. For example, C ,alkyl means an alkyl group that has 3 carbon atoms (e.g., n-propyl or isopropyl). For example, a Chalky1 refers to an alkyl group having 1 to 6 carbon atoms. Where a range is indicated, all members of that range and all subgroups within that range are envisioned. For example, a Chalky 1 includes alkyl groups having 1, 2, 3, 4, 5, or 6 carbon atoms (or any combination of the foregoing), as well as all subgroups in the indicated range (e.g., 1-2, 1-3, 1-4, 1-5, 1-6, 2-3, 2-4, 2-5, 2-6, 3-4, 3-5, 3-6, 4-5, 4-6, or 5-6 carbon atoms, or any combination of the foregoing ranges)). A “Ci-4 alkyl” includes, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-buty 1, or t-buty 1. Nonlimiting examples of alkyl groups include methyl, ethyl, n-propyl, isopropy l, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, and n-hexyl.

[0016] The term “alkeny1” refers to a straight or branched chain hydrocarbon containing the indicated number of carbon atoms and having one or more carbon-carbon double bonds. For example, Cjalkeny 1 means the alkenyl group has 3 carbon atoms (e.g., 1-propenyl or 2-propenyl). For example, a C2-6alkenyl refers to an alkeny 1 group having 2 to 6 carbon atoms. Where a range is indicated, all members of that range and all subgroups within that range are envisioned. For example, a C2-ealkenyl includes alkenyl groups having 2, 3, 4, 5, or 6 carbon atoms (or any combination of the foregoing), as well as all subgroups in the indicated range (e.g., 2-3, 2-4, 2-5, 2-6. 3-4, 3-5, 3-6, 4-5, 4-6, or 5-6 carbon atoms, or any combination of the foregoing ranges). A C2-4alkenyl includes, for example, ethenyl. 1-propenyl, 2-propenyl, isopropenyl, 1-butenyl, 2-butenyl. or 3-butenyl. Non-limiting examples of alkenyl groups include ethenyl (vinyl), 1-propenyl, 2-propenyl (allyl), isopropenyl, 2- methyl-1-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, and 5-hexenyl.

[0017] The term “alkynyl” refers to a straight or branched chain hydrocarbon containing the indicated number of carbon atoms and having one or more carbon-carbon triple bonds. For example, C3alkynyl means the alkynyl group has 3 carbon atoms. For example, a C3-6alkynyl refers to an alkynyl group having 2 to 6 carbon atoms. Where a range is indicated, all members of that range and all subgroups within that range are envisioned. For example, a C3-6alkynyl includes any alky nyl groups having 2, 3, 4, 5, or 6 carbon atoms (or any combination of the foregoing), as well as all subgroups in the indicated range (c.g., 2-3, 2-4, 2-5, 2-6, 3-4, 3-5, 3-6, 4-5, 4-6, or 5-6 carbon atoms, or any combination of the foregoing ranges). For illustration, C2-4alkynyl includes, for example, ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, or 3-butynyl. Nonlimiting examples of alkynyl groups include ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, and 5-hexynyl.

[0018] The term “cycloalkyl” refers to a saturated, hydrocarbon monocyclic ring, or a saturated, hydrocarbon polycyclic ring system containing the indicated number of carbon atoms as ring members in the ring or ring system. No ring in a cycloalkyl ring or ring system has s double bond, a heteroatom, or is aromatic. When a cycloalkyl is a ring system, two or more rings may be joined together in a fused-, bridged-, or spiro-conncctcd fashion. For example, Cjcycloalkyl refers to a cycloalkyl group that has 5 carbon atoms in the ring or ring system. Where a range is indicated, all members of that range and all subgroups within that range are envisioned. For example, a C3. cycloalkyl includes cycloalkyl groups having 3, 4, 5, 6, or 7 carbon atoms in the ring (or any combination of the foregoing), as well as all subgroups in the indicated range (e.g., 3-4, 3-5, 3-6, 3-7, 4-5. 4-6, 4-7, 5-6, 5-7, or 6-7 carbon atom ring members, or any combination of the foregoing ranges). Nonlimiting examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl. norbomyl, decalinyl, and 7,7-dimethylbicyclo[2.2.1]heptanyl.

[0019] The term “aryl” refers to a monocyclic aromatic, hydrocarbon ring (i.e., phenyl, or a polycyclic (e.g., bicyclic, tricyclic, or tetracyclic) aromatic hydrocarbon ring system containing the indicated number of carbon atoms. For example, Cioaryl refers to an aryl group that has 10 carbon atoms in the ring system (e.g., naphthyl). When an aryl group is a polycyclic ring system, each ring in the ring system is aromatic, and no ring in the ring system contains a heteroatom. Where a range is indicated, all members of that range and all subgroups within that range are envisioned. For example, a Ce-uaryl includes aryl groups having 6-14 (e.g., 6, 10, or 14) carbon atoms in the ring or ring system (or combinations of the foregoing), as well as all subgroups in the indicated range (e.g., 6-10 or 10-14 carbon atom ring members in the ring or ring system, or combinations of the foregoing). Nonlimiting examples of aryl groups include pheny l, naphthyl, and anthracenyl.

[0020] The term “heteroatom,” unless otherwise stated herein, refers to oxygen, sulfur, nitrogen, and phosphorus.

[0021] The term “heterocycloalkyl” refers to a saturated, monocyclic ring or saturated, polycyclic ring system comprising carbon atoms and one or more heteroatoms (e.g., one or more of N, O. and S), and having the indicated number of total ring atoms (the sum of carbon atoms and heteroatoms in the ring). When a heterocycloalkyl is a ring system, two or more rings may be joined together in a fused-, bridged-, or spiro-connected fashion. No ring in a heterocycloalkyl ring or ring system contains a double bond or is aromatic. For example, a heterocycloalkyl group having 5 total atoms and 2 heteroatoms independently selected from N. O, and S, refers to a ring having 3 carbon atoms and 2 heteroatoms, wherein each heteroatom of the ring independently is N. O, or S. Where a range is indicated, all members of that range and all subgroups within that range are envisioned. For example, a heterocycloalkyl group having 5-7 total ring atoms and 1-3 heteroatoms independently selected from N, O, and S includes rings having 5, 6, or 7 total atoms, or any combination of the foregoing, as well as all subgroups in the indicated range (e.g., 5-6 or 6-7 total ring atoms, or any combination of the foregoing), wherein 1, 2, or 3 of the atoms in the ring are heteroatoms and each heteroatom independently is selected from N, O, and S. Thus, a heterocycloalkyl having 5-7 total ring atoms and 1-3 heteroatoms independently selected from N, O, and S encompasses rings containing, for example, 4 carbon atoms and 1 heteroatom, 3 carbon atoms and 2 heteroatoms, 2 carbon atoms and 3 heteroatoms, 5 carbon atoms and 1 heteroatom, 4 carbon atoms and 2 heteroatoms, 3 carbon atoms and 3 heteroatoms, 6 carbon atoms and 1 heteroatom, 5 carbon atoms and 2 heteroatoms, and 4 carbon atoms and 3 heteroatoms, wherein each heteroatom of the foregoing is independently selected from N, O, and S. Nonlimiting examples of heterocycloalkyl groups include but are not limited to aziridinyl, oxiranyl, thiiranyl. azetidinyl, oxetanyl. thietanyl, pyrrolidinyl. tetrahydrofuranyl, tetrahydrothiophene-yl, pyrazolidinyl, imidazolidinyl, isoxazolidinyl. oxazolidinyl, isothiazolidinyl, thiazolidinyl, oxatliiolidinyl, piperidinyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperazinyl, dioxanyl, dithianyl, morpholinyl. thiomorpholinyl, azepanyl. hexahydro-IH-pyrrolizinyl, and 1,4-diazepanyl.

[0022] The term “heteroaryl” refers to a monocyclic aromatic ring comprising carbon and one or more heteroatoms, and having the indicated number of total ring atoms (the sum of carbon atoms and heteroatoms in the ring), or a polycyclic (e.g., bicyclic, tricyclic, or tetracyclic) aromatic ring system having one or more heteroatoms and the indicated number of total ring atoms (the sum of carbon atoms and heteroatoms in the ring system). When a heteroaryl group is a polycyclic ring system, each ring in the ring system is aromatic. For example, a heteroaryl group having 5 total atoms and 2 heteroatoms independently selected from N, O, and S. refers to an aromatic ring having 3 carbon atoms and 2 heteroatoms, wherein each heteroatom of the ring independently is N, O, or S. Where a range is indicated, all members of that range and all subgroups within that range are envisioned. For example, a heteroaryl having 5-7 total ring atoms and 1-3 heteroatoms independently selected from N, 0, and S refers to an aromatic ring having a total number of ring atoms in the indicated range (e.g., 5, 6. or 7 total atoms, or any combination of the foregoing), as well as encompassing all subgroups (e.g., 5-6 or 6-7 total ring atoms, or any combination of the foregoing), wherein 1, 2, or 3 of the atoms in the ring are heteroatoms and each heteroatom is independently selected from N, 0, and S. A heteroaryl having 5-7 total ring atoms and 1-3 heteroatoms independently selected from N, 0, and S encompasses rings containing, for example, 4 carbon atoms and 1 heteroatom, 3 carbon atoms and 2 heteroatoms, 2 carbon atoms and 3 heteroatoms. 5 carbon atoms and 1 heteroatom, 4 carbon atoms and 2 heteroatoms, 3 carbon atoms and 3 heteroatoms. 6 carbon atoms and 1 heteroatom, 5 carbon atoms and 2 heteroatoms, and 4 carbon atoms and 3 heteroatoms, wherein each heteroatom of the foregoing independently is selected from N. 0, and S. Nonlimiting examples of monocyclic heteroaryl groups include: pyrrolyl, furanyl, thiophene-yl (or thienyl), pyrazolyl, imidazolyl, isoxazolyl. oxazolyl, isothiazolyl, thiazolyl, triazolyl. oxadiazolyl, 1,3,4-oxadiazolyl. thiadiazolyl, tetrazolyl, pyridinyl (or pyridyl), pyridazinyl, pyrimidinyl, pyrazinyl, and triazinyl. Nonlimiting examples of bicyclic heteroaryl groups include benzofuranyl. benzothienyl, benzimidazolyl, benzoisoxazolyl. benzoxazolyl, benzothiazolyl, benzothiadiazolyl, benzotriazolyl, furopyridinyl (e.g.. furo[2,3-b]pyridinyl), imidazopyridinyl (imidazo[4,5-b]pyridinyl), imidazothiazolyl (e.g., imidazo[4.5-d]thiazolyl), indolizinyl, indolyl, indazolyl, isobenzofuranyl, isoindolyl. isoquinolinyl, naphthyridinyl, oxazolopyridinyl (e.g., oxazolo[5,4-b]pyridinyl), phthalazinyl, pteridinyl, purinyl, pyrrolopyridyl (e.g., pyrrolo[2,3-b]pyridyl), quinolinyl, quinoxalinyl, quinazolinyl, benzoxazolyl, cinnolinyl, isoquinolyl, pyrazolopyridinyl (e.g., pyrazolo[3,4-b]pyridinyl), and thiazolopyrindinyl (e.g., thiazolo[5,4-b]pyridinyl). Nonlimiting examples of tricyclic heteroary l groups include carbazolyl, 4,5-bcnzindolyl, dibcnzofuranyl, dibcnzothiophcnc-yl, phcnazinyl, and acridinyl.

[0023] The term “alky lene” refers to a divalent saturated, straight or branched hydrocarbon chain diradical containing the indicated number of carbon atoms. For example, C3 alkylene means the alky lene group has 3 carbon atoms. Where a range is indicated, all members of that range and all subgroups within that range are envisioned. For example, Ci-calkylene means an alkylene group having a 1, 2, 3, 4, 5. or 6 carbon atoms, or any combination of the foregoing), as well as all subgroups in the indicated range (e.g., 1-2, 1-3, 1-4, 1-5, 1-6. 2-3, 2-4, 2-5, 2-6, 3-4, 3-5, 3-6, 4-5, 4-6, and 5-6 carbon atoms, or any combination of the foregoing). When the number of carbon atoms in an alky lene group is indicated as “Co,” then the alky lene group is not present and the recited substituent is directly attached to the rest of the compound. For example, the term Co-ealkylene-OH indicates that die OH group can be directly attached to the compound or through a Ci-ealkylene linker. Examples of alky lene groups include methylene (—CH2—), ethylene (—CH2CH2—), n-propylene (— CH2CH2CH2—). isopropylene (—CH(CH3)CH2—), 1-butylene (—CH2CH2CH2CH2—), 1-methylbutylene (—CH(CH3)CH2CH2—), 2-methylbutylene (—CH2CH(CH3)CH2—), and3-methylbutylene (—CH2CH2CH(CH3)—).

[0024] The term “halogen” or “halo” refers to fluoro (F), chloro (Cl), bromo (Br). or iodo (I).

[0025] The term “haloalkyl” refers to an alkyl group in which one or more of the hydrogen atoms is replaced by a halogen. The halogen is independently selected at each occurrence. The term includes, for example, monohaloalkyl (e.g., CH2F, CH(CH2F)CH3) dihaloalky I (e.g.. CHF2. CH(CHF2)CH3), trihaloalkyl (e.g.. CF3, CH(CF3)CH3), and polyhaloalkyl (e.g., CF(CF3)CH3). A haloalkyl group may7 or may not be perhalogenated (e.g., perfluorinated, such as CF(CF3)CF3). For example, the term “Ci.haloalkyl” refers to a Ci^alkyl, wherein one or more hydrogen atoms is substituted with a halogen. For illustration, Ci^haloalkyl includes, for example, CH2F, CHF2. CF3, CHFC1, CH2CF3, CFHCF3, CF2CF3, CH(CF3)2, CF(CHF2)2, CH(CH2F)(CF3), CH2C1, CHC12. CC13, CHFC1, CH2CC13, CCIHCCh, CC12CC13, CH(CC13)2, CC1(CHC12)2, CH(CH2C1)CC13, and CH2CF(CH3)2.

[0026] The term “hydroxyalkylene” or “hydroxylalkylene” refers to a saturated straight chain alky lene or saturated branched chain alkylene containing the indicated number of carbon atoms substituted with one or two hydroxy groups in place of a hydrogen, provided that if Iw o hy droxy groups are present they are not both on the same carbon atom. Nonlimiting examples hydroxy alkylene include but are not limited to. hydroxymethylene, 2-hydroxy7ethylene. 2-hydroxypropylene, 3-hydroxypropylene. l-(hydroxymethyl)-2- methylpropylene. 2-hydroxybutylene, 3-hydroxybutylene, 4-hydroxybutylene, 2,3-dihydroxypropylene, l-(hydroxymethyl)-2-hydroxyethylene, 2,3-dibydroxybutylene, 3,4-dihydroxybuty lene and the like.

[0027] The term “oxo” refers to a substituent oxygen atom connected to another atom by a double O K bond (e.g., =O). For example, an oxo substituent on a cyclopentyl ring can be depicted as: '—'. O

[0028] The term “carbonyl” refers to a divalent C=O radical, such as

[0029] The terms “hydroxy” and “hydroxyl” are interchangeable and refer to a —OH group.

[0030] The terms "alkoxy " and “alkoxyl” are interchangeable and refer to an —O-alkyl group, where the alkyl group is as defined elsewhere herein. For example, a C3alkoxy group means the alkoxy group has 3 carbon atoms (e.g., OCH2CH2CH3). Where a range is indicated, all members of that range and all subgroups within that range are envisioned. For example, a Cuealkoxy includes alkoxy groups having 2, 3, 4, 5, or 6 carbon atoms, or any combination of the foregoing, as well as all subgroups in the indicated range (e.g., 2-3, 2-4, 2-5, 2-6, 3-4, 3-5, 3-6, 4-5, 4-6, and 5-6 carbon atoms, or any combination of the foregoing). Nonlimiting examples of alkoxy groups include methoxy, ethoxy, n-propoxy, 1-methylethyloxy (iso-propoxy), n-butoxy, isobutoxy, sec-butoxy, and tertbutoxy.

[0031] The terms “haloalkoxy” and “haloalkoxyl” are interchangeable and refer to an alkoxy group in which one or more of the hydrogen atoms is replaced by a halogen. The halogen is independently selected at each occurrence. The term includes monohaloalkoxy (e.g.. OCH2F, OCH(CH2F)CH3) dihaloalkoxy' (e.g., OCHF2, OCH(CHF2)CH3). trihaloalkoxy (e.g., OCF3, OCH(CF3)CH3), and polyhaloalkoxy’ (e.g., OCF(CF3)CH3). A haloalkoxy group may or may not be pcrhalogcnatcd (e.g., perfluorinated, such as OCF(CF3)CF3). For example, the term “Ci.4haloalkoxy” refers to a Ci.4alkoxy as defined herein, wherein one or more hydrogen atoms is substituted with a halogen. Representative examples of CiJraloalkoxy’ include OCH2F, OCHF2, OCF3, OCHFC1, OCH2CF3, OCFHCF3, OCF2CF3, OCH(CF3)2. OCF(CHF2)2, OCH(CH2F)(CF3), OCH2C1, OCHCh, OCF3, OCHFC1, OCH2CC13, OCC1HCC13, OCC12CC13, OCH(CC13)2, OCC1(CHC12)2, OCH(CH2C1)CC13, and OCH2CF(CH3)2.

[0032] The term “cyano” refers to a —CN group.

[0033] The term “deutero” as used herein as a prefix to another term for a chemical group refers to a modification of the chemical group, wherein one or more hydrogen atoms are substituted with deuterium (“D” or “2H”). For example, the term “Ci / |deuteroalkyl” refers to a Ciialkvl as defined herein, wherein one or more hydrogen atoms are substituted with D. Representative examples of Ci-4deuteroalkyl include, but are not limited to, -CH2D, -CHD2, -CD3, -CH2CD3, -CDHCD3, -CD2CD3, -CH(CD3)2, -CD(CHD2)2, and -CH(CH2D)(CD3).

[0034] The term “amino” refers to —NH2.

[0035] The term “alky lamino” refers to a — NRH group in which R is alkyl.

[0036] The term “ether” refers to an oxygen atom bonded to two alkyl or ary l groups (R-O-R). The term “ether bridge” refers to an ether group that forms a bridge on a ring, wherein the bridge has the indicated number of carbon atoms. For example, a Ci ether bridge ( ) on a cyclohexylene ring cyclohexylene ring can be depicted as, for example,

[0037] The term “solvate” refers to a molecular aggregate comprising a compound or a pharmaceutically acceptable salt thereof as described herein and a stoichiometric or non-stoichiometric amount of one or more pharmaceutically acceptable solvent molecules.

[0038] The term “hydrate" refers to a solvate in which the solvent is water.

[0039] The term “geminal” refers to substituents that are attached to the same atom. Geminal R T R (Yr RR     II groups on a chain and ring can be depicted as:              and JL , respectively.

[0040] The term “vicinal” refers to substituents that are attached to adjacent atoms along a chain or R within a ring. Vicinal R groups along a chain and within a ring can be depicted as R and R 1^ R —I—    , respectively.

[0041] The term “non-neighboring” refers to substituents that are attached to atoms along a chain or within a ring that are not attached to adjacent atoms and that are not geminal. Non-neighboring R R^AyR R R II groups along a chain and within a ring can be depicted as              and respectively.

[0042] The term “protecting group” refers to a removable moiety that modifies a desired functional group to block the desired functional group from reacting in a subsequent chemical reaction. For example, the term “nitrogen protecting group” refers to a removable moiety that modifies a functional group having a nitrogen atom to block the functional group having a nitrogen atom from reacting in a subsequent chemical reaction (e.g., tert-butyloxycarbonyl). Examples of protecting groups are detailed in Greene, T. W., Wuts, P. G, “Protective Groups in Organic Synthesis”, Third Edition, John Wiley & Sons, New York: 1999 (and other editions of the book, such as Wuts, P.G.M. and Greene, T.W. “Greene’s Protective Groups in Organic Synthesis,” Fourth Edition. John Wiley & Sons, Hoboken: 2007).

[0043] As used herein, if any variable occurs more than one time in a chemical formula, its definition on each occurrence is independent of its definition at every other occurrence.

[0044] The term “substituted” refers to the replacement of one or more hydrogen radicals in a given structure or functional group with the radical of a specified substituent. A substituted structure or functional group may have a substituent at any substitutable position of the structure or functional group. When more than one position in a given structure can be substituted with more than one substituent, the substituent may be either the same or different at each position.

[0045] The term “pharmaceutically acceptable” refers to a species or component that is generally safe, non-toxic, and neither biologically nor otherwise undesirable for use in a subject.

[0046] The term “pharmaceutically acceptable salt” refers to a salt of a compound that possesses the desired pharmacological activity of the parent compound and that is not biologically or otherwise undesirable for its end use. Pharmaceutically acceptable salts include, for example, acid addition salts formed with inorganic acids (e.g.. hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid) or formed with organic acids (e.g., acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl) benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid). Pharmaceutically acceptable salts also include, for example, salts formed when an acidic proton present in the parent compound either is replaced by a metal ion (e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion) or associates with an organic base (e.g., ethanolamine, diethanolamine, triethanolamine, N-methylglucamine, dicyclohexylamine). Additionally, the salts of the compounds described herein, can exist in either hy drated or anhy drous form or as solvates with other solvent molecules.

[0047] The term “pharmaceutically acceptable excipient” refers to a broad range of ingredients that may be combined with a compound, solvate, or salt disclosed herein to prepare a pharmaceutically acceptable composition or formulation. Excipients include, for example, vehicles (e.g.. solvents, dispersion media), coatings, isotonic and absorption delaying agents, diluents, colorants, glidants, disintegrants, flavoring agents, coatings, binders, sweeteners, lubricants, sorbents, and preservatives (e.g., antibacterial and antifungal agents).

[0048] The term “therapeutically effective amount” as used herein refers to that amount of a compound disclosed herein that elicits a desired biological or medical response in a cell, a tissue, a system, or a subject.

[0049] The term “patient” or “subject” refers to humans and other mammals. The term “mammal” as used herein includes, for example, humans, non-human primates, cattle, sheep, goats, pigs, horses, cats, dog, rabbits, rodents (e.g.. rats or mice), and monkeys. Human subjects include neonates, infants, juveniles, adults, and geriatric subjects.

[0050] For clarity and avoidance of doubt, the divalent structural elements of L1 as provided herein are to be inserted into Formula (I) such that the left hand side is attached to the nitrogen-containing hetercycloalkyl group and the right hand side is attached to the aryl ring. For example, if L1 is OH (Example 1.040).

[0051] For clarity and avoidance of doubt, the divalent structural elements of L2 as provided herein are to be inserted into Formula (I) such that the left hand side in the markush definition (e.g.. -O-C1.4 alkylene) is attached to the nitrogen-containing heterocycloalkyl and the right hand side is attached to the R1 moiety. For example, if L2 is -O-methylene or -O-CH2-, then the compound of Formula (I) is COMPOUNDS OF FORMULA (I)

[0052] Provided herein as Embodiment 1 are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein; X is -CH2- or -O- Z is C-H, C-halogen. C-CN, C-C1.4 alkyl, C-C1.4 haloalkyl. C-C1.4 alkoxy. C-C1.4 haloalkoxy. C-C3-7 cycloalkyl or N; Q is CH. C-halogen, C-C1-4 alkyl, C-C1.4 haloalkyl or N; B is a C3-7 cycloalkyl or 3-7 membered heterocycloalkyl; n is 0, 1 or 2; m is 0. 1 or 2; p is 0, 1 or 2; q is 0, 1 or 2; each Rx independently is hydroxyl, halogen, oxo, cyano, -N(RZ)2, C1-4 alkyl, C1.4 deuteroalkyl, C1-4 alkoxy, C1-4 haloalkyl, C1.4 haloalkoxy, C1-4 hydroxyalkylene, 5-7 membered heteroaryl, -S(O)2-Ci.4alkyl, -S('O)2N(RZ)2. -C(O)RZ. -C(O)ORZ, -C^N / R^z, -C1.4 alkylene-C(O)-Ci. 4alkyl, -C1-4 alkylene-C(O)N(Rz)2, C1.4 alkylene-S(O)2-Ci-4alkyl, or -S-Ci-4alkyl; L2 is a bond, Ci-e alkylene, -O-C1-6 alkylene, -S-C1-6 alkylene. NRZ, O or S, wherein each Ci-6 alkylene, -O-Ci-6 alkylene and -S-C1-6 alkylene chain is substituted with 0-2 occurrences of R2; R1 is hydrogen, hydroxyl. Ce-io aryl, 5-10 membered heteroaryl, C3-8 cycloalkyl or 4-15 membered heterocycloalkyl, wherein each aryl, heteroaryl, cycloalkyl or heterocycloalkyl is substituted with 0-3 occurrences of R3; each R2 independently is halogen, deuterium, hydroxyl or C1-4 alkyl; wherein two geminal R2 groups, together with die atom to which they are attached form a spiro-Cs-? cycloalkyl group substituted with 0-2 occurrences of Rw; or wherein two adjacent R2 groups, together with the atoms to which they are attached form a fused-Cs-? cycloalkyd group substituted with 0-2 occurrences of Rw; R4 is hydrogen, hydroxyl, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 lialoalkyl, C2-4 alkenyl, C2-4 alkynyl. C3-7 cycloalkyl or cyano: each R5 independently is halogen, cyano, oxo, -T-Ry, hydroxyl. -N(RZ)2, Cm alkyl, Cm haloalkyl. Cm alkoxy or -O-C2-4 alkynyl; each R6a R6bandR6c independently is hydrogen, halogen, hydroxyl, cyano, -N(RZ)2, -C(O)RZ. -C(O)ORZ, Cm alkyl, Cm alkoxy, Cm haloalkyl, Cm haloalkoxy, C2-4 alkynyl or C3-6 cycloalkyl or R6il and R6b, together with the atom to which they are attached form a fused C3-7 cycloalkyl; R6d is hydrogen, -C(O)-Ci-8 alkyl or -C(O)-OCi-s alkyl; T is Cm alkylene. -S(O)2-, -C(O)-. -Cm alkylene-C(O)-, Cm alkylene-S(O)2- or -S-; each Rw independently is Cm alkyl, Cm alkoxy, -C(0)-Cm alkyl, -C(0)-0-Cm alkyl, halogen, hydroxyl or Cm haloalkyl; Ry is halogen, Cm alkyl, Cm haloalkyl, hydroxyl, cyano or -N(RZ)2; and each Rz independently is hydrogen or Cm alkyl.

[0053] Provided herein as Embodiment 2 is the compound or salt of Embodiment 1, wherein the compound is a compound of Formula (I-B): (I-B) or a pharmaceutically acceptable salt thereof, wherein; X is -CH2- or -O- Z is C-H, C-halogen, C-CN, C-C1-4 alkyl, C-C1-4 haloalkyl, C-C1.4 alkoxy, C-C1.4 haloalkoxy, C-C3-7 cycloalkyl or N; Q is CH. C-halogen, C-C1-4 alkyl, C-C1.4 haloalkyl or N; B is a C3-7 cycloalkyl or 3-7 membered heterocycloalkyl; n is 0, 1 or 2; m is 0, 1 or 2; p is 0, 1 or 2; q is 0, 1 or 2; each Rx independently is hydroxyl, halogen, oxo, cyano, -N(RZ)2, C1-4 alkyd, Cm deuteroalkyl, Cm alkoxy, Cm haloalkyl, Cm haloalkoxy, Cm hydroxyalkylene, 5-7 membered heteroaryl, -S(O)2-CMalkyl, -S(O)2N(RZ)2, -C(O)RZ, -C(O)ORZ, -C(O)N(RZ)2. -Cm alkylene-C(O)-Ci. 4alkyl, -Cm alkylene-C(O)N(Rz)2, Cm alkylene-S(O)2-Ci-4alkyl, or -S-Ci.4alkyl; L2 is a bond. Cm alkylene, -O-Cm alkylene. -S-Cm alkylene, NRZ, O or S, wherein each Cie alkylene, -O-Cm alky dene and -S-Cm alkylene chain is substituted with 0-2 occurrences of R2; L1 is            V R1 is hydrogen, hydroxyl. Ce-io aryl, 5-10 membered heteroaryl, C3-8 cycloalkyl or 4-15 membered heterocycloalkyl, wherein each aryl, heteroaryl, cycloalkyl or heterocycloalkyl is substituted with 0-3 occurrences of R3; each R2 independently is halogen, deuterium, hydroxyl or C1.4 alkyl; wherein two geminal R2 groups, together with die atom to which they are attached form a spiro-Cs-? cycloalkyl group substituted with 0-2 occurrences of Rw; or wherein two adjacent R2 groups, together with the atoms to which they are attached form a fused-Cs-? cycloalkyd group substituted with 0-2 occurrences of Rw; R4 is hydrogen, hydroxyl, halogen. Cm alkyl. Cm alkoxy, Ci-4 haloalkyl, C2-4 alkenyl, C2-4 alkynyl, C3-7 cycloalkyl or cyano; each R5 independently is halogen, cyano, oxo, -T-Ry, hydroxy l. -N(RZ)2, Cm alkyl, Cm haloalkyl, Cm alkoxy or -O-C2-4 alkynyl; each R6a R6bandR6c independently is hydrogen, halogen, hydroxy l, cyano, -N(RZ)2, -C(O)RZ. -C(O)ORZ, Cm alkyl, Cm alkoxy, Cm haloalkyl, Cm haloalkoxy, C2-4 alkynyl or C3-6 cycloalkyl or R6a and R6b, together with the atom to which they are attached form a fused C3-7 cycloalkyl; T is Cm alkylene, -S(O)2-, -C(O)-, -Cm alky lene-C(O)-. Cm alkylene-S(O)2- or -S-; each Rw independently is Cm alkyl. Cm alkoxy, halogen, hydroxyl or Cm haloalkyl; Ry is halogen, Cm alkyl, Cm haloalkyl, hydroxyl, cyano or -N(RZ)2; and each Rz independently is hydrogen or Cm alky1.

[0054] Provided herein as Embodiment 3 is the compound or salt of Embodiment 1. wherein the compound is a compound of Formula (II): (II) or a pharmaceutically acceptable salt of said compound, wherein X, Z, p, n, Rx, L2, L1, R1, R2, R4, R5, R6a, R* R6c, R6d, Rw, T, Ry and Rz are as defined above for Formula (I).

[0055] Provided herein as Embodiment 4 is the compound or salt of Embodiment 2, wherein the compound is a compound of Formula (II-B): Rw (II-B) or a pharmaceutically acceptable salt of said compound, wherein X, Z, p, n, Rx, L2, L1, R1, R2, R4, R5, R6a, R41’. R6c, Rw, T, Ry and Rz are as defined above for Formula (I-B).

[0056] Provided herein as Embodiment 5 is the compound or salt of Embodiment 1, wherein the compound is a compound of Formula (III): (HI) or a pharmaceutically acceptable salt of said compound, wherein X, Z, p, n, Rx, L2, L1, R1. R2, R4, R5, R6a, R66, R6c, R6d, Rw, T, Ry and Rz are as defined above for Formula (I).

[0057] Provided herein as Embodiment 6 is the compound or salt of Embodiment 2, wherein the compound is a compound of Formula (III-B): Rw (III-B) or a pharmaceutically acceptable salt of said compound, wherein X, Z, p, n, Rx, L2, L1, R1. R2, R4, R5, R6a, R66, R6c, Rw, T, Ry and Rz are as defined above for Formula (I-B).

[0058] Provided herein as Embodiment 7 is the compound or salt of Embodiment 1, wherein the compound is a compound of Formula (IV): (IV) or a pharmaceutically acceptable salt of said compound, wherein X, Z, p, n. Rx, L1, R4, R6a, R66, R6c, R6d, Rw, T, Ry and Rz are as defined above for Formula (I).

[0059] Provided herein as Embodiment 8 is the compound or salt of Embodiment 2, wherein the compound is a compound of Formula (IV-B): (IV-B) or a pharmaceutically acceptable salt of said compound, wherein X, Z, p. n, Rx, L1, R4, R&, R11. R6c, rw t Ry anj RZ are as jefjnej above for Formula (I-B).

[0060] Provided herein as Embodiment 9 is the compound or salt of Embodiment 1, wherein the compound is a compound of Formula (V): (V) or a pharmaceutically acceptable salt of said compound, wherein Z, L1, R4, R6a, R6b, R6c, R6d, Rw, T, Ry and Rz are as defined above for Formula (I).

[0061] Provided herein as Embodiment 10 is the compound or salt of Embodiment 2, wherein the compound is a compound of Formula (V-B): Rw (V-B) or a pharmaceutically acceptable salt of said compound, wherein Z, L1, R4, R6a, R6b, R6c, Rw, T, Ry and Rz are as defined above for Formula (I-B).

[0062] Provided herein as Embodiment 11 is the compound or salt of Embodiment 1, wherein the compound is a compound of Formula (VI): (VI) or a pharmaceutically acceptable salt of said compound, wherein L1, R6a, R6d, Rw, T, Ry and Rz are as defined above for Formula (I).

[0063] Provided herein as Embodiment 12 is the compound or salt of Embodiment 2, wherein the compound is a compound of Formula (VI-B): RW (VI-B) or a pharmaceutically acceptable salt of said compound, wherein L1, R6a, Rw, T, Ry and Rz are as defined above for Formula (I-B).

[0064] Provided herein as embodiment 13 is the compound or salt of any of Embodiments 1-2, wherein Z is C-H, C-F, C-CN, C-CH3, C-CF3, C-OMc, C-Cl or N. Provided herein as embodiment 14 is the compound or salt of embodiment 13, wherein Z is N. Provided herein as embodiment 15 is the compound or salt of embodiment 13, wherein Z is CH. Provided herein as embodiment 16 is the compound or salt of embodiment 13, wherein Z is CF.

[0065] Provided herein as Embodiment 17 is the compound of salt of any of Embodiments 1-16, wherein Q is CH, C-C1-4 alkyl or N. Provided herein as Embodiment 18 is the compound or salt of Embodiment 17, wherein Q is CH. Provided herein as Embodiment 19 is the compound or salt of Embodiment 17. wherein Q is C-CH3. Provided herein as Embodiment 20 is the compound or salt of Embodiment 17. wherein Q is N.

[0066] Provided herein as Embodiment 21 is the compound or salt of Embodiment 1, wherein Z is N and Q is CH. Provided herein as Embodiment 22 is the compound or salt of Embodiment 1, wherein Z is N and Q is C-CH3. Provided herein as Embodiment 23 is the compound or salt of Embodiment 1, wherein Z is N and Q is N.

[0067] Provided herein as Embodiment 24 is the compound or salt of any of Embodiments 1-23. wherein L2 is -O-methylene, -O-ethylene or -O-n-propylene substituted with 0-2 occurrences of R2

[0068] Provided herein as Embodiment 25 is the compound or salt of Embodiment 24, wherein L2 is -O-methylene substituted with 0 occurrences of R2. Provided herein as Embodiment 26 is the compound or salt of Embodiment 25. wherein R1 is heterocycloalkyl substituted with 0-3 occurrences ofR5.

[0069] Provided herein as Embodiment 27 is the compound or salt of Embodiment 26, wherein R1 is 7a-(hexahydro-lH-pyrrolizinyl), 2-azetidinyl or 2-pyrrolidinyl substituted with 0-3 occurrences of R5. Provided herein as Embodiment 28 is the compound or salt of Embodiment 27, wherein R1 is unsubstituted 7a-(hexahydro-lH-pyrrolizinyl), unsubstituted 5-(l-azabicyclo[3.2.0]heptanyl), unsubstituted 2-azetidinyl or unsubstituted 2-pyrrolidinyl. Provided herein as Embodiment 29 is the compound or salt of Embodiment 28. wherein R1 is unsubstituted 7a-(hexahydro-lH-pyrrolizinyl). Provided herein as Embodiment 30 is the compound or salt of Embodiment 28, wherein R1 is unsubstituted 2-pyrrolidinyl. Provided herein as Embodiment 31 is the compound or salt of Embodiment 28. wherein R1 is unsubstituted 5-(l-azabicyclo[3.2.0]heptanyl).

[0070] Provided herein as Embodiment 32 is the compound or salt of Embodiment 27 wherein R1 is 7a-(hexahydro-lH-pyrrolizinyl), 2-azetidinyl or 2-pyrrolidinyl substituted with one occurrence of R5. Provided herein as Embodiment 33 is the compound or salt of Embodiment 32, wherein R5 is halogen or C1.4 alkyl. Provided herein as Embodiment 34 is the compound or salt of Embodiment 33, wherein R5 is fluorine or methyl.

[0071] Provided herein as Embodiment 35 is the compound or salt of Embodiment 32, wherein R1 is 7a-(hexahydro-lH-pyrrolizinyl) substituted with one occurrence of R5. Provided herein as Embodiment 36 is the compound or salt of Embodiment 35, wherein R3 is halogen (e.g., fluorine).

[0072] Provided herein as Embodiment 37 is the compound or salt of Embodiment 32, wherein R1 is 2-pyrrolidinyl substituted with one occurrence of R5. Provided herein as Embodiment 38 is the compound or salt of Embodiment 37, wherein R5 is Ci-4 alkyl (e.g., methyl or ethyl).

[0073] Provided herein as Embodiment 39 is the compound or salt of Embodiment 32, wherein R1 is 2-azetidinyl substituted with one occurrence of R5. Provided herein as Embodiment 40 is the compound or salt of Embodiment 39, wherein R5 is Ci-4 alkyl (e.g., methyl).

[0074] Provided herein as Embodiment 41 is the compound or salt of Embodiment 27, wherein R1 is 2-pyrrolidinyl or 5-(l-azabicyclo[3.2.0]heptanyl) substituted with two occurrences of R5. Provided herein as Embodiment 42 is the compound or salt of Embodiment 41, wherein R1 is 2-pyrrolidinyl substituted with two occurrences of R\ Provided herein as Embodiment 43 is the compound or salt of Embodiment 42, wherein one R5 is methyl and the other R3 is halogen (e.g., fluorine). Provided herein as Embodiment 44 is the compound or salt of Embodiment 42, wherein both R5 are Ci-4 alkyl (e.g., methyl or ethyl). Provided herein as Embodiment 45 is the compound or salt of Embodiment 44, wherein both R5 are methyl. Provided herein as Embodiment 46 is the compound or salt of Embodiment 44, wherein one R5 is methyl and the other R3 is ethyl.

[0075] Provided herein as Embodiment 47 is the compound or salt of Embodiment 41. wherein R1 is 5-(l-azabicyclo[3.2.0]heptanyl) substituted with two occurrences of R5. Provided herein as Embodiment 48 is the compound or salt of Embodiment 47, wherein both R3 are halogen (e.g., fluorine).

[0076] Provided herein as Embodiment 49 is the compound or salt of Embodiment 24, wherein L2 is -O-methylene substituted with 2 occurrences of R2. Provided herein as Embodiment 50 is the compound or salt of Embodiment 49. wherein both R2 are deuterium. Provided herein as Embodiment 51 is the compound or salt of Embodiment 50, wherein R1 is 7a-(hexahydro-lH-pyrrolizinyl) substituted with one occurrence of R3. Provided herein as Embodiment 52 is the compound or salt of Embodiment 51, wherein R3 is halogen (e.g.. fluorine).

[0077] Provided herein as Embodiment 53 is the compound or salt of Embodiment 24, wherein L2 is -O-«-propylene substituted with two occurrences of R2. Provided herein as Embodiment 54 is the compound or salt of Embodiment 53. wherein two geminal R2 groups, together with the atom to which they are attached form a spiro-Cs-? cycloalkyl (e.g., cyclopropyl) substituted with 0-2 occurrences of Rw. Provided herein as Embodiment 55 is the compound or salt of Embodiment 54, wherein two geminal R2 groups, together with the atom to which they are attached form a spirocyclopropyl substituted with tw o occurrences of Rw. Provided herein as Embodiment 56 is the compound or salt of Embodiment 55, w herein both Rw are halogen (e.g.. fluorine). Provided herein as Embodiment 57 is the compound or salt of Embodiment 56, wherein R1 is -N(Rz)z and Rz are methyl.

[0078] Provided herein as Embodiment 58 is the compound or salt of any of Embodiments 24-57, compound or salt of Embodiment 58, wherein -L2-R' is Provided herein as Embodiment 61 is the compound or salt of as Embodiment 63 is the compound or salt of Embodiment 62, wherein -L2-R' is Provided herein as Embodiment 64 is the compound or salt of Embodiment 62, wherein -L2-R] is . Provided herein as Embodiment 65 is the compound or salt of Embodiment 62, wherein -L2-R' is Provided herein as Embodiment 66 is the compound or salt of Embodiment 62. wherein -L2-R1 is Provided herein as Embodiment 67 is the compound or salt of Embodiment 61, wherein -L2-R' is

[0079] Provided herein as Embodiment 68 is the compound or salt of any of Embodiments 1-67, wherein X is O.

[0080] Provided herein as Embodiment 69 is the compound or salt of Embodiment 68, wherein n is 2 and m is 0. Provided herein as Embodiment 70 is the compound or salt of Embodiment 69, wherein p is 0. Provided herein as Embodiment 71 is the compound or salt of Embodiment 70, wherein B is C3.7 cycloalkyl. Provided herein as Embodiment 72 is the compound or salt of Embodiment 71, wherein B is cyclobuty l and q is 0. Provided herein as Embodiment 73 is the compound or salt of Embodiment 71. wherein B is cyclobutyl and q is 1. Provided herein as Embodiment 74 is the compound or salt of Embodiment 73, wherein Rw is halogen or hydroxy l. Provided herein as Embodiment 75 is the compound or salt of Embodiment 74, wherein Rw is hydroxyl. Provided herein as Embodiment 76 is the compound or salt of Embodiment 74, wherein Rw is fluorine.

[0081] Provided herein as Embodiment 77 is the compound or salt of Embodiment 68, wherein n is 2 and m is 1. Provided herein as Embodiment 78 is the compound or salt of Embodiment 77, wherein p is 0. Provided herein as Embodiment 79 is the compound or salt of Embodiment 78. wherein B is C3-7 cycloalkyl. Provided herein as Embodiment 80 is the compound or salt of Embodiment 79, wherein B is cyclobuty l and q is 0. Provided herein as Embodiment 81 is the compound or salt of Embodiment 79, wherein B is cyclobutyl and q is 1. Provided herein as Embodiment 82 is the compound or salt of Embodiment 81, wherein Rw is halogen or hydroxy l. Provided herein as Embodiment 83 is the compound or salt of Embodiment 82, wherein Rw is hydroxyl. Provided herein as Embodiment 84 is the compound or salt of Embodiment 82, wherein Rw is fluorine.

[0082] Provided herein as Embodiment 85 is the compound or salt of any of Embodiments 68-84, . Provided herein as Embodiment 86 is the compound or salt of Embodiment 85. or *7*         . Provided herein as Embodiment 87 is the compound or salt of At / <rx>p—C Embodiment 86. wherein          ■■■■I""               is (R Embodiment 88 is the compound or salt of Embodiment 86, wherein 1 . Provided herein as m |Bj-(Rw)q x. p & J —1—            is OH . Provided herein as Embodiment 89 is the compound or salt of Embodiment 86, wherein ...1...               is *1*         . Provided herein as Embodiment 90 is the compound or salt of Embodiment 86, wherein ■■■I"-              is Provided herein as Embodiment 91 is the compound or salt of Embodiment 86, wherein is

[0083] Provided herein as Embodiment 92 is the compound or salt of any of Embodiments 1-67, wherein X is -CH2-.

[0084] Provided herein as Embodiment 93 is the compound or salt of Embodiment 92, wherein n is 1 and m is 0 or n is 0 and m is 1. Provided herein as Embodiment 94 is the compound or salt of Embodiment 93, wherein p is 0. Provided herein as Embodiment 95 is the compound or salt of Embodiment 94, wherein B is C3-7 cycloalkyl. Provided herein as Embodiment 96 is the compound or salt of Embodiment 95, wherein B is cyclobutyl and is q is 0.

[0085] Provided herein as Embodiment 97 is the compound or salt of Embodiment 92, wherein n is 2 and m is 0. Provided herein as Embodiment 98 is the compound or salt of Embodiment 97, wherein p is 0.

[0086] Provided herein as Embodiment 99 is the compound or salt of Embodiment 98. wherein B is C3-7 cycloalkyl. Provided herein as Embodiment 100 is the compound or salt of Embodiment 99. wherein B is cyclobutyl and q is 0. Provided herein as Embodiment 101 is the compound or salt of Embodiment 99, wherein B is cyclobutyl and q is 1. Provided herein as Embodiment 102 is the compound or salt of Embodiment 101, wherein Rw is hydroxyl. -C(O)-Ci-4 alkyl or halogen. Provided herein as Embodiment 103 is the compound or salt of Embodiment 102, wherein Rw is hydroxyl or halogen. Provided herein as Embodiment 104 is the compound or salt of Embodiment 103, wherein Rw is hydroxyl. Provided herein as Embodiment 105 is the compound or salt of Embodiment 103, wherein Rw is fluorine. Provided herein as Embodiment 106 is the compound or salt of Embodiment 102, wherein Rw is -C(O)-CH3.

[0087] Provided herein as Embodiment 107 is the compound or salt of Embodiment 98, wherein B is 3-7 membered heterocycloalkyl. Provided herein as Embodiment 108 is the compound or salt of Embodiment 107, wherein B is 2-oxetanyl and q is 0.

[0088] Provided herein as Embodiment 109 is the compound or salt of Embodiment 107. wherein L1 Fp B is            and q is 0.

[0089] Provided herein as Embodiment 110 is the compound or salt of Embodiment 97, wherein p is 1. Provided herein as Embodiment 111 is the compound or salt of Embodiment 110. wherein Rx is hydroxyl, halogen, Ci-4 alkyl or C1-4 haloalky 1. Provided herein as Embodiment 112 is the compound or salt of Embodiment 111. wherein Rx is hydroxyl.

[0090] Provided herein as Embodiment 113 is the compound or salt of Embodiment 112, wherein B is C3-7 cycloalkyl. Provided herein as Embodiment 114 is the compound or salt of Embodiment 113, wherein B is cyclobutyl and q is 0. Provided herein as Embodiment 115 is the compound or salt of Embodiment 113. wherein B is cyclobutyl and q is 1. Provided herein as Embodiment 116 is the compound or salt of Embodiment 115, wherein Rw is hydroxyl, -C(O)-Ci-4 alkyl or halogen. Provided herein as Embodiment 117 is the compound or salt of Embodiment 116, wherein Rw is hydroxyl or halogen. Provided herein as Embodiment 118 is the compound or salt of Embodiment 117, wherein Rw is hydroxyl. Provided herein as Embodiment 119 is the compound or salt of Embodiment 117, wherein Rw is fluorine. Provided herein as Embodiment 120 is the compound or salt of Embodiment 116. wherein Rw is -C(O)-Ci 4 alkyl (e g., -C(O)-CH3).

[0091] Provided herein as Embodiment 121 is the compound or salt of any of Embodiments 92- is the compound or salt of Embodiment 121, wherein OH compound or salt of Embodiment 122, wherein is Provided herein as Embodiment 124 is the compound or salt of Embodiment 123, wherein Embodiment 125 is the compound or salt of Embodiment 123, wherein Provided herein as Provided herein as Embodiment 126 is the compound or salt of Embodiment 123, Provided herein as Embodiment 127 is the compound or salt of Embodiment 123, wherein OH Provided herein as Embodiment 128 is the compound or salt of Embodiment 123. wherein compound or salt of Embodiment 123, wherein Provided herein as Embodiment 130 is the compound or salt of Embodiment 123, wherein compound or salt of Embodiment 123, wherein Provided herein as Embodiment 131 is the Provided herein as Embodiment 132 is the compound or salt of Embodiment 122, wherein

[0092] Provided herein as Embodiment 133 is the compound or salt of any of Embodiments 1-132,

[0093] Provided herein as Embodiment 134 is tire compound or salt of Embodiment 133, wherein

[0094] Provided herein as Embodiment 135 is the compound or salt of Embodiment 133, wherein Provided herein as Embodiment 136 is the compound or salt of Embodiment 133, wherein L1 is Provided herein as Embodiment 137 is the compound or salt of Embodiment 133, wherein L1 is Embodiment 138 is the compound or salt of Embodiment 133, wherein L1 is Provided herein as Provided herein as Embodiment 139 is the compound or salt of Embodiment 133, wherein L1 is Provided herein as Embodiment 140 is the compound or salt of Embodiment 133, wherein L1 is Provided herein as Embodiment 141 is the compound or salt of Embodiment 133, wherein L1 is Provided herein as Embodiment 142 is the compound or salt of Embodiment 133, wherein L1 is H Provided herein as Embodiment 143 is the compound or salt of Embodiment 133, wherein L1 is Provided herein as Embodiment 144 is the compound or salt of O Embodiment 133, wherein L1 is H                . Provided herein as Embodiment 145 is the compound or salt of Embodiment 133. wherein L1 is Embodiment 146 is the compound or salt of Embodiment 133, wherein L1 is Provided herein as Provided herein as Embodiment 147 is the compound or salt of Embodiment 133, wherein L1 is Provided herein as Embodiment 148 is the compound or salt of N-N Embodiment 133, wherein L1 is *             f . Provided herein as Embodiment 149 is the compound or salt of Embodiment 133, wherein L1 is N—O Provided herein as Embodiment 150 is the compound or salt of Embodiment 133, wherein L1 is Provided herein as Embodiment 151 is the compound or salt of Embodiment 133, wherein L1 is Provided herein as Embodiment 152 is the compound or salt of Embodiment 133, wherein L1 is Provided herein as Embodiment 153 is the compound or salt of Embodiment 133, wherein L1 is Provided herein as Embodiment 154 O is the compound or salt of Embodiment 133. wherein L1 is                       . Provided herein as Embodiment 155 is the compound or salt of Embodiment 133, wherein L1 is Provided herein as Embodiment 156 is the compound or salt of Embodiment 133, wherein L1 is Provided herein as Embodiment 157 is the compound or salt of Embodiment 133, wherein L1 is

[0095] Provided herein as Embodiment 158 is the compound or salt of any of Embodiments 1-157, wherein R4 is hydrogen, hydroxyl, halogen, Cm alkyl or Cm alkoxy. Provided herein of Embodiment 159 is the compound or salt of Embodiment 158, wherein R4 is halogen or Cm alkyl. Provided herein of Embodiment 160 is the compound or salt of Embodiment 159. wherein R4 is fluorine.

[0096] Provided herein as Embodiment 161 is the compound or salt of any of Embodiments 1-160, wherein each R6'1 R6b and R6c independently is hydrogen, halogen, Cm alkyl, Cm alkoxy' or Cm haloalkyl. Provided herein as Embodiment 162 is the compound or salt of Embodiment 161. wherein R6a R6bandR6c are each hydrogen. Provided herein as Embodiment 163 is the compound or salt of Embodiment 161, wherein R6b and R6c arc each hy drogen and R6a is halogen (c.g., fluorine or chlorine). Provided herein as Embodiment 164 is the compound or salt of Embodiment 163, wherein R6b and R6c are each hydrogen and R6a is chlorine. Provided herein as Embodiment 165 is the compound or salt of Embodiment 163, wherein R66 and R6c are each hydrogen and R6a is fluorine. Provided herein as Embodiment 166 is the compound or salt of Embodiment 161, wherein Rfib and Rfic are each hydrogen and R6a is Cm alkyl (e.g., methyl or ethyl). Provided herein as Embodiment 167 is the compound or salt of Embodiment 166, wherein R6b and R6c are each hydrogen and R6a is methyl.

[0097] Provided herein as Embodiment 168 is the compound or salt of any of Embodiments 1-167, wherein R6d is hydrogen. Provided herein as Embodiment 169 is the compound or salt of any of Embodiments 1-167. wherein R6d is -C(O)-Ci-8 alkyl. Provided herein as Embodiment 170 is the compound or salt of Embodiment 169, wherein R6d is -C(O)Me

[0098] Provided herein as Embodiment 171 is tire compound or salt of Embodiment 1, wherein the compound is: Table 1 Compound Compound Compound 1.006 1.010 1.033 1.035 1.036 1.037 1.039 1.041 Compound 1.044 1.043 1.052 1.054 1.055 1.059 O N-NH 1.062 Compound Compound Compound 1.065 1.066 1.067 F n-nh 1.068 1.069 1.070 1.071 1.073 Compound Compound Compound O Cl N-N, n-nh n-nh 0 1.077 1.075 1.076 OH OH OH Cl n-nh N—NH N-NH 1.082 1.081 1.083 OH OH OH Cl n-nh n-nh N—NH 1.084 1.086 1.087 OH OH OH cis, rac Cl n-nh n-nh 1.090 1.089 1.088 N-NH or Compound Compound Compound 1.091

[0099] Provided herein as Embodiment 172 is the compound or salt of Embodiment 1, wherein the compound is: Compound Compound Compound 1.001 1.002 OH 1.003 OH 1.035 Compound Compound 1.082 1.050 100100] Provided herein as Embodiment 173 is the compound or salt of Embodiment 1, wherein the compound is: 1.010a 1.033a Compound 1.035a 1.050a OH n-nh 1.082a 1.083a 1.084a OH 1.089a

[00101] Provided herein as Embodiment 174 is the compound or salt of Embodiment 1, wherein the compound is: Compound Compound Compound 1.002 1.010 1.033 1.083

[00102] Provided herein as Embodiment 175 is tire compound or salt of Embodiment 1, wherein the compound is: 1.083a

[00103] Provided herein as Embodiment 176 is the compound or salt of Embodiment 1, wherein the compound is:

[00104] Provided herein as Embodiment 177 is the compound or salt of Embodiment 1. wherein the compound is:

[00105] Provided herein as Embodiment 178 is the compound or salt of Embodiment 171, wherein die compound is OH (Compound 1.050). Provided herein as Embodiment 179 is the compound or salt of Embodiment 173, wherein the compound is OH N-nh (Compound 1.050a). Provided herein as Embodiment 180 is the compound of salt of Embodiment 171, wherein the compound is (Compound 1,052). Provided herein as Embodiment 181 is the compound of salt of Embodiment OH 171, wherein the compound is                      n—NH (Compound 1.010). Provided herein as Embodiment 182 is the compound of salt of Embodiment 173, wherein the compound is OH n-nh (Compound 1.010a). Provided herein as Embodiment 183 is the compound of salt of Embodiment 171, wherein the compound is OH (Compound 1.002). Provided herein as Embodiment 184 is the compound of salt of Embodiment 173, wherein the compound is OH (Compound 1.002a). Provided herein as Embodiment 185 is the compound of salt of Embodiment 171, wherein the compound is OH (Compound 1.040). Provided herein as Embodiment 186 is the compound of salt of Embodiment 173, wherein the compound is OH (Compound 1.040a). Provided herein as Embodiment 187 is the compound of salt of Embodiment herein as Embodiment 188 is the compound of salt of Embodiment 173, wherein the compound is OH (Compound 1.003a). Provided herein as Embodiment 189 is the compound of salt of Embodiment 171, wherein the compound is (Compound 1.033). Provided herein as Embodiment 190 is the compound of salt of Embodiment 173, wherein the compound is                     n-NH (Compound 1.033a). Provided herein as Embodiment 191 is the compound of salt of Embodiment 171, wherein tire compound is OH N—NH (Compound 1.083). Provided herein as Embodiment 192 is the OH compound of salt of Embodiment 173, wherein the compound is                     N—NH (Compound 1.083a). Provided herein as Embodiment 193 is the compound of salt of Embodiment 171, wherein the compound is                     n—NH (Compound 1,001). Provided herein as Embodiment 194 is the compound of salt of Embodiment 173, wherein the compound is W I N-NH (Compound 1.001a). Provided herein as Embodiment 195 is the compound of salt of Embodiment 171, wherein the compound is OH (Compound 1.035). Provided herein as Embodiment 196 is the compound of salt of Embodiment 173, wherein the compound is OH (Compound 1.035a). Provided herein as Embodiment 197 is the compound of salt of Embodiment 171, wherein the compound is OH Cl N—nh (Compound 1.082). Provided herein as Embodiment 198 is the compound of salt of Embodiment 173, wherein the compound is OH n-nh (Compound 1.082a). Provided herein as Embodiment 199 is the compound of salt of Embodiment (Compound 1.084). Provided herein as Embodiment 200 is the compound of salt of Embodiment 173, wherein tire compound is OH N—NH (Compound 1.084a). Provided herein as Embodiment 201 is the compound of salt of Embodiment 171. wherein the compound is OH (Compound 1.089). Provided herein as Embodiment 202 is the compound of salt of Embodiment 173, wherein the compound is OH (Compound 1.089a).

[00106] In another aspect of the disclosure, Embodiment 203 provides a compound from the table below: Table 2 1.007 Compound Compound 1.008 1.009 1.011 OH 1.014 1.015 1.018 1.019 1.020 1.021 1.022 Compound Compound Compound 1.024 OH 1.027 1.028 1.029 1.030 Compound Compound Compound F 1.051 OH OH 1.053 OH 1.056 1.057 1.058 1.072 1.078 OH 1.085

[00107] Provided herein as Embodiment 204 is the compound or salt of Embodiment 203, wherein the compound is: Compound OH 1.013 1.014 Compound F 1.018 1.019 1.020 OH 1.021 OH N-NH 1.024 OH 1.034 F 1.038 1.047 1.051 OH 1.078 Compound Compound

[00108] Provided herein as Embodiment 205 is the compound or salt of Embodiment 203, wherein the compound is: 1.018 Compound 1.021 OH 1.079

[00109] Provided herein as Embodiment 206 is the compound or salt of Embodiment 203, wherein the compound is:

[00110] Provided herein as Embodiment 207 is the compound or salt of Embodiment 203, wherein the compound is: OH (Compound 1.013). Provided herein as Embodiment 208 is the compound or salt of Embodiment 203, wherein the compound is: (Compound 1.018). Provided herein as Embodiment 209 is the compound or salt of Embodiment 203, wherein the compound is: (Compound 1.038). Provided herein as Embodiment 210 is the compound or salt of Embodiment 203, wherein the compound is: ci n-nh (Compound 1.051). Provided herein as Embodiment 211 is the compound or salt of Embodiment 203, wherein tire compound is: OH (Compound 1.014). Provided herein as Embodiment 212 is the compound or salt of Embodiment 203, wherein the compound is: (Compound 1.053). Provided herein as Embodiment 213 is the compound or salt of Embodiment F 203, wherein the compound is:                     N-NH (Compound 1.018). Provided herein as Embodiment 214 is the compound or salt of Embodiment 203, wherein the compound is: OH N-NH (Compound 1.079)

[00111] It is understood that selections of values of each variable are those that result in the formation of stable or chemically feasible compounds. Stereoisomers

[00112] The compounds of die present disclosure may contain, for example, double bonds, one or more asymmetric carbon atoms, and bonds with a hindered rotation, and therefore, may exist as stereoisomers, such as double-bond isomers (i.e., geometric isomers (E / Z)), enantiomers, diastereomers, and atropoisomers. Accordingly, the scope of the present disclosure is to be understood to encompass all possible stereoisomers of the illustrated compounds, including the stereoisomerically pure form (for example, geometrically pure, enantiomeric ally pure, diastereomerically pure, and atropoisomerically pure) and stereoisomeric mixtures (for example, mixtures of geometric isomers, enantiomers, diastereomers, and atropoisomers, or mixture of any of the foregoing) of any chemical structures disclosed herein (in whole or in part), unless the stereochemistry is specifically identified.

[00113] If the stereochemistry of a structure or a portion of a structure is not indicated with, for example, bold or dashed lines, the structure or portion of the structure is to be interpreted as encompassing all stereoisomers of the structure. If the stereochemistry of a structure or a portion of a structure is indicated with, for example, bold or dashed lines, the structure or portion of the structure is to be interpreted as encompassing only the stereoisomer indicated, unless otherwise noted. For example,   —nh represents   —nh   and   —nh . Similarly, for example, the chemical name (4R)-4-methoxy-5-methyl-4,5,6,7-tetrahydro-2H-isoindole represents (4R,5R)-4-methoxy-5-methyl-4.5,6,7-tetrahydro-2H-isoindole and (4R,5S)-4-methoxy-5-methyl-4,5,6,7-tetrahydro-2H-isoindole. A bond drawn with a wavy line may be used to indicate that both stereoisomers are encompassed. This is not to be confused with a wavy line drawn perpendicular to a bond which indicates the point of attachment of a group to the rest of the molecule.

[00114] The term “stereoisomer” or “stereoisomerically pure” compound refers to one stereoisomer (for example, geometric isomer, enantiomer, diastereomer and atropoisomer) of a compound that is substantially free of other stereoisomers of that compound. For example, a stereoisomerically pure compound having one chiral center will be substantially free of the mirror image enantiomer of the compound and a stereoisomerically pure compound having tw o chiral centers will be substantially free of the other enantiomer and diastereomers of the compound. A typical stereoisomerically pure compound comprises greater than about 80% by weight of one stereoisomer of the compound and equal or less than about 20% by weight of other stereoisomers of the compound, greater than about 90% by weight of one stereoisomer of the compound and equal or less than about 10% by weight of the other stereoisomers of the compound, greater than about 95% by weight of one stereoisomer of the compound and equal or less than about 5% by weight of the other stereoisomers of the compound, or greater than about 97% by weight of one stereoisomer of the compound and equal or less than about 3% by weight of the other stereoisomers of the compound.

[00115] This disclosure also encompasses the pharmaceutical compositions comprising stereoisomerically pure forms and the use of stereoisomerically pure forms of any compounds disclosed herein. Further, this disclosure also encompasses pharmaceutical compositions comprising mixtures of stereoisomers of any compounds disclosed herein and the use of said pharmacal compositions or mixtures of stereoisomers. These stereoisomers or mixtures thereof may be synthesized in accordance with methods well known in the art and methods disclosed herein. Mixtures of stereoisomers may be resolved using standard teclmiques, such as chiral columns or chiral resolving agents. See, for example, Jacques et al., Enantiomers, Racemates and Resolutions (Wileylnterscience, New York. 1981); Wilen et al., Tetrahedron 33:2725; Eliel, Stereochemistry of Carbon Compounds (McGrawHill, NY. 1962); and Wilen. Tables of Resolving Agents and Optical Resolutions, page 268 (Eliel, Ed., Univ, of Notre Dame Press, Notre Dame, IN, 1972). Tautomers

[00116] As known by those skilled in the art, certain compounds disclosed herein may exist in one or more tautomeric forms. Because one chemical structure may only be used to represent one tautomeric form, it w ill be understood that for convenience, referral to a compound of a given structural formula includes other tautomers of said structural formula. For example, HN—n represents HN—n   and N~NH . Similarly, for example, the chemical name (4R.5R)-4- methoxy-5-methyl-4,5.6,7-tetrahydro-lH-indazole represents (4R,5R)-4-methoxy-5-methy 1-4,5,6,7-tetrahydro-lH-indazole and (4R,5R)-4-methoxy-5-methyl-4,5,6,7-tetrahydro-2H-indazole. Accordingly, the scope of the present disclosure is to be understood to encompass all tautomeric forms of the compounds disclosed herein. Isotopically-Labeled Compounds |00117] In some cases, the scope of the present disclosure includes pharmaceutically acceptable isotopically-labeled compounds of the compounds disclosed herein, wherein one or more atoms are replaced by atoms having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes suitable for inclusion in the compounds disclosed herein include isotopes of hydrogen, such as 2H and 3H, carbon, such as nC, 13C and 14C, chlorine, such as 36C1, fluorine, such as 18F, iodine, such as 123I and 2d. nitrogen, such as 13N and 15N, oxygen, such as 150,17O and 18O, phosphorus, such as 32P, and sulfur, such as 35S. Certain isotopically-labelled compounds of the compounds disclosed herein, such as those incorporating a radioactive isotope, are useful in drug and / or substrate tissue distribution studies. The radioactive isotopes tritium (3H) and carbon-14 (14C) are particularly useful for this purpose in view of their ease of incorporation and ready means of detection. Substitution with isotopes such as deuterium (2H or D) may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be advantageous in some circumstances. As such, the term “deuterated’’ refers to the substitution of one or more hydrogen atoms with one or more deuterium atoms on a particular structure or functional group. Substitution with positron emitting isotopes, such as nC, 18F, 15O and 13N, can be useful in Positron Emission Topography (PET) studies, for example, for examining target occupancy. Isotopically-labelled compounds of the compounds disclosed herein can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying GENERAL SYNTHETIC PROCEDURES and EXAMPLES sections using an appropriate isotopically-labelled reagent in place of the non-labelled reagent previously employed. BIOLOGICAL ACTIVITY

[00118] In some cases, the compounds or salts disclosed herein (such as compounds of Formula (I). Formula (I-B). Formula (II), Formula (IT-B), Formula (III), Formula (III-B), Formula (IV), Formula (IV-B), Formula (V). Formula (V-B), Formula (VI) or Formula (VI-B). or compounds listed in Table 1, Table 2 or compounds of Embodiments 1-214, or a pharmaceutically acceptable salt of any of the foregoing), have an IC5o value of less than 5 pM, or less than 4 pM, or less than 3 pM. or less than 2 pM. or less than 1 pM, or less than 0.9 pM, or less than 0.7 pM, or less than 0.6 pM, or less than 0.5 pM, or less than 0.4 pM, or less than 0.3 pM, or less than 0.2 pM, or less than 0.1 pM, or less than 0.09 pM, or less than 0.08 pM, or less than 0.07 pM, or less than 0.06 pM, or less than 0.05 pM, or less than 0.04 pM, or less than 0.03 pM, or less than 0.02 pM, or less than 0.01 pM in the G12D Couple Exchange assay, AsPC-1 p-ERK assay, AsPC-1 CTG assay or the SW620 CTG assay, described in “SECTION 3: Biochemical and Cellular Assays.” In some cases, the compounds disclosed herein, and pharmaceutically acceptable salts of the foregoing, have an IC50 value of between 0.001 to 0.200 pM. FORMULATION AND ROUTE OF ADMINISTRATION

[00119] While it may be possible to administer a compound disclosed herein alone in the uses described, the compound administered normally will be present as an active ingredient in a pharmaceutical composition. Thus, further provided herein is a pharmaceutical composition comprising a compound or salt disclosed herein (such as compounds of Formula (I), Formula (I-B). Formula (II), Formula (II-B). Formula (III). Formula (III-B), Formula (IV), Formula (IV-B), Formula (V), Formula (V-B). Formula (VI) or Formula (VI-B). or compounds listed in Table 1, Table 2 or compounds of Embodiments 1-214. or a pharmaceutically acceptable salt of any of the foregoing), in combination with one or more pharmaceutically acceptable excipients and, if desired, other active ingredients. See, e.g.. Remington: The Science and Practice of Pharmacy, Volume I and Volume II, twenty-second edition, edited by Loyd V. Allen Jr., Philadelphia, PA, Pharmaceutical Press, 2012; Pharmaceutical Dosage Forms (Vol. 1-3), Liberman et al., Eds., Marcel Dekker, New York, NY, 1992; Handbook of Pharmaceutical Excipients (3rd Ed.), edited by Arthur H. Kibbe, American Pharmaceutical Association, Washington, 2000; Pharmaceutical Formulation: The Science and Technology of Dosage Forms (Drug Discovery), first edition, edited by GD Tovey, Royal Society’ of Chemistry, 2018. In some cases, the pharmaceutical composition described herein comprises a therapeutically effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt thereof.

[00120] The compound(s) disclosed herein may be administered by any suitable route in the form of a pharmaceutical composition adapted to such a route and in a dose effective for the treatment intended. The compounds and compositions presented herein may, for example, be administered orally, mucosally, topically, transdermally, rectally, puhnonarily, parentally, intranasally, intravascularly, intravenously, intraarterial, intraperitoneally, intrathecally, subcutaneously, sublingually , intramuscularly, intrasternally, vaginally or by infusion teclmiques, in dosage unit formulations containing conventional pharmaceutically acceptable excipients.

[00121] The pharmaceutical composition may be in the form of, for example, a tablet, chewable tablet, minitablet, caplet, pill, bead, hard capsule, soft capsule, gelatin capsule, granule, powder, lozenge, patch, cream, gel, sachet, microneedle array, syrup, flavored syrup, juice, drop, injectable solution, emulsion, microemulsion, ointment, aerosol, aqueous suspension, or oily suspension. In some cases, the pharmaceutical composition is made in the form of a dosage emit containing a particular amount of the active ingredient.

[00122] Thus, a further aspect of the disclosure is a pharmaceutical composition comprising one or more of the compounds disclosed herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. Further provided herein is a compound of the disclosure, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition described herein, for use as a medicament.

[00123] Provided herein as Embodiment 215 is pharmaceutical composition comprising the compound or salt of any one of Embodiments 1 to 214, and a pharmaceutically acceptable excipient. METHODS OF USE

[00124] The compounds described herein (such as compounds of Formula (I). Formula (I-B), Fonnula (II), Formula (H-B), Formula (III), Formula (III-B), Formula (IV), Formula (IV-B), Fonnula (V), Formula (V-B), Formula (VI) or Formula (VLB), or compounds listed in Table 1, Table 2 or compounds of Embodiments 1-214, or a pharmaceutically acceptable salt of any of the foregoing) can competitively bind to KRAS G12D, G12V, G12A, G12S, G12R. G13D, Q61H. Q61L, Q61R or G12C or a mutated KRAS comprising one or more mutations selected from G12D, G12V. G12A, G12S, G12R, G13D, Q61H, Q61L, Q61R and G12C. In some cases, the compounds described herein can act as inhibitors of KRAS G12D. In some cases, the compounds described herein can act as inhibitors of KRAS G12V. In some cases, the compounds described herein can act as inhibitors of KRAS G12A. In some cases, the compounds described herein can act as inhibitors of KRAS G12S. In some cases, the compounds described herein can act as inhibitors of KRAS G13D. In some cases, the compormds described herein can act as inhibitors of KRAS Q61H. In some cases, the compounds described herein can act as inhibitors of KRAS Q61R. In some cases, the compounds described herein can act as inhibitors of KRAS Q61L. In some cases, the compounds described herein can act as inhibitors of KRAS G12R. In some cases, the compounds described herein can act as inhibitors of KRAS G12C. Without intending to be bound by any particular theory, the compormds of the disclosure can, in some cases, inhibit KRAS G12D, G12V, G12A, G12S, G12R, G13D, Q61H, Q61L, Q61R or G12C, leading to an improvement in conditions or symptoms mediated by a KRAS G12D, G12V, G12A, G12S, G12R, G13D, Q61H, Q61L, Q61R or G12C mutation (e.g., reduction in tumor size).

[00125] Besides being useful for human treatment, the compounds provided herein may be useful for veterinary treatment of companion animals, exotic animals, and farm animals, including mammals, rodents, and the like. For example, animals including horses, dogs, and cats may be treated with compounds provided herein.

[00126] In several embodiments, as disclosed elsewhere herein, a method of treating a patient is provided. In several embodiments, the method comprises administering a therapeutic amount of a compound or salt disclosed herein (such as compounds of Formula (I), Formula (LB), Formula (II), Formula (II-B), Formula (III), Formula (III-B), Formula (IV), Formula (IV-B), Formula (V), Formula (V-B), Formula (VI) or Formula (VI-B), or compounds listed in Table 1, Table 2 or compounds of Embodiments 1-214, or a pharmaceutically acceptable salt of any of the foregoing) to a patient.

[00127] Another aspect of the disclosure provides methods of using the compounds disclosed herein, or pharmaceutically acceptable salts thereof, or the pharmaceutical compositions of the present disclosure to treat disease conditions, including but not limited to conditions mediated by a KRAS G12D, G12V, G12A, G12S, G12R, G13D, Q61H, Q61L, Q61R or G12C mutation.

[00128] Another aspect of the disclosure provides a compound or salt disclosed herein (such as compounds of Formula (I), Formula (I-B), Formula (II), Formula (II-B), Formula (III), Formula (III-B), Formula (IV), Formula (TV-B), Formula (V), Formula (V-B), Formula (VI) or Formula (VI-B). or compounds listed in Table 1, Table 2 or compounds of Embodiments 1-214. or a pharmaceutically acceptable salt of any of the foregoing), or a pharmaceutical composition disclosed herein, for use in treating cancer.

[00129] Yet another aspect of the disclosure provides a compound disclosed herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition disclosed herein, in the preparation of a medicament for treating cancer.

[00130] A further aspect provided by the disclosure is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition disclosed herein.

[00131] In some cases, the cancer disclosed herein is non-small cell lung cancer, small bowel cancer, appendiceal cancer, colorectal cancer, cancer of unknown primary', endometrial cancer, mixed cancer types, pancreatic cancer, hepatobiliary cancer, small cell lung cancer, cervical cancer, genn cell cancer, ovarian cancer, gastrointestinal neuroendocrine cancer, bladder cancer, myelodysplastic / myeloproliferative neoplasms, head and neck cancer, esophagogastric cancer, soft tissue sarcoma, mesothelioma, thyroid cancer, leukemia, or melanoma. In some cases, the cancer is non-small cell lung cancer, colorectal cancer, pancreatic cancer, appendiceal cancer, endometrial cancer, esophageal cancer, cancer of unknown primary', ampullary cancer, gastric cancer, small bowel cancer, sinonasal cancer, bile duct cancer, or melanoma. In some cases, the cancer is non-small cell lung cancer. In some cases, the cancer is colorectal cancer. In some cases, the cancer is pancreatic cancer.

[00132] Provided herein as Embodiment 216 is a method of treating cancer in a subject in need of treatment, the method comprising administering to tire subject a therapeutically effective amount of the compound or salt of any one of Embodiments 1 to 214. or the composition of Embodiment 215.

[00133] Provided herein as Embodiment 217 is a method of treating cancer in a subject in need diereof, the method comprising administering to the subject a therapeutically effective amount of the compound according of any one of Embodiments 1 to 214, or the composition of Embodiment 215, wherein one or more cells express KRAS G12D mutant protein.

[00134] Provided herein as Embodiment 218 is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound according of any one of Embodiments 1 to 214, or the composition of Embodiment 215, wherein one or more cells express KRAS G12V mutant protein.

[00135] Provided herein as Embodiment 219 is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound according of any one of Embodiments 1 to 214, or the composition of Embodiment 215. wherein one or more cells express KRAS G12A mutant protein.

[00136] Provided herein as Embodiment 220 is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound according of any one of Embodiments 1 to 214, or the composition of Embodiment 215, wherein one or more cells express KRAS G12S mutant protein.

[00137] Provided herein as Embodiment 221 is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound according of any one of Embodiments 1 to 214. or the composition of Embodiment 215, wherein one or more cells express KRAS G13D mutant protein.

[00138] Provided herein as Embodiment 222 is a method of treating cancer in a subject in need diereof, the method comprising administering to the subject a therapeutically effective amount of the compound according of any one of Embodiments 1 to 214. or the composition of Embodiment 215, wherein one or more cells express KRAS Q61H mutant protein.

[00139] Provided herein as Embodiment 223 is a method of treating cancer in a subject in need diereof, the method comprising administering to the subject a therapeutically effective amount of the compound according of any one of Embodiments 1 to 214, or the composition of Embodiment 215, wherein one or more cells express KRAS Q61L mutant protein.

[00140] Provided herein as Embodiment 224 is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound according of any one of Embodiments 1 to 214, or the composition of Embodiment 215. wherein one or more cells express KRAS Q61R mutant protein.

[00141] Provided herein as Embodiment 225 is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound according of any one of Embodiments 1 to 214, or the composition of Embodiment 215, wherein one or more cells express KRAS G12R mutant protein.

[00142] Provided herein as Embodiment 226 is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound according of any one of Embodiments 1 to 214, or the composition of Embodiment 215, wherein one or more cells express KRAS G12C mutant protein.

[00143] Provided herein as Embodiment 1T1 is the method according to any one of embodiments 216-226. wherein the cancer is non-small cell lung cancer, small bowel cancer, appendiceal cancer, colorectal cancer, cancer of unknown primary, endometrial cancer, mixed cancer types, pancreatic cancer, hepatobiliary cancer, small cell lung cancer, cervical cancer, germ cell cancer, ovarian cancer, gastrointestinal neuroendocrine cancer, bladder cancer, myelodysplastic / myeloproliferative neoplasms, head and neck cancer, esophagogastric cancer, soft tissue sarcoma, mesothelioma, thyroid cancer, leukemia, or melanoma.

[00144] Provided herein as Embodiment 228 is the method according to Embodiment 1T1. wherein the cancer is non-small cell lung cancer, colorectal cancer, pancreatic cancer, appendiceal cancer, endometrial cancer, esophageal cancer, cancer of unknown primary', ampullary cancer, gastric cancer, small bowel cancer, sinonasal cancer, bile duct cancer, or melanoma. Provided herein as Embodiment 229 is the method according to Embodiment 228, wherein the cancer is non-small cell lung cancer. Provided herein as Embodiment 230 is the method according to Embodiment 228 wherein the cancer is colorectal cancer. Provided herein as Embodiment 231 is the method according to Embodiment 228. wherein the cancer is pancreatic cancer.

[00145] Provided herein as Embodiment 232 is the compound or salt of any one of Embodiments 1 to 214, or the pharmaceutical composition of Embodiment 215 for use as a medicament.

[00146] Provided herein as Embodiment 233 is the compound or salt of any one of Embodiments 1 to 214, or the pharmacal composition of Embodiment 215 for use in the treatment of cancer.

[00147] Provided herein as Embodiment 234 is the use of the compound or salt of any one of Embodiments 1 to 214, or the pharmaceutical composition of Embodiment 215, for the manufacture of a medicament for the treatment of cancer.

[00148] Provided herein as Embodiment 235 is the use of the compound or salt of any one of Embodiments 232 to 234, wherein the cancer is cancer is non-small cell lung cancer, small bowel cancer, appendiceal cancer, colorectal cancer, cancer of unknown primary, endometrial cancer, mixed cancer types, pancreatic cancer, hepatobiliary cancer, small cell lung cancer, cervical cancer, germ cell cancer, ovarian cancer, gastrointestinal neuroendocrine cancer, bladder cancer, myelodysplastic / myeloproliferative neoplasms, head and neck cancer, esophagogastric cancer, soft tissue sarcoma, mesothelioma, thyroid cancer, leukemia, or melanoma, or any combination of the foregoing.

[00149] Provided herein as Embodiment 236 is the method according to Embodiment 235, wherein the cancer is non-small cell lung cancer, colorectal cancer, pancreatic cancer, appendiceal cancer, endometrial cancer, esophageal cancer, cancer of unknown primary’, ampullary cancer, gastric cancer, small bowel cancer, sinonasal cancer, bile duct cancer, or melanoma. Provided herein as Embodiment 237 is the method according to Embodiment 236, wherein the cancer is non-small cell lung cancer. Provided herein as Embodiment 238 is the method according to Embodiment 236, wherein the cancer is colorectal cancer. Provided herein as Embodiment 239 is the method according to Embodiment 236, wherein the cancer is pancreatic cancer. Combination therapy

[00150] The present disclosure also provides methods for combination therapies in which an agent known to modulate other pathways, or other components of the same pathway, or even overlapping sets of target enzymes are used in combination with a compound or salt disclosed herein (such as compounds of Formula (I). Formula (I-B), Formula (II), Formula (II-B), Formula (III), Formula (III-B), Formula (IV), Formula (IV-B), Formula (V). Formula (V-B), Formula (VI) or Formula (VLB), or compounds listed in Table 1, Table 2 or compounds of Embodiments 1-214. or a pharmaceutically acceptable salt of any of the foregoing). In one aspect, such therapy includes but is not limited to the combination of one or more compounds of the disclosure with chemotherapeutic agents, therapeutic antibodies, and radiation treatment, to provide a synergistic or additive therapeutic effect. See, e.g., See, e.g., U.S. Patent No. 10,519,146 B2, issued December 31, 2019; specifically, the sections from column 201 (line 37) to column 212 (line 46) and column 219 (line 64) to column 220 (line 39), which are herewith incorporated by reference.

[00151] The compounds of the disclosure can be administered simultaneously, separately, or sequentially with an effective amount of a second compound in any of the methods described herein. In some cases, the second compound is wherein the second compound is an Aurora kinase A inhibitor, AKT inhibitor, arginase inhibitor, CDK4 / 6 inhibitor, ErbB famity inhibitor, ERK inhibitor, FAK inhibitor. FGFR inhibitor, glutaminase inhibitor, IGF-1R inhibitor, KIF18A inhibitor, MCL-1 inhibitor, MEK inhibitor. mTOR inhibitor, PD-1 inhibitor, PD-L1 inhibitor, PI3K inhibitor, Raf kinase inhibitor, SHP2 inhibitor, S0S1 inhibitor, Src kinase inhibitor, or one or more chemotherapeutic agent. In some cases, the second compound is administered as a pharmaceutically acceptable salt. In some cases, the second compound is administered as a pharmaceutical composition comprising the second compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.

[00152] Aurora Kinase A Inhibitors. In some cases, the compounds of the disclosure can be administered simultaneously, separately, or sequentially with an effective amount of a second compound, wherein the second compound is an Aurora kinase A inhibitor.

[00153] Exemplary Aurora kinase A inhibitors for use in the methods provided herein include, but are not limited to, alisertib, cenisertib. danusertib, tozasertib, LY3295668 ((2R,4R)-l-[(3-chloro-2-fluorophenyl)methyl]-4-[[3-fluoro-6-[(5-methyl-lH-pyrazol-3-yl)amino]pyridin-2-yl]methyl]-2-methylpiperidine-4-carboxylic acid), ENMD-2076 (6-(4-methylpiperazin-l-yl)-N-(5-methyl-lH-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine), TAK-901 (5-(3-ethylsulfonylphenyl)-3,8-dimcthyl-N-(l-mcthylpipcridin-4-yl)-9H-pyrido[2,3-b]indolc-7-carboxamidc), TT-00420 (4-[9-(2-chlorophenyl)-6-methyl-2,4,5,8,12-pentazatricyclo[8.4.0.03,7]tetradeca-l(14),3,6,8,10,12-hexaen-13-yl]morpholine), AMG 900 (N-[4-[3-(2-aminopyrimidin-4-yl)pyridin-2-yl]oxyphenyl]-4-(4-methylthiophen-2-yl)phthalazin-l-amine), MLN8054 (4-[[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid), PF-03814735 (N-[2-[(lR,8S)-4-[[4-(cy clobuty lamino)-5 -(trifluoromethy l)pyrimidin-2-y 1] amino] -11 -azatricy clo[6.2.1.02,7]undeca-2(7),3,5-trien-ll-yl]-2-oxoethyl]acetamide), SNS-314 (l-(3-chlorophenyl)-3-[5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethy 1] -1,3 -thiazol-2-yl]urea), CYC116 (4-methy 1-5 -[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]-l,3-thiazol-2-amine), TAS-119, BI 811283, and TTP607.

[00154] AKT Inhibitors. In some eases, the compounds of the disclosure can be administered simultaneously, separately, or sequentially with an effective amount of a second compound, wherein die second compound is an AKT inhibitor.

[00155] Exemplary AKT inhibitors for use in the methods provided herein include, but are not limited to, afuresertib, capivasertib, ipatasertib, uprosertib, BAY1125976 (2-[4-(l- aminocyclobutyl)phenyl]-3-phenylimidazo[l,2-b]pyridazine-6-carboxamide), ARQ 092 (3-[3-[4-(l-aminocy clobuty l)phenyl]-5-phenylimidazo[4,5-b]pyridin-2-yl]pyridin-2-amine), MK2206 (8-[4-(l-aminocyclobutyl)phenyl]-9-phenyl-2H-[l,2.4]triazolo[3,4-f|[l,6]naphthyridin-3-one), SR13668 (indolo[2,3-b]carbazole-2,10-dicarboxylic acid, 5,7-dihydro-6-methoxy-, 2,10-diethyl ester), ONC201 (ll-benzyl-7-[(2-methylphenyl)methyl]-2,5,7,ll-tetrazatricyclo[7.4.0.02,6]trideca-l(9),5-dien-8-one), ARQ 751 (N-(3-aminopropyl)-N-[(lR)-l-(3-anilino-7-chloro-4-oxoquinazolin-2-yl)but-3-ynyl]-3-chloro-2-fluorobenzamide), RX-0201, and LY2780301.

[00156] Arginase Inhibitors. In some cases, the compounds of the disclosure can be administered simultaneously, separately, or sequentially with an effective amount of a second compound, wherein the second compound is an Arginase inhibitor. Exemplary arginase inhibitors for use in the methods provided herein include, but are not limited to, munidargistat and CB 280.

[00157] CDK4 / 6 Inhibitors. In some cases, the compounds of the disclosure can be administered simultaneously, separately, or sequentially with an effective amount of a second compound, wherein die second compound is an CDK4 / 6 inhibitor. The term “CDK 4 / 6” as used herein refers to cyclin dependent kinases (“CDK”) 4 and 6, which are members of the mammalian serine / threonine protein kinases. The term “CDK 4 / 6 inhibitor” as used herein refers to a compound that is capable of negatively modulating or inhibiting all or a portion of the enzymatic activity' of CDK 4 and / or 6.

[00158] Exemplary CDK 4 / 6 inhibitors for use in the methods provided herein include, but are not limited to, abemaciclib, palbociclib. ribociclib, trilaciclib, and PF-06873600 ((pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(difluoromethyl)-8-[(lR,2R)-2-hydroxy-2-methylcyclopentyl]-2-[[l-(methylsulfony 1)-4-piperidinyl]amino]).

[00159] ErbB Family Inhibitors. In some cases, the compounds of the disclosure can be administered simultaneously, separately, or sequentially with an effective amount of a second compound, wherein the second compound is an ErbB Family inhibitor. The term “ErbB family” as used herein refers to a member of a mammalian transmembrane protein tyrosine kinase family including: ErbBl (EGFR HER1), ErbB2 (HER2), ErbB3 (HER3), and ErbB4 (HER4). The term “ErbB family inhibitor” as used herein refers to an agent, e.g., a compound or antibody, that is capable of negatively modulating or inhibiting all or a portion of the activity of at least one member of the ErbB family. The modulation or inhibition of one or more ErbB tyrosine kinase may occur through modulating or inhibiting kinase enzy matic activity of one or more ErbB family member or by blocking homodimcrization or hctcrodimcrization of ErbB family members.

[00160] In one embodiment, the ErbB family inhibitor is an EGFR inhibitor, e.g., an anti-EGFR antibody. Exemplary anti-EGFR antibodies for use in the methods provided herein include, but are not limited to, zalutumumab, nimotuzumab, matuzumab, necitumumab. panitumumab. and cetuximab.

[00161] In another embodiment the ErbB family inhibitor is a HER2 inhibitor, e.g., an anti-HER2 antibody. Exemplary anti-HER-2 antibodies for use in the methods provided herein include, but are not limited to, pertuzumab, trastuzumab, and trastuzumab emtansine.

[00162] In yet another embodiment the ErbB family inhibitor is a HER3 inhibitor, e.g., an anti-HER3 antibody, such as HMBD-001 (Hummingbird Bioscience).

[00163] In one embodiment, the ErbB family inhibitor is a combination of an anti-EGFR antibody and anti-HER2 antibody.

[00164] In one embodiment, the ErbB family inhibitor is an irreversible inhibitor. Exemplary irreversible ErbB family inhibitors for use in the methods provided herein include, but are not limited to, afatinib, dacomitinib, canertinib. poziotinib, AV 412 ((N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[3 -methyl-3-(4-methy 1-1 -piperaziny 1)-1 -butyn-1 -y 1] -6-quinazolinyl] -2-propenamide)), PF 6274484 ((N-[4-[(3-chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-2-propenamide), and HKI 357 ((E)-N-[4-[3-chloro-4-[(3-fluorophenyl)methoxy ]anilino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enainide).

[00165] In one embodiment, the ErbB family inhibitor is a reversible inhibitor. Exemplary reversible ErbB family inhibitors for use in the methods provided herein include, but are not limited to erlotinib, gefitinib, sapitinib, varlitinib, tarloxotinib, TAK-285 (N-(2-(4-((3-chloro-4-(3-(trifluoromethyl)phenoxy)phenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl)ethyl)-3-hydroxy-3-methylbutanamide), AEE788 ((S)-6-(4-((4-ethylpiperazin-l-yl)methyl)phenyl)-N-(l-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine), BMS 599626 ((3S)-3-morpholinyhnethyl-[4-[[l-[(3- fluorophcny l)mcthyl] -1 H-indazol-5-yl] amino] -5-mcthylpyrrolo[2,1 -f| [ 1,2,4]triazin-6-yl] -carbamate), and GW 583340 (N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[2-[(2- methylsulfony lethy lamino)methy 1] -1,3 -thiazol-4-yl] quinazolin-4-amine).

[00166] ERK Inhibitors. In some cases, the compounds of the disclosure can be administered simultaneously, separately, or sequentially with an effective amount of a second compound, wherein the second compound is an ERK inhibitor.

[00167] Exemplary ERK inhibitors for use in the methods provided herein include, but are not limited to, ulixertinib, ravoxertinib, CC-90003 (N-[2-[[2-[(2-methoxy-5-methylpyridin-4-yl)amino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]-5-methylphenyl]prop-2-enamide). LY3214996 (6,6-dimethyl-2-[2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-5-(2-morpholin-4-y lethy l)thieno[2,3-c]pyrrol-4-one), KO-947 (1.5.6,8-tetrahydro-6-(phenylmethyl)-3-(4-pyridinyl)-7H-pyrazolo[4,3-g]quinazolin-7-one), ASTX029, LTT462, and JSI-1187.

[00168] FAK Inhibitors. In some cases, the compounds of the disclosure can be administered simultaneously, separately, or sequentially with an effective amount of a second compound, wherein the second compound is an FAK inhibitor.

[00169] Exemplary' FAK inhibitors for use in the methods provided herein include, but are not limited to. GSK2256098 (2-[[5-chloro-2-[(5-methyl-2-propan-2-ylpyrazol-3-yl)amino]pyridin-4-yl]amino]-N-methoxybenzamide), PF-00562271 (N-methyl-N-[3-[[[2-[(2-oxo-l,3-dihydroindol-5-yl)amino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]methyl]pyridin-2-yl]methanesulfonamide), VS-4718 (2-[[2-(2-methoxy-4-morpholin-4-ylanilino)-5-(trifluoromethyl)pyridin-4-yl] amino]-N-methylbenzamide), and APG-2449.

[00170] FGFR Inhibitors. In some cases, the compounds of the disclosure can be administered simultaneously, separately, or sequentially with an effective amount of a second compound, wherein the second compound is an FGFR inhibitor.

[00171] Exemplary' FGFR inhibitors for use in the methods provided herein include, but are not limited to, futibatinib, pemigatinib, ASP5878 (2-[4-[[5-[(2,6-difluoro-3,5- dimethoxyphenyl)methoxy]pyrimidin-2-yl]amino]pyrazol-l-yl]ethanol), AZD4547 (N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-lH-pyrazol-3-yl]-4-[(3S,5R)-3,5-dimetliylpiperazin-l-yl]benzamide), debio 1347 ([5-amino-l-(2-methyl-3H-benzimidazol-5-yl)pyrazol-4-yl]-(lH-indol-2-yl)methanone), INCB062079, H3B-6527 (N-[2-[[6-[(2,6-dichloro-3,5-dimethoxyphenyl)carbamoyl- methy lamino]py rirnidin-4-y 1] amino] -5 -(4-ethyIpiperazin-1 -yl)pheny l]prop-2-enamide), ICP-105, CPL304110, HMPL-453, and HGS1036.

[00172] Glutaminase Inhibitors. In some cases, the compounds of the disclosure can be administered simultaneously, separately, or sequentially with an effective amount of a second compound, wherein the second compound is a glutaminase inhibitor.

[00173] Exemplary glutaminase inhibitors for use in the methods provided herein include, but are not limited to, telaglenastat. IPN60090, and OP 330.

[00174] IGF-1R Inhibitors. In some cases, the compounds of the disclosure can be administered simultaneously, separately, or sequentially with an effective amount of a second compound, wherein the second compound is an IGF-1R inhibitor.

[00175] Exemplary' IGF-1R inhibitors for use in the methods provided herein include, but are not limited to. eixutumumab, dalotuzumab, linsitinib, ganitumab, robatumumab, BMS-754807 ((2S)-l-[4-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]pyrrolo[2,l-f][l,2,4]triazin-2-yl]-N-(6-fhioropyridin-3-yl)-2-methylpyrrolidine-2-carboxamide), KW-2450 (N-[5-[[4-(2-hydroxyacetyl)piperazin-l-yl]methyl]-2-[(E)-2-(lH-indazol-3-yl)ethenyl]phenyl]-3-methylthiophene-2-carboxamide). PL225B, AVE1642, and BIIB022.

[00176] KIF18A Inhibitors. In some cases, the compounds of the disclosure can be administered simultaneously, separately, or sequentially with an effective amount of a second compound, wherein the second compound is a KIF18A inhibitor.

[00177] Exemplary' KIF18A inhibitors for use in the methods provided herein include, but are not limited to, the inhibitors disclosed in US 2020 / 0239441, WO 2020 / 132649, WO 2020 / 132651, and WO 2020 / 132653, each of which is herewith incorporated by reference in its entirety'.

[00178] MCL-1 Inhibitors. In some cases, the compounds of the disclosure can be administered simultaneously, separately, or sequentially with an effective amount of a second compound, wherein the second compound is an MCL-1 inhibitor.

[00179] Exemplary' MEK inhibitors for use in the methods provided herein include, but are not limited to. murizatoclax. tapotoclax, AZD 5991 ((3aR)-5-chloro-2.11,12,24,27,29-hexahydro-2.3.24,33-tetramethyl-22H-9,4.8-(metheniminomethyno)-14.20:26.23-dimetheno-10H,20H-pyrazolo[4,3-l][2,15,22,18.19]benzoxadithiadiazacyclohexacosine-32-carboxylic acid), MIK 665 ((aR)-a-[[(5S)-5-[3-Chloro-2-methyl-4-[2-(4-methyl-l-piperazinyl)ethoxy]phenyl]-6-(4- fluorophenyl)thieno[2,3-d]py rimidin-4-yl]oxy] -2-[[2-(2-methoxypheny 1)-4-pyrimidinyl]methoxy]benzenepropanoic acid), and ABBV-467.

[00180] MEK Inhibitors. In some cases, the compounds of tire disclosure can be administered simultaneously, separately, or sequentially with an effective amount of a second compound, wherein the second compound is an MEK inhibitor.

[00181] Exemplary MEK inhibitors for use in the methods provided herein include, but are not limited to, trametinib. cobimetinib, selumetinib, pimasertib, refametinib, PD-325901 (N-[(2R)-2,3-dihydroxypropoxy]-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzamide), AZD8330 (2-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-l,5-dimethyl-6-oxopyridine-3-carboxamide). GDC-0623 (5-(2-fluoro-4-iodoanilino)-N-(2-hydroxy ethoxy)imidazo[l,5-a]pyridine-6-carboxamide), RO4987655 (3,4-difluoro-2-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-5-[(3-oxooxazinan-2-yl)methyl]benzamide), TAK-733 (3-[(2R)-2,3-dihydroxypropyl]-6-fluoro-5-(2-fluoro-4-iodoanilino)-8-methylpyrido[2,3-d]pyrimidine-4,7-dione), PD0325901 (N-[(2R)-2,3-dihydroxypropoxy]-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzamide), CI-1040 (2-(2-chloro-4-iodophenylamino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide), PD318088 (5-bromo-N-(2,3-dihydroxypropoxy)-3.4-difhioro-2-(2-fluoro-4-iodophenylamino)benzamide), PD98059 (2-(2-amino-3-methoxypheny 1)-4H-chromen-4-one), PD334581 (N-[5-[3,4-Difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl]-1,3,4-oxadiazol-2-yl]-4-morpholinccthanaminc), FCN-159, CS3006, HL-085, SHR 7390, and WX-554.

[00182] mTOR Inhibitors. In some cases, the compounds of the disclosure can be administered simultaneously, separately, or sequentially with an effective amount of a second compound, wherein the second compound is an mTOR inhibitor.

[00183] Exemplary mTOR inhibitors for use in the methods provided herein include, but are not limited to. everolimus. rapamycin, zotarolimus (ABT-578), ridaforolimus (deforolimus. MK-8669), sapanisertib, buparlisib, pictilisib, vistusertib, dactolisib, Torin-1 (l-(4-(4-propionylpiperazin-l-yl)-3-(trifluoromethyl)cyclohexyl)-9-(quinolin-3-yl)benzo[h][l,6]naphthyridin-2(lH)-one), GDC-0349 ((S)-1-ethy 1-3-(4-(4-(3-methy lmorpholino)-7-(oxetan-3-y 1)-5.6.7.8-tetrahydropyrido[3.4-d]pyrimidin-2-yl)phenyl)urea), and VS-5584 (SB2343. (5-(8-methyl-2-morpholin-4-yl-9-propan-2-ylpurin-6-yl)pyrimidin-2-amine).

[00184] PD-1 Inhibitors. In some cases, the compounds of the disclosure can be administered simultaneously, separately, or sequentially with an effective amount of a second compound, wherein the second compound is a PD-1 inhibitor.

[00185] Exemplary PD-1 inhibitors for use in the methods provided herein include, but are not limited to. pembrolizumab. nivolumab, cemiplimab, spartalizumab (PDR001), camrelizumab (SHR1210), sintilimab (IBI308), tislelizumab (BGB-A317), toripalimab (JS 001), dostarlimab (TSR-042, WBP-285). INCMGA00012 (MGA012). AMP-224, AMP-514, and the anti-PD-1 antibody as described in US 10,640,504 B2 (the “Anti-PD-1 Antibody A,” column 66, line 56 to column 67, line 24 and column 67, lines 54-57), which is incorporated herein by reference.

[00186] PD-L1 Inhibitors. In some cases, the compounds of the disclosure can be administered simultaneously, separately, or sequentially with an effective amount of a second compound, wherein the second compound is a PD-L1 inhibitor.

[00187] Exemplary PD-L1 inhibitors for use in the methods provided herein include, but are not limited to, atezolizumab, avelumab, durvalumab. ZKAB001, TG-1501, SHR-1316. MSB2311, MDX-1105, KN035, IMC-001, HLX20. FAZ053, CS1001. CK-301, CBT-502, BGB-A333, BCD-135, and A167.

[00188] PI3K Inhibitors. In some cases, the compounds of the disclosure can be administered simultaneously, separately, or sequentially with an effective amount of a second compound, wherein the second compound is a PI3K inhibitor.

[00189] Exempla^ PI3K inhibitors for use in the methods provided herein include, but are not limited to, idelalisib, copanlisib, duvelisib, alpelisib, taselisib, perifosine, buparlisib. umbralisib, pictilisib, dactolisib, voxtalisib. sonolisib, tenalisib, serabelisib, acalisib, CUDC-907 (N-hydroxy-2-[[2-(6-methoxypyridin-3-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxamide), ME-401 (N-[2-methyl-l-[2-(l-methylpiperidin-4-yl)phenyl]propan-2-yl] -4-(2 -methylsulfonylbenzimidazol-l-yl)-6-morpholin-4-yl-1.3,5-triazin-2-amine), IPI-549 (2-amino-N-[(lS)-l-[8-[2-(l-methylpyrazol-4-yl)ethynyl]-l-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[l,5-a]pyrimidine-3-carboxamide). SF1126 ((2S)-2-[[(2S)-3-carboxy-2-[[2-[[(2S)-5-(diaminomethylideneamino)-2-[[4-oxo-4-[[4-(4-oxo-8-phenyIchromen-2-yl)morpholin-4-ium-4-yl]methoxy]butanoyl]amino]pentanoyl]amino]acetyl]amino]propanoyl]ammo]-3 -hydroxypropanoate). XL 147 (N-[3 -(2,1,3 -benzothiadiazol-5 -ylamino)quinoxalin-2-yl]-4-methylbenzenesulfonamide), GSK1059615 ((5Z)-5-[(4-pyridin-4-ylquinolin-6-yl)methylidene]-l,3-thiazolidine-2,4-dione), and AMG 319 (N-[(lS)-l-(7-fluoro-2-pyridin-2-ylquinolin-3-yl)ethyl]-7H-purin-6-amine).

[00190] Raf Kinase Inhibitors. In some cases, the compounds of the disclosure can be administered simultaneously, separately, or sequentially with an effective amount of a second compound, wherein the second compound is a Raf Kinase inhibitor. The term “RAF kinase” as used herein refers to a member of a mammalian serine / threonine kinases composed of three isofonns (C-Raf. B-Raf and A-Raf) and includes homodimers of each isoform as well as heterodimers between isoforms, e.g.. C-Raf / B-Raf heterodimers. The term “Raf kinase inhibitor” as used herein refers to a compound that is capable of negatively modulating or inhibiting all or a portion of the enzymatic activity of one or more member of the Raf family kinases or is capable of disrupting Raf homodimer or heterodimer formation to inhibit activity.

[00191] Exemplary Raf kinase inhibitors include, but is not limited to, encorafenib, sorafenib, lifirafenib, vemurafenib, dabrafenib, PLX-8394 (N-(3-(5-(2-cyclopropylpyrimidin-5-yl)-3a,7a-dihy dro-lH-pyrrolo[2,3-b]pyridine-3-carbony 1)-2,4-difluorophenyl)-3-fluoropyrrolidine-l-sulfonamide), Raf-709 (N-(2-methyl-5,-morpholino-6‘-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluorometh}'l)benzamide), LXH254 (N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide), LY3009120 (1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea), Tak-632 (N-(7-cyano-6-(4-fluoro-3-(2-(3- (trifluoromethyl)phenyl)acetamido)phenoxy)benzo[d]thiazol-2-yl)cyclopropanecarboxamide), CEP-32496 (1-(3-((6.7-dimethoxyquinazolin-4-yl)oxy)pheny 1)-3-(5-(1, l,l-trifluoro-2-methy lpropan-2-yl)isoxazol-3-yl)urea). CCT196969 (1 -(3-(tert-butyl)-1 -phenyl-1 H-pyrazol-5-yl)-3-(2-fluoro-4-((3-oxo-3,4-dihydropyrido[2,3-b]pyrazin-8-yl)oxy)phenyl)urea). and RO5126766 (N-[3-fluoro-4-[[4-methyl-2-oxo-7-(2-pyrimidinyloxy)-2H-l-benzopyran-3-yl]methyl]-2-pyridinyl]-N'-methyl-sulfamide).

[00192] SHP2 Inhibitors. In some cases, the compounds of the disclosure can be administered simultaneously, separately, or sequentially with an effective amount of a second compound, wherein the second compound is a SHP2 inhibitor.

[00193] Exemplary' SHP2 inhibitors for use in the methods provided herein include, but arc not limited to, SHP-099 (6-(4-amino-4-methylpiperidin-l-yl)-3-(2,3-dichlorophenyl)pyrazin-2-amine dihydrochloride), RMC-4550 ([3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-(2,3-dichlorophenyl)-5-methylpyrazin-2-yl]methanol), TNO155, (3S.4S)-8-[6-amino-5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine), and vociprotafib (RMC-4630 - Revolution Medicine).

[00194] In another embodiment, exemplar}' SHP2 inhibitors for use in the methods provided herein include, but are not limited to, 3-[(lR,3R)-l-amino-3-methoxy-8-azaspiro[4.5]dec-8-yl]-6-(2,3-dichlorophenyl)-5-methyl-2-pyrazinemethanol (CAS 2172651-08-8), 3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl]-6-[(2,3-dichlorophenyl)thio]-5-methy 1-2-pyrazinemethanol (CAS 2172652-13-8), 3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl]-6-[[3-chloro-2-(3-hydroxy-l-azetidinyl)-4-pyridinyl]thio]-5-meth}'l-2-pyrazinemethanol (CAS 2172652-38-7), and 6-[(2-amino-3-chloro-4-pyridinyl)thio]-3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl]-5-methy 1-2-pyrazinemethanol (CAS 2172652-48-9).

[00195] In another embodiment, exemplary SHP2 inhibitors for use in the methods provided herein include, but are not limited to, l-[5-(2,3-dichlorophen}'l)-6-methylimidazo[l,5-a]pyrazin-8-yl]-4-methyl-4-piperidinamine (CAS 2240981-75-1), (lR)-8-[5-(2,3-dichlorophenyl)-6-methylimidazo[l,5-a]pyrazin-8-yl]-8-azaspiro[4.5]dccan-l-aminc (CAS 2240981-78-4), (3S,4S)-8-[7-(2,3- dichlorophenyl)-6-methylpyrazolo[l,5-a]pyrazin-4-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine (CAS 2240982-45-8), (3S,4S)-8-[7-[(2-amino-3-chloro-4-pyridinyl)thio]pyrazolo[l,5-a]pyrazin-4-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine (CAS 2240982-57-2), 4-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl]-7-(2,3-dichlorophenyl)-6-methyl-pyrazolo[l,5-a]pyrazine-2-methanol (CAS 2240982-69-6), 7-[(2-amino-3-chloro-4-pyridinyl)thio]-4-[(3S.4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl]-6-methyl-pyrazolo[l,5-a]pyrazine-2-methanol (CAS 2240982-73-2), and (3S,4S)-8-[7-[(2-amino-3-chloro-4-pyridinyl)thio]-6-methylpyrazolo[l,5-a]pyrazin-4-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine (CAS 2240982-77-6).

[00196] In another embodiment, exemplary SHP2 inhibitors for use in the methods provided herein include, but are not limited to 3-[(lR)-l-amino-8-azaspiro[4.5]dec-8-yl]-6-(2,3-dichloropheny 1)-5-hydroxy-2-pyridinemethanol (CAS 2238840-54-3), 3-[(lR)-l-amino-8-azaspiro[4.5]dec-8-yl]-6-[(2,3-dichlorophenyl)thio]-5-hydroxy-2-pyridinemethanol (CAS 2238840-56-5), 5-[(lR)-l-amino-8-azaspiro[4.5]dec-8-yl]-2-(2,3-dichlorophenyl)-3-pyridinol (CAS 2238840-58-7), 3-[(lR)-l-amino-8-azaspiro[4.5]dec-8-yl]-6-(2,3-dichlorophenyl)-5-methy 1-2-pyridinemethanol (CAS 2238840-60-1), (lR)-8-[6-(2,3-dichlorophenyl)-5-methyl-3-pyridmyl]-8-azaspiro[4.5]decan-l-amine (CAS 223884062-3). 3-[(lR)-l-amino-8-azaspiro[4.5]dec-8-yl]-6-[(2,3-dichlorophenyl)thio]-5-methyl-2-pyridinemethanol (CAS 2238840-63-4), (lR)-8-[6-[(2,3-dichlorophenyl)thio]-5-methyl-3-pyridinyl]-8-azaspiro[4.5]decan-l-amine (CAS 2238840-64-5), 5-(4-amino-4-methyl-l-piperidinyl)-2-[(2,3-dichlorophenyl)thio]-3-pyridinol (CAS 2238840-65-6), 5-[(lR)-l-amino-8-azaspiro[4.5]dec-8-yl]-2-[(2.3-dichlorophenyl)thio]-3-pyridinol (CAS 2238840-66-7). 6-[(2-ammo-3-chloro-4-pyridinyl)thio]-3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl]-5-hydroxy-2-pyridinemethanol (CAS 2238840-67-8), 3-(4-amino-4-methyl-l-piperidinyl)-6-(2,3-dichlorophenyl)-5-hydroxy-2-pyridinemethanol (CAS 2238840-68-9). 3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl]-6-(2.3-dichlorophenyl)-5-methy 1-2-pyridinemethanol (CAS 2238840-69-0), 6-[(2-amino-3-chloro-4-pyridinyl)thio]-3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl]-5-methyl-2-pyridinemethanol (CAS 2238840-70-3). 3-(4-amino-4-methyl-l-piperidinyl)-6-(2.3-dichlorophenyl)-5-methyl-2-pyridinemethanol (CAS 2238840-71-4), 6-[(2-amino-3-chloro-4-pyridinyl)thio]-3-(4-amino-4-methyl-l-piperidinyl)-2-pyridinemethanol (CAS 2238840-72-5). 5-[(2-amino-3-chloro-4-pyridinyl)thio]-2-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl]-6-methyl-3-pyridinemethanol (CAS 2238840-73-6). 2-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl]-5-(2.3-dichlorophenyl)-6-methyl-3-pyridinemethanol (CAS 2238840-74-7), 3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl]-6-(2.3-dichlorophenyl)-5-hydroxy-2-pyridinemethanol (CAS 2238840-75-8), and 2-[(2-amino-3-chloro-4-pyridyl)sulfanyl]-5-[(3S,4S)-4-amino-3- mcthyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-(hydroxymethyl)pyridin-3-ol.

[00197] In one embodiment, the SHP inhibitor for use in the methods provided herein is 3-[(lR)-l-amino-8-azaspiro[4.5]dec-8-yl]-6-[(2,3-dichlorophenyl)thio]-5-hydroxy-2-pyridinemethanol (CAS 2238840-56-5). In one embodiment, the SHP2 inhibitor for use in the methods provided herein is an inhibitor disclosed in US 10,590,090 B2, US 2020 / 017517 Al, US 2020 / 017511 Al, or WO 2019 / 075265 Al.

[00198] S0S1 Inhibitors. In some cases, the compounds of the disclosure can be administered simultaneously, separately, or sequentially with an effective amount of a second compound, wherein the second compound is a S0S1 inhibitor.

[00199] Exemplary S0S1 inhibitors for use in the methods provided herein include, but are not limited to, BI 3406 (N-[(lR)-l-[3-amino-5-(trifluoromethyl)phenyl]ethyl]-7-methoxy-2-methyl-6-[(3S)-oxolan-3-yl]oxyquinazolin-4-amine), and BI 1701963.

[00200] Src Kinase Inhibitors. In some cases, the compounds of the disclosure can be administered simultaneously, separately, or sequentially with an effective amount of a second compound, wherein the second compound is a Src Kinase inhibitor. The term "Src kinase” as used herein refers to a member of a mammalian nonreceptor Urosine kinase family including: Src. Yes, Fyn. and Fgr (Src A subfamily); Lek. Hck, Blk. and Lyn (SrcB subfamily), and Frk subfamily. The term “Src kinase inhibitor” as used herein refers to a compound that is capable of negatively modulating or inhibiting all or a portion of the enzymatic activity of one or more member of the Src kinases.

[00201] Exemplar,' Src kinase inhibitors for use in the methods provided herein include, but are not limited to. dasatinib, ponatinib. vandetanib, bosutinib, saracatinib, KX2-391 (N-benzyl-2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)acetamide), SU6656 ((Z)-N,N-dimethyl-2-oxo-3-((4,5.6.7-tetrahydro-lH-indol-2-yl)methylene)indoline-5-sulfonamide), PP 1 (l-(tert-butyl)-3-(p-tolyl)-lH-pyrazolo[3,4-d]pyrimidin-4-amine), WH-4-023 (2,6-dimethylphenyl(2.4-dimethoxyphenyl)(2-((4-(4-meth}’lpiperazin-l-yl)phenyl)amino)pyrimidin-4-yl)carbamate), and KX-01 (N-benzy 1-2-(5 -(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)acetamide).

[00202] Chemotherapeutic Agents. In some cases, the compounds of the disclosure can be administered simultaneously, separately, or sequentially with an effective amount of a second compound, wherein the second compound is one or more chemotherapeutic agents.

[00203] Exemplar}' chemotherapeutic agents for use in the methods provided herein include, but are not limited to, leucovorin calcium (calcium folinate), 5-fluorouracil, irinotecan, oxaliplatin, cisplatin, carboplatin, pemetrexed, docetaxel, paclitaxel, gemcitabine, vinorelbine, chlorambucil, cyclophosphamide, and methotrexate. GENERAL SYNTHETIC PROCEDURES

[00204] The compounds provided herein can be synthesized according to the procedures described in this and the following sections. The synthetic methods described herein are merely exemplar}', and die compounds disclosed herein may also be syndiesized by alternate routes utilizing alternative synthetic strategies, as appreciated by persons of ordinary skill in the art. It should be appreciated that the general synthetic procedures and specific examples provided herein are illustrative only and should not be construed as limiting the scope of the present disclosure in any manner.

[00205] Generally, the compounds of Formula (I) can be synthesized according to the following schemes. Variables used in the following schemes are the variables as defined for Formula (I), unless otherwise noted. All starting materials are either commercially available, for example, from Sigma-Aldrich, Combi-Blocks, Strem, Oakwood, TCI America, Fisher, Arcos, Alfa Aesar or known in the art and may be synthesized by employing known procedures using ordinary skill. Starting materials may also be synthesized via the procedures disclosed herein. Suitable reaction conditions, such as solvent, reaction temperature, and reagents, for the Schemes discussed in this section, may be found in die examples provided herein.

[00206] In general, the compounds of Formula (I) can be synthesized according to Schemes I-IV as shown below: Scheme I

[00207] Compounds of Formula (I-A) can be prepared according to Scheme I. In step A. compound (1-1) reacts with an alcohol under strong base such as NaH or Lewis acid in a solvent such as THF / DMF or toluene to give compound (1-2). In step B. compound (1-2) undergoes borylation with a reagent, such as M2 (e.g.. bis(pinacolate)diboron) under Pd catalyzed conditions to give compound (I-3). In step C, compound (1-3) is coupled with a bromide on a pyridopyrimidine to give compound (I-4). This coupling reaction proceeds in a solvent or mixture of solvents such as 2-Me THF and water, and a catalyst such as cataCXium A Pd G3 (CAS No. 1651823-59-4). with or without a base such as potassium phosphate. In step D, compound (1-4) is hydrolyzed to give compound (1-5) using a reagent such as HC1 in dioxane or TFA. In step E. compound (1-5) is cyclized under conditions such as PyBrop or Brop and DIPEA in a solvent such as CH3CN and DMSO to give compounds of Formula (I-A). Scheme II TBSO„ 11-3 C 11-4 1) CDI 2) TBAF D acid ll-A

[00208] Compounds of Formula (II-A) can also be prepared according to Scheme II. In step A, compound (II-l) undergoes SnAt reaction with an optionally substituted cyclic amine or aliphatic amine bearing an alcohol or protected amine in a solvent such as acetonitrile and in the presence of a base such as Hunig’s base to give compound (II-2). In step B, compound (II-2) undergoes SNAr reaction with a nucleophile having the formula R'-L-H in a solvent such as acetonitrile, in the presence of a base such as Hunig’s base to give compound (II-3). In step C. compound (II-3) is coupled with an organometallic reagent or a boronic acid (ester) attached to a ary l or hetereoary I bearing a terminal TBS protected alcohol to give compound (II-4). This coupling reaction proceeds in a solvent or mixture of solvents such as 2-Me THF and water, and a catalyst such as cataCXium A Pd G3 (CAS No. 1651823-59-4), with or without a base such as potassium phosphate. In step D, compound (H-4) is reacted with CDI, followed by treated with a desilyated regent such as TBAF in solvent such as THF to give compounds of Formula (II-5). In step E, compound (II-5) is hydrolyzed to give compound (II-A) using a reagent such as HC1 in dioxane or TFA. Scheme III

[00209] Compounds of Formula (III-A) can be prepared according to Scheme III. In step A. compound (III-1) reacts with a mesylate or tosylate under strong base such as NaH or KOlBu in a solvent such as THF / DMF to give compound (III-2). In step B, compound (III-2) undergoes borylation with a reagent such as bis(pinacolate)diboron under Pd catalyzed conditions to give compound (III-3). In step C, compound (III-3) is coupled with a bromide on a pyridopyrimidine to give compound (III-4). This coupling reaction proceeds in a solvent or mixture of solvents such as 2-Me THF and water, and a catalyst such as cataCXium A Pd G3 (CAS No. 1651823-59-4), with or without a base such as potassium phosphate. In step D, compound (HI-4) is hydrolyzed to give compound (HI-5) using a reagent such as HC1 in dioxane or TFA. In step E, compound (III-5) is cyclized under conditions such as PyBrop or Brop and DIPEA in a solvent such as CH3CN and DMSO to give compounds of Formula (III-A). Scheme IV OH l-A

[00210] Compounds of Formula (IV-A) can also be prepared according to Scheme IV. In step A, compound (I-A) undergoes an acylation reaction with an acyl chloride in a solvent such as DCM, THF or acetonitrile and in the presence of a base such as Hiinig’s base or triethylamine to produce IVA. Alternatively, compound (I-A) can undergo an acylation reaction upon treatment with an acid anhydride or a chloroformate in a solvent such DCM, THF or acetonitrile in the presence of a catalyst such as DMAP and a base such as Hiinig’s base or triethylamine to produce IV-A.

[00211] As can be appreciated by the skilled artisan, the above synthetic scheme and representative examples arc not intended to comprise a comprehensive list of all means by which the compounds described and claimed in this application may be synthesized. Further methods will be evident to those of ordinary' skill in the art. Additionally, the various synthetic steps described above may be performed in an alternate sequence or order to give tire desired compounds.

[00212] Purification methods for the compounds described herein are known in the art and include, for example, crystallization, chromatography (for example, liquid, gas phase, and supercritical fluid), filtration, sublimation, lyophilization, extraction, distillation, trituration, and reverse phase HPLC.

[00213] The following examples are given for the purpose of illustrating various embodiments of the disclosure and are not meant to limit the present disclosure in any fashion. One skilled in the art will appreciate readily that the present disclosure is well-adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those objects, ends, and advantages inherent herein. Changes therein and other uses which are encompassed within the spirit of the disclosure as defined by the scope of the claims will occur to those skilled in the art. EXAMPLES

[00214] This section provides specific examples of compounds of Formula (I) and methods of making the same. List of Abbreviations Ac acetyl AcCl acetyl chloride AcOH acetic acid aq or aq. aqueous Bn benzyl B2Pin2 bis(pinacolato)diboron BOC or Boc tert-butyloxy carbonyl BroP bromotris(dimethylamino)phosphonium hexafluorophosphate Burgess reagent methyl A-(triethylammoniumsulfonyl)carbamate BuOH n-butanol cataCXium A Pd G3 (CAS No. 165182359-4) [(di( 1 -adamanty l)-butylphosphine)-2-(2 ’ -amino-1,1’-biphcny 1)] palladium (II) methane sulfonate Cbz benzyloxycarbonyl CbzCl benzyl chloroformate CDI carbonyldiimidazole COD or cod 1,5-cyclooctadiene DABCO l,4-diazabicyclo[2.2. 2]octane DBU 1.8-diazabicyclo[5.4.0]undec-7-ene DCE dichloroethane DCM dichloromethane DHP 3,4-dihydro-2H-pyran DIPEA diisopropylcthylaminc DMA N, A-dime thy lacetamide DMAP AA-dimethylpyridin-4-amine DMC dimethyl carbonate DMF AA-dimethy Iformamide DMI l,3-dimethyl-2-imidazolidinone DMSO dimethyl sulfoxide Dppf, DPPF or dppf 1.1’ -bis(diphenylphosphino)ferrocene Dtbbpy 4,4’-di-tert-butyl-2,2’-dipyridyl eq or eq. or equiv. equivalent ESI or ES electrospray ionization Et ethyl EtOAc ethyl acetate EtOH ethanol g or gr gram(s) h hour(s) HATU 1 -[bis(dimethy lamino)methy lene] -1H-1,2,3 -triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate HBpin 4,4,5,5-tetramethyl-1.3,2-dioxaborolane HMPA hexamethylphosphoramide HOAc acetic acid HPLC high pressure liquid chromatography IBX 2-iodoxybenzoic acid iPr iso -propyl iPr2NET or DIPEA A-ethyl diisopropylamine (Hiinig’s base) KOAc potassium acetate KOtBu potassium Zert-butoxide LAH lithium aluminum hydride LC MS, LCMS. LC- MS or LC / MS liquid chromatography mass spectroscopy LHMDS or LiHMDS lithium hexamethyldisilazide m / z mass divided by charge Me methyl MeCN acetonitrile McOH methanol mg milligrams min minutes mL milliliters MS mass spectra MTBE methyl tert-butyl ether NaHMDS sodium hexamethylsilazide NFSI A-fluorobenzenesulfonimide NIS A-iodosuccinimide NMO 4-methyhnorpholine 4-oxide NMP N-methyl-2-pyrrolidinone NMR nuclear magnetic resonance PCy3 Pd G2 Chloro [ (tricy clohe xy Ipho spine) -2 -(2 ’ -aminobipheny 1) ] palladium (II) Pd-diAc palladium diacetate Pd(dppf)Cl2DCM, Pd(dppf)Cl2 [1,1'- bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane Pd(dtbpf)Cl2 [ 1.1 '-bis(di-tert- butylphosphino)ferrocene]dichloropalladium(II) Pd(PPh3)4 tetrakis(triphenylphosphine)palladium(0) PEPPSI-IPr [ 1,3 -bis(2,6-diisopropylpheny l)imidazol-2-y lidene] (3 -chloropyridyl)palladium(II) dichloride Ph phenyl PhMe toluene Pin pinacolato Piv pivaloyl PivCl pivaloyl chloride PMB 4-methoxybenzyl PPNCI bis(triphenylphosphoranylidene)ammonium chloride PTSA or pTsOH p-tohicncsulfomc acid Rbf or rbf round-bottomed flask RP-HPLC reverse phase high pressure liquid chromatography RT or rt or r.t. room temperature sat. or satd. saturated SFC supercritical fluid chromatography TBAC1 te / ra-n-butydammonium chloride TBAF tetra-w-butylammonium fluoride TBDPS tert-butyldiphenylsilyl TBDPSC1 tert-butyldiphenylsilyl chloride TBS tert-butyldimethylsilyl TBSC1 tert-butyldimethylsilyl chloride tBu tert-butyl TC thiophene-2-carboxy late TEA or Et3N triethylamine temp temperature Tf trifluoromethylsulfonyl TFA trifluoroacetic acid THF tetrahydrofuran TIPS triisopropylsilyl TIPSC1 triisopropylsilyl chloride TLC thin layer chromatography UV ultraviolet XPhos 2-dicyclohexylphosphino-2',4'.6'-triisopropyl-l.r-biphenyl Y(OTI)3 yttrium (III) triflate

[00215] Provided in this section are descriptions of the general analytical and purification methods used to prepare the specific examples provided herein.

[00216] Chromatography: Unless otherwise indicated, product-containing residues were purified by passing the material or concentrate through (a) Biotage High Capacity7 D column or (b) ISCO RediSep Gold High Performance column or (c) ISCO RediSep Rf HP Cl8 Gold column or (d) Biotage Isolute SCX-2 column; and eluting the product from the column with a solvent gradient as indicated.

[00217] Preparative HPLC Method: Where indicated, the compounds described herein were purified via reversed phase HPLC using Waters FractionLynx or Gilson semi-preparative HPLC-MS system using one of the following two HPLC columns: (a) Phenomenex Gemini column (5 micron, C18. 150 x 30 mm) or (b) Waters X-select CSH column (5 micron, C18, 100 x 30 mm). A typical run through the instrument included: eluting at 45 mL / min with a linear gradient of 10% (v / v) to 100% MeCN (0.1% v / v formic acid) in water (0.1% formic acid) over 10 minutes. Conditions can be varied to achieve improved separations.

[00218] Proton NMR Spectra: Unless otherwise indicated, all 1H NMR spectra were collected on a Bruker NMR instrument at 300. 400 or 500 MHz. All observed protons are reported as parts-per-million (ppm) downfield from tetramethylsilane (TMS) using the internal solvent peak as reference. Some 1H signals may be missing due to exchange with D from MeOD, or due to signal suppression.

[00219] Mass Spectra (MS): Unless otherwise indicated, all mass spectral data for starting materials, intermediates and / or exemplary compounds are reported as mass / charge (m / z), having an [M+H]+ molecular ion. The molecular ion reported was obtained by electrospray detection method (commonly referred to as an ESI MS) utilizing a Waters Acquity UPLC / MS system. Compounds having an isotopic atom, such as bromine and the like, are generally reported according to the detected isotopic pattern, as appreciated by those skilled in the art.

[00220] Fluorine NMR Spectra: Unless otherwise indicated, all 19F NMR spectra were collected on a Bruker NMR instrument at 300, 400 or 500 MHz under ’H-decoupled conditions. All observed fluorines are reported as parts-per-million (ppm).

[00221] Provided in this section is the synthesis of various intermediates used to prepare compounds of Formula (I). All starting materials are either commercially available from Sigma-Aldrich, Combi-Blocks, Enamine, PharmaCore, PharmaBlock. Synnovator, Chemscene, AA blocks, Oakwood or Ambeed, or similar vendors, unless otherwise noted, or known in the art and may be synthesized by employing known procedures using ordinary skill. SECTION 1: Synthesis of Intermediates Intermediate A: 3-(4-Biomo-6-chloio-l-(tetiahydio-2 / / -pyran-2-yl)-1 W-indazol-5-yl)piopan-l-ol. Intermediate A

[00222] Step 1: 3-(4-Bromo-6-chloro-l-(tetrahydro-27f-pyran-2-yl)-l / 7-indazol-5-yl)propanal. To a 40 mL vial was charged with 4-bromo-6-chloro-5-iodo-l-(tetrahydro-2H-pyran-2-yl)-\H-indazole (3.00 g, 6.80 mmol, Lab Network), sodium bicarbonate (1.43 g, 17.0 mmol), TBAC1 (1.95 g, 6.82 mmol), and AyV-dimethylformamide (14 mL). The solution was degassed by nitrogen bubbling for 10 min. Then palladium(II) acetate (77 mg, 0.34 mmol) and allyl alcohol (0.7 mL, 10 mmol) were added at 50 °C. The reaction mixture was stirred at 50 °C for 18 h. After cooling to room temperature, the reaction was diluted with saturated aqueous ammonium chloride and extracted with EtOAc. The organic layer was washed with saturated aqueous sodium chloride, dried over sodium sulfate, and concentrated. The crude material was purified by column chromatography on silica gel, eluting with a gradient of 0-50% 3:1 EtOAc / EtOH in heptane, to provide 3-(4-bromo-6-chloro-l-(tetrahydro-2H-pyran-2-yl)-lH-indazol-5-yl)propanal (2.12 g, 5.70 mmol, 84% yield), m'Z (ESI): 371.0 (M+H)+.

[00223] Step 2: 3-(4-Bromo-6-chloro-l-(tetrahydro-2 / f-pyran-2-yl)-l77-indazol-5-yl)propan-l-ol. To a 100-mL round-bottom flask was added 3-(4-bromo-6-chloro-l-(tctrahydro-2H-pyran-2-yl)-lH-indazol-5-yl)propanal (1.06 g, 2.86 mmol) in tetrahydrofuran (5 mL) / methanol (5 mL). The reaction mixture was cooled to 0 °C. Then, sodium borohydride (0.11 g, 2.86 mmol) was slowly added in portion. The reaction mixture was stirred at 0 °C for 30 minutes, then was slowly quenched with saturated NH4C1 and extracted with EtOAc. The combined organic layers were washed with brine, dried over MgSO4, filtered, and concentrated under reduced pressure to provide 3-(4-bromo-6-chloro-l-(tetrahydro-2H-pyran-2-yl)-l / f-indazol-5-yl)propan-l-ol (1.03 g, 2.76 mmol, 97% yield). m / z (ESI): 289.0 (M-THP+H)+. Intermediate B: tert-Butyl l-oxa-7-azadispiro[2.1.5s.l3]undecane-7-carboxylate.

[00224] Step 1: tert-Butyl 2-hydroxy-6-azaspiro[3.5]nonane-6-carboxyIate. A 250-mL roundbottom flask was charged with 6-azaspiro[3.5] nonan-2-olhydrochloride (15 g, 84 mmol. Ambeed, Inc.), di- / ert-butyl dicarbonate (22.11 g, 101 mmol) and sodium carbonate (17.90 g, 169 mmol) in tetrahydrofuran (61 mL) / water (23 mL). The reaction mixture was stirred at 80 °C for 2 h. After cooling to room temperature, saturated aqueous sodium chloride was added and the reaction was extracted with EtOAc, dried over sodium sulfate, filtered, and concentrated to give tert-butyl 2-hydroxy-6-azaspiro[3.5]nonanc-6-carboxylatc (20.4 g, 84 mmol, 100% yield) as crude product which was used in the subsequent step without further purification, m.'z (ESI): 186.1 (M+H-'Bu).

[00225] Step 2: tert-Butyl 2-oxo-6-azaspiro[3.5]nonane-6-carboxylate. A 250-mL round-bottom flask was charged with fert-butyl 2-liydroxv-6-azaspiro|3.5|nonane-6-carbo\vlatc (20.4 g, 84 mmol) and dichloromethane (150 mL). The reaction mixture was cooled to 0 °C and Dess-Martin periodinane (38.7 g, 91 mmol) was added slowly. The reaction mixture was allowed to stir at room temperature for 18 h. poured into an aqueous sodium thiosulfate solution (10%) and filtered. The aqueous phase was extracted with DCM and the combined organic phases were dried over sodium sulfate, filtered, and concentrated. The residue was purified by column chromatography on silica gel, eluting with a gradient of 0-80% EtOAc in heptane, to give tert-butyl 2-oxo-6-azaspiro[3.5]nonane-6-carboxylate (14.2 g, 59.3 mmol, 71% yield), m / z (ESI): 184.2 (M+H-'Bu / . *H NMR (400 MHz, CDCI3) 5 ppm 3.46 (s, 2H), 3.4-3.4 (m, 2H), 2.8 - 2.9 (m, 2H), 2.6 - 2.8 (m. 2H), 1.7-1.8 (in, 2H), 1.6- 1.6 (m, 2H), 1.46 (s, 9H).

[00226] Step 3: tert-Butyl l-oxa-7-azadispiro[2.1.55.l3]undecane-7-carboxylate. To a 150-mL round-bottom flask was charged with trimethylsulfoxonium iodide (3.73 g, 17.0 mmol) in dimethyl sulfoxide (22 mL). Potassium Zert-butoxide (2.00 g, 17.8 mmol) was added and the reaction was stirred at 0 °C to room temperature over 1 h. Then, tert-butyl 2-oxo-6-azaspiro[3.5]nonane-6-carboxylatc (2.03 g, 8.48 mmol) in MM-dimcthylformamidc (2 mL) was added dropwisc. The reaction mixture was stirred at room temperature for 1 h, then diluted with sat. NaiIC CL solution and extracted with EtOAc. The combined organic layers were washed with brine, dried over MgSO4, filtered, and concentrated under reduced pressure. The crude material was purified by column chromatography on silica gel, eluting with a gradient of 0-40% EtOAc in hexanes, to provide tert-butyl l-oxa-7-azadispiro[2.1.55.l3]undecane-7-carboxylate (0.39 g, 1.5 mmol, 18% yield), m / z (ESI): 276.1 (M+Na)+. ]H NMR (400 MHz, CDCI3) 5 ppm 3.41 (s, 2H), 3.3 - 3.4 (m, 2H), 2.7 - 2.8 (m, 2H), 2.0 -2.3, (m, 4H), 1.6 - 1.8 (m, 2H). 1.5 - 1.6 (m, 2H), 1.4 - 1.5 (m, 9H). Mixture of two diastereomers. Intermediate C: 4-(tert-Butoxy)-7-chloro-8-fluoro-2-(((27?,7a5)-2-fluorotetrahydro-177-pyrrolizin-7a(5H)yl)methoxy)pyrido[4,3-J|pyrimidine. t-BuOK THF Step 1

[00227] Step 1: 4-(tert-Butoxy)-2,7-dichloro-8-fluoropyrido[4,3-rf]pyrimidine. To a solution of 2,4,7-tricliloro-8-fluoropyrido[4,3-t / |pyrimidine (50.0 g, 198 mmol) in tetrahydrofuran (1.5 L) was added t-BuOK (1 M in THF, 190 mL, 190 mmol) dropwise at -60 °C and the reaction mixture was stirred at -60 °C for 2 h. The mixture was diluted with EtOAc and water and extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, fdtered and concentrated under reduced pressure. The crude product was triturated with petroleum ether at room temperature for 1 h. The suspension was filtered, and the cake was concentrated under reduced pressure to give 4-(tert-butoxy)-2,7-dichloro-8-fluoropyrido[4,3-J|pyrimidine (30 g, 103 mmol, 54% yield). 'HNMR (400 MHz, CDCl3) 5 ppm 9.08 (s, 1 H). 1.74 (s, 9 H).

[00228] Step 2: 4-(tert-Butoxy)-7-chloro-8-fluoro-2-(((27?,7a5)-2-fluorotetrahydro-17T-pyrrolizin-7a(5H)yl)methoxy)pyrido[4,3-rf|pyrimidine. To a solution of 4-(tert-butoxy)-2.7-dichloro-8-fIuoropyrido[4,3-<7|pyrimidine (50.0 g, 172 mmol) and 4A MS (10 g) in 1,4-dioxane (1 L) was added ((2J?,7a>S)-2-fluorotctrahydro-lH-pyrrolizin-7a(5 / 7)-yl)mcthanol (30.2 g, 190 mmol) and DIPEA (60.0 g, 431 mmol) in sequence. Then the mixture was stirred at 80 °C for 5 h. After cooling to room temperature, the reaction mixture was diluted with EtOAc and water and extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4. filtered, and concentrated under reduced pressure. The crude product was triturated with MTBE at room temperature for 1 h. The suspension was filtered, and the cake was concentrated under reduced pressure to give 4-(Zert-butoxy)-7-chloro-8-fluoro-2-(((2A,7a5)-2-fluorotetrahydro-l / 7-pyrrolizin-7a(5H)yl)methoxy)pyrido[4,3-t / |pyrimidine (40 g. 97 mmol, 56% yield), m / z (ESI): 413.2 / 415.2 (M+H)+. Intermediate D: rac-((17?,25)-2-(4-Bromo-6-chloro-l-(tetrahydro-2 / / -pyran-2-yl)-l / 7-indazol-5-yl)cyclopropyl)methanol. Intermediate D

[00229] Step 1. rac-Ethyl (17?,2S)-2-(4-bromo-6-chloro-l-(tetrahydro-2ZI-py ran-2-yl)-lZ7-indazol-5-yl)cyclopropane-l-carboxylate. A vial was charged with 4-bromo-6-chloro-5-iodo-l-(tetrahydro-2 / / -pyran-2-yl)-lH-indazole (0.75 g, 1.70 mmol, Lab Network), rac-ethyl (lR,2S)-2-(tetramethy 1-1,3,2-dioxaborolan-2-yl)cyclopropane-l-carboxylate (0.49 mL, 2.04 mmol, Enamine), l.r-bis(diphenylphosphino)ferrocene-palladium dichloride (0.12 g, 0.17 mmol), potassium phosphate tribasic (1.26 g, 5.95 mmol) in toluene (5 mL) and water (1 mL). The reaction mixture was flushed with nitrogen and heated at 100 °C for 16 h. After cooling to room temperature, the reaction mixture was concentrated and the residue purified by column chromatography on silica gel, eluting with a gradient of 0-60% EtOAc / lieptane to provide rac-ethyl (lR,2S)-2-(4-bromo-6-chloro-l-(tetrahydro-2H-pyran-2-y 1)-1 H-indazol-5-yl)cyclopropane-1 -carboxylate (0.24 g. 0.56 mmol, 33% yield), m / z (ESI): 448.8 (M+Na)1.

[00230] Step 2. rac-((17?,25)-2-(4-Bromo-6-chloro-l-(tetrahydro-2H-pyran-2-yl)-lH-indazol-5-yl)cyclopropyl)methanol. To a stirred solution of rac-ethyl (lR,2S)-2-(4-bromo-6-chloro-l-(tetrahydro-2H-pyran-2-yl)-l / 7-indazol-5-yl)cyclopropane-l-carbo.xylate (0.95 g, 2.23 mmol) in tetrahydrofuran (6 mL) at -78 °C was added diisobutylaluminum hydride solution (1.0 M in DCM, 5.6 mL, 5.6 mmol) slowly. The resulting mixture was allowed to warm to room temperature and stirred for another 30 minutes. The reaction mixture was poured slowly into Rochelle's salt aqueous solution in an ice bath and extracted with EtOAc. The combined organic layers were dried (Na2SO4) and concentrated. The residue was purified by column chromatography on silica gel, eluting with a gradient of 0-60% EtOAc / heptane to afford rac-((lR,2S)-2-(4-bromo-6-chloro-l-(tetrahydro-2H-pyran-2-yl)-l / 7-indazol-5-yl)cyclopropyl)methanol (0.69 g, 1.78 mmol, 80% yield). m / z (ESI): 384.8 (M+H)+. Intermediate E: 2-(4-Bromo-6-chloro-l-(tetrahydro-2H-pyran-2-yl)-lH-indazol-5-yI)ethan-l-ol. 1) Pd(dppf)CI2, K3PO4 1,4-dioxane 2) TFA 3) NaBH4, MeOH Intermediate E

[00231] A vial was charged with (£)-1 -ethoxyethene-2-boronic acid pinacol ester (2.02 g, 10.2 mmol, Aurum Pharmatech), 4-bromo-6-chloro-5 -iodo-1 -(tetrahydro-2H-pyran-2-y 1)-1 / / -indazole (3.00 g, 6.80 mmol, LabNetwork), tripotassium phosphate (5.05 g, 23.8 mmol), 1,1'-bis(diphcnylphosphino)fcrroccnc-palladium dichloridc (0.50 g, 0.68 mmol), water (4 mL) and 1,4-dioxane (19 mL). The reaction mixture was heated to 100 °C for 1.5 h. After cooling to room temperature, the crude material was diluted with EtOAc and saturated aqueous sodium bicarbonate. The aqueous layer was extracted with EtOAc, and the combined organics were dried (Na2SO4) and concentrated. This crude product was then diluted with 1,4-dioxane (18 mL) and water (1 mL) and to it was added trifluoroacetic acid (7.8 mL, 102 mmol) dropwise. The reaction mixture was stirred at 40 °C for 6 h. After cooling to room temperature, the reaction mixture was concentrated and the residue was purified by column chromatography on silica gel, eluting with 0-100% (3:1 EtOAc:EtOH + 2% triethylamine) in heptane, to provide 2-(4-bromo-6-chloro-l-(tetrahydro-2H-pyran-2-yl)-l / / -indazol-5-yl)acetaldehyde (2.40 g, 6.71 mmol, 99% yield), which was treated with triethylamine and filtered to neutralize the remaining TFA. mz (ESI): 357.0 (M+H)+.

[00232] To a 250 mL round-bottom flask was charged with the above aldehyde (2.40 g, 6.71 mmol) and ethanol (70 mL). The reaction mixture was cooled to 0 °C and sodium borohydride (0.53 g, 14 mmol) was added portionwise. The solution was allowed to warm to room temperature with stirring for 30 minutes. The reaction was then carefully quenched by the addition of methanol, water, and saturated aqueous ammonium chloride. The resulting solution was extracted with EtOAc. The combined organics were dried (Na2SO4) and concentrated. The residue was purified by reverse phase chromatography using a C18 column, eluting with 0-100% acetonitrile + 0.1% TFA in water + 0.1% TFA, to provide 2-(4-bromo-6-chloro-l-(tetrahydro-2 / / -pyran-2-yl)-l / / -indazol-5-yl)ethan-l-ol (0.20 g. 0.56 mmol. 8% yield), m / z (ESI): 359.0 (M+H) . Intermediate F: l-Azido-4-(4-bromo-6-chloro-l-(tetrahydro-2£f-pyran-2-yl)-l£f-indazol-5-yl)butan-2-one.

[00233] Step 1. 4-(4-Bromo-6-chloro-l-(tetrahydro-27 / -pyran-2-yl)-177-indazol-5-yl)butan-2-one. To a 40 mL vial was charged with 4-bromo-6-chloro-5-iodo- l-(tctrahvdro-2 / / -pvran-2-yl)-lH-indazole (2.04 g, 4.62 mmol. Pharmablock, Inc.), sodium bicarbonate (0.97 g. 11.6 mmol), TBAC1 (1.28 g. 4.62 mmol). palladium(II) acetate (52 mg. 0.23 mmol), 3-buten-2-ol (0.6 mL. 6.9 mmol) and MA-dimethylformamide (10 mL). The reaction mixture was heated at 65 °C for 68 h. After cooling to room temperature, the reaction was diluted with saturated aqueous ammonium chloride and extracted with ethyl acetate. The organic layer was washed with water, dried over sodium sulfate, filtered, and concentrated. The crude material was purified by column chromatography on silica gel, eluting with 0-50% EtOAc in heptane to provide 4-(4-bromo-6-chloro-l-(tetrahydro-2H-pyran-2-yl)-l / 7-indazol-5-yl)butan-2-one (1.42 g. 3.68 mmol, 80% yield), m / z (ESI): 406.9 / 408.9 (M+Na)+.

[00234] Step 2. l-Bromo-4-(4-bromo-6-chloro-l-(tetrahydro-2H-pyran-2-yl)-lH-indazol-5-yl)butan-2-one. To a 250-inL round-bottom flask was charged with lithium diisopropylamide (1 M solution in THF / hexanes, 4.1 mL, 4.1 mmol) in anhydrous tetrahydrofuran (35 mL). The mixture was cooled to 78 °C and 4-(4-bromo-6-chloro-l-(tetrahydro-2H-pyran-2-yl)-lH-indazol-5-yl)butan-2-one (1.33 g, 3.45 mmol) in 8 mL anhydrous THF was added dropwise under nitrogen. The reaction mixture was stirred at -78 °C for 30 minutes. Chlorotrimethylsilane (0.70 mL, 5.5 mmol) was then added dropwise at -78 °C. The reaction mixture was stirred at -78 °C for an additional 30 minutes. Saturated NaHCO3 solution was added, and the mixture was allowed warm to room temperature. Ethyl acetate was added, the layers were separated, and the organic layer was dried over Na2SO4. filtered, and concentrated. The crude product was diluted in anhydrous THF (10 mL) and cooled to 0 °C. Sodium bicarbonate (0.44 g, 5.17 mmol) and A-bromosuccinimide (0.61 g, 3.45 mmol) was then added and the mixture was stirred at room temperature for 15 h. The reaction mixture was filtered and concentrated. The crude material was purified by column chromatography on silica gel, eluting with 0-100% EtOAc in heptane, to provide l-bromo-4-(4-bromo-6-chloro-l-(tctrahydro-2H-pyran-2-yl)-lH-indazol-5-yl)butan-2-one (1.16 g, 2.50 mmol, 72% yield), m / z (ESI): 462.8 / 464.8 / 466.8 (M+H)+.

[00235] Step 3. l-Azido-4-(4-bromo-6-chloro-l-(tetrahydro-2 / / -pyran-2-yl)-17f-indazol-5-yl)butan-2-one. To a 40-mL vial was added l-bromo-4-(4-bromo-6-chloro-l-(tetrahydro-2H-pyran-2-yl)-lA-indazol-5-yl)butan-2-one (1.16 g, 2.50 mmol) in acetone (10 mL). Sodium azide (0.21 g, 3.3 mmol) was added, and the reaction mixture was stirred at room temperature for 2 h. The mixture was filtered over celite, and the filtrate was concentrated. The residue was purified by column chromatography on silica gel, eluting with 0-50% EtOAc in heptane, to provide l-azido-4-(4-bromo-6-chloro-l-(tetrahydro-2H-pyran-2-yl)-lH-indazol-5-yl)butan-2-one (0.70 g, 1.64 mmol, 66% yield). m / z (ESI): 448.0 / 450.0 (M+Na)+. Intermediate G: (2S,47?)-6-(tert-Butoxycarbonyl)-2-fluoro-6-azaspiro[3.5]nonane-2-carboxylic acid. 2) Boc2O H2O, Na2CO3 Bocf 1) HF-pyridine, CH2CI2 Step 1 Phl(OAc)2, TEMPO CH3CN, h2o Step 2 Intermediate G

[00236] Step 1. tert-Butyl (2S',41?)-2-fluoro-2-(hydroxymethyl)-6-azaspiro[3.5]nonane-6-carboxylate. In a 250-mL round-bottom flask was added hydrogen fluoride (70% in 30% pyridine, 4.76 g, 48.0 mmol) and the flask was cooled to -78 °C. / ert-Butyl l-oxa-7-azadispiro[2.1.5'’.l3]undecane-7-carboxylate (Intermediate B, 4.30 g, 17.0 mmol) in dichloromethane (15 mL) was added dropwise, and the reaction mixture was stirred at -78 °C for 2 h. The mixture was quenched by addition of 1 M Na2COs solution and dichloromethane and then allowed to warm to 0 °C. Di-tert-butyl dicarbonate (3.70 g, 17 mmol) was added at 0 °C and the mixture was gradually warmed to room temperature with stirring for 16 h. The resulting mixture was extracted with CH2O2 and the combined organic layers were dried over Na2SO4, filtered, and concentrated. The crude was purified by column chromatography on silica gel, eluting with 0-50% EtOAc in heptane (detected by an ELS detector), to provide tert-butyl (2S,47?)-2-fluoro-2-(hydroxymethyl)-6-azaspiro[3.5]nonane-6-carboxylate (0.96 g, 3.5 mmol, 21% yield). m>z (ESI): 218.2 (M-*Bu+H)+.

[00237] Step 2. (25',47?)-6-(tert-Butoxycarbonyl)-2-fluoro-6-azaspiro[3.5]nonane-2-carboxylic acid. To a 40-mL vial was charged with Zert-butyl (2S,4I?)-2-fluoro-2-(hydroxymethyl)-6-azaspiro[3.5]nonane-6-carboxylate (0.96 g, 3.5 mmol) in water (8 mL) and acetonitrile (12 mL). TEMPO (0.11 g, 0.70 mmol) and (diacetoxyiodo)benzene (2.83 g, 8.78 mmol) was added, and the reaction mixture was heated at 60 °C for 2 h. Acetonitrile was removed under vacuum, and the resulting aqueous mixture was basified with saturated NaHCOs solution, washed with EtOAc. The aqueous phase was acidified by 1 M KHSO4 solution and extracted by EtOAc. The combined organic layers were dried over Na2SO4, filtered, and concentrated to provide (25,,47?)-6-(tert-butoxycarbonyl)-2-fluoro-6-azaspiro[3.5]nonane-2-carboxylic acid (0.62 g, 2.2 mmol, 61% yield), m z (ESI): 310.1 (M+Na)+. Intermediate H: 3-(4-Bromo-6-chloro-l-(tetrahydro-2H-pyran-2-yl)-lZ / -indazoI-5-yl)propanehydrazide. Intermediate A                                                          Intermediate H

[00238] Step 1.3-(4-Bromo-6-chloro-l-(tetrahydro-2 / / -pyran-2-yl)-l / / -indazol-5-yl)propanoic acid. To a solution of 3-(4-bromo-6-chloro-l-(tetrahydro-2H-pyran-2-yl)-lH-indazol-5-yl)propan-l-ol (Intermediate A, 4.30 g, 11.5 mmol) at 0 °C in acetone (115 mL) was added chromium trioxide solution in sulfuric acid (7.0 mL, 15 mmol) dropwise. The reaction mixture was stirred at room temperature for 16 h. Sodium thiosulfate was added, and the solution was stirred for 10 minutes, filtered and the fdtrate was concentrated in vacuo to provide 3-(4-bromo-6-chloro-l-(tetrahydro-277-pyran-2-yl)-IH-mdazol-5-yl)propanoic acid (4.40 g, 11.0 mmol, 99% yield). m,z (ESI): 387.0 / 389.0 (M+H)+. ’HNMR (400 MHz, DMSO-de) 5 ppm 12.1-12.5 (m, 1H), 8.0-8.1 (m, 1H), 8.02 (s, 1H), 5.88 (dd, 1H, J=2.4, 9.4 Hz), 3.8-3.9 (m, 1H), 3.7-3.8 (m, 1H), 3.2-3.3 (m, 2H), 2.4-2.5 (m, 2H), 2.3-2.4 (m, 1H), 1.9-2.1 (m, 2H), 1.6-1.8 (m, 1H), 1.5-1.6 (m, 2H).

[00239] Step 2. 3-(4-Bromo-6-chloro-l-(tetrahydro-2Z / -pyran-2-yl)-177-indazol-5-yl)propanehydrazide. To solution of 3-(4-bromo-6-chloro-1 -(tetrahydro-2H-pyran-2-yl)-17f-indazol-5-yl)propanoic acid (1.02 g, 2.63 mmol) in acetonitrile (8 mL) and AW-dimethylacetamide (2 mL) was added DIPEA (0.5 mL) and HATU (1.26 g, 3.32 mmol). The mixture was stirred at room temperature for 20 minutes. Then the solution was added dropwise to the solution of hydrazine (0.19 mL, 6.1 mmol) and DIPEA (0.5 mL) in MeCN (10 mL) cooled in an ice bath. The reaction mixture was diluted with EtOAc and saturated NH4C1. The organic phase was washed with water and brine, dried over Na^SO, and concentrated. The crude material was purified by column chromatography on silica gel, eluting with a gradient of 0-100% 3:1 EtOAc / EtOH in heptane, to provide 3-(4-bromo-6-chloro-l-(tetrahydro-2H-pyran-2-yl)-l / f-indazol-5-yl)propanehydrazide (0.62 g, 1.50 mmol, 58%). m / z (ESI): 423 / 425 (M+Na)+. ’H NMR (400 MHz, DMSO-d6) 5 ppm 9.06 (br s, 1H), 8.06 (s, 1H), 8.01 (s, 1H), 5.9-5.9 (m, 1H), 4.19 (br s, 2H), 3.8-3.9 (m, 1H), 3.7-3.8 (m, 1H), 3.1-3.3 (m, 2H), 2.22.4 (m, 3H). 2.0-2.1 (m, 2H). 1.7-1.8 (m, 1H). 1.5-1.6 (m, 2H). Intermediate I: l-Amino-4-(4-bromo-6-chloro-l-(tetrahydro-277-pyran-2-yl)-177-indazol-5-yl)butan-2-one. Intermediate F                                      Intermediate I

[00240] To a solution of 5% Pd on activated carbon (5.00 g, 46.9 mmol) in ethanol (IL) was added 1 -azido-4-(4-bromo-6-chloro- l-(tetrahydro-2H-pyran-2-yl)-lH-indazol-5-yl)butan-2-one (20.0 g. 46.9 mmol) and HC1 (4 M in 1,4-dioxane, 8.0 mL, 32 mmol). The suspension was degassed and purged with H2 three times. The reaction mixture was stirred under 15 psi of hydrogen at room temperature for 15 minutes. Upon completion the reaction was filtered through celite and concentrated. The crude material was triturated with ethyl acetate to give 1 -amino-4-(4-bromo-6-chloro-l -(tetrahydro-2H-pyran-2-yl)-lH-indazol-5-yl)butan-2-one (8.50 g, 19.4 mmol, 42% yield). Intermediate J: (25,45)-6-(7-Chloro-8-fluoro-2-(((27?,7a5)-2-fluorotetrahydro-lH-pyrrolizin- 7a(57f)-yl)methoxy)pyrido[4,3-rf]pyrimidin-4-yl)-6-azaspiro[3.5]nonan-2-ol.

[00241] Step 1. Benzyl 2-hydroxy-6-azaspiro[3.5]nonane-6-carboxylate. To a solution of 6-azaspiro[3.5]nonan-2-ol hydrochloride (50.0 g, 281 mmol, LabNetwork) and K2CO3 (78.0 g, 563 mmol) in tetrahydrofuran (500 mL) and water (500 mL) was added CBz-Cl (44 mL, 310 mmol) dropwise at 0 °C. The reaction mixture was stirred at room temperature for 12 h. The reaction was combined with another 8 batches (50 g scale), diluted with H2O, and extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated. The residue was purified by column chromatography on silica gel, eluting with a gradient of 5-30% EtOAc in petroleum ether, to provide benzy l 2-hydroxy-6-azaspiro[3.5]nonane-6-carboxylate (550 g, 2.00 mol, 79% yield).

[00242] Step 2. Benzyl (27?,4^)-2-hydroxy-6-azaspiro[3.5]nonane-6-carboxylate. Benzyl 2-hydroxy-6-azaspiro[3.5]nonane-6-carboxylate (550 g) was separated by SFC (Column: DAICEL CHIRALCEL OZ, 25 cm x 5 cm, 10 mm; Mobile phase: 25% EtOH (0.1%NH3inH2O); Flow rate: 200 mL / min) to give peak 1 benzyl (2S,47?)-2-hydroxy-6-azaspiro[3.5]nonane-6-carboxylate (270 g, 981 mmol, 49% yield) and peak 2 benzy l (27?,45)-2-hydroxy-6-azaspiro[3.5]nonane-6-carboxylate (92 g. 334 mmol, 17% yield).

[00243] Step 3. (27?,45)-6-Azaspiro[3.5]nonan-2-ol hydrochloride. To a solution benzyl (2 / ?.4.S)-2-hydroxy-6-azaspiro[3.5]nonane-6-carboxylate (45.0 g, 163 mmol) in MeOH under argon atmosphere was added Pd / C (10%, 5 g, 4.7 mmol). The mixture was stirred under H2 (45 psi) at 40 °C for 12 h. HC1 (4 M in MeOH, 100 mL, 400 mmol) was added to the reaction mixture and stirring was continued for 0.5 h. The reaction was combined another two batches (45 g scale, 2 g scale), filtered through a pad of celite. The filtrate was concentrated under reduced pressure to give (2R,45)-6-azaspiro[3.5]nonan-2-ol hydrochloride (60.0 g, 338 mmol, 100% yield). '11 NMR (400 MHz, DMSO-d / ) 5 ppm 9.00 (s, 2H), 4.00-4.15 (m, 1H), 2.81-2.93 (m, 4H), 2.00-2.11 (m, 2H), 1.49-1.76 (m, 6H).

[00244] Step 4. 7-Chloro-8-fIuoro-2-(((27?,7«5)-2-fluorotetrahydro-lH-pyrrolizin-7a(5 / 7)-yl)methoxy)quinazolin-4-ol hydrobromide. 4-(teri-Butoxy)-7-chloro-8-fluoro-2-(((27?.7a5)-2-fluorotetrahydro-1 W-pyrrolizin-7a(5H)yl)methoxy)pyrido|4.3-(7|pyriinidine (Intermediate C, 29.4 g, 71.4 mmol) in HBr (33% in AcOH, 250 mL, 71.4 mmol) was stirred at room temperature for 4 h. This procedure was repeated on similar scale 2 additional times. The reaction mixtures were diluted with EtOAc, and the suspension was filtered. The filter cake was triturated with EtOAc (100 mL) at room temperature for 20 minutes. The suspension was filtered, and the fdter cake was washed with EtOAc, dried under vacuum to give 7-chloro-8-fluoro-2-(((27?,7a5)-2-fluorotetrahydro-177-pyrrolizin-7a(577)-yl)methoxy)pyrido[4,3-<7|pyrimidin-4-ol hydrobromide (96.0 g, 219 mmol, HBr salt), m / z (ESI): 357.2 (M+H)+.

[00245] Step 5. (25,45)-6-(7-Chloro-8-fluoro-2-(((27?,7a5)-2-fluorotetrahydro-l7 / pyrrolizin 7a(5Zf)-yl)methoxy)pyrido[4,3-< / ]pyrimidin-4-yl)-6-azaspiro[3.5]nonan-2-ol. To a 100 mL roundbottom flask was charged with 7-chloro-8-fluoro-2-(((2R,7«>S)-2-fluorotetrahydro-17 / -pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-<7|pyrimidin-4-ol hydrobromide (2.59 g, 5.90 mmol) and A-ethyl-M-isopropylpropan-2-amine (3.1 mL, 18 mmol) in DMF (29 mL). HATU (3.36 g, 8.8 mmol) was added in one portion and the reaction mixture was stirred at room temperature for 30 minutes. (277,45)-6-Azaspiro[3.5]nonan-2-ol hydrochloride (1.15 g, 6.5 mmol) was then added. The reaction mixture was stirred at room temperature for 2 h. The mixture was partitioned between ethyl acetate and saturated aqueous sodium chloride solution. The aqueous layer was extracted with EtOAc, and the combined organics were washed with brine, dried, and concentrated. The crude material was purified by column chromatography on silica gel, eluting with 0-100% 3:1 (EtOAc:EtOH with 2% triethylamine) in heptane, to provide (25',45)-6-(7-chloro-8-fluoro-2-(((27?,7a5)-2-fluorotetrahydro-l.A-pyrrolizin-7a(5F / )-yl)methoxy)pyrido[4,3-^pyrimidin-4-yl)-6-azaspiro[3.5]nonan-2-ol (2.60 g, 5.80 mmol. 98% yield), m / z (ESI): 479.2 (M+H)+. *H NMR (400 MHz, DMSO-d / ) 5 ppm 8.90 (s, 1 H). 5.34 (d, J=54.0 Hz, 1H), 4.94 (s, 1H), 4.15-4.32 (m, 2H), 4.02-4.11 (m, 1H), 3.88 (s, 2H), 3.80 (s, 2H), 3.58-3.64 (m, 1H), 3.09-3.19 (m, 2H), 2.89 (s, 1H), 2.73 (s, 1H), 2.12-2.27 (m, 2 H), 2.00-2.10(m, 3H), 1.79-1.88 (m, 2H), 1.67 (s, 4H), 1.52-1.60 (m, 2H). Intermediate K: rac-5-((l1S',21f)-2-(((ter / -Butyldiphenylsilyl)oxy)methyl)cyclopropyl)-6-chloro-l-(tetrahydro-2 / / -pyran-2-yl)-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l / / -indazole. Pd(dppf)CI2, Cs2CO3 dioxane / water Step 2 o, p-~l— b—b r o' O-\~ Intermediate K

[00246] Step 1. rac-4-Bromo-5-((lS',21?)-2-((( / ert-butyldiphenylsilyl)oxy)methyl)cyclopropyl)-6-chloro-l-(tetrahydro-2 / / -pyran-2-yl)-l / / -indazole To a solution of ((lA.25)-2-(4-bromo-6-chloro-l-(tetrahydro-2 / / -pyran-2-yl)-l / / -indazol-5-yl)cyclopropyl)methanol (Intermediate D, 35.0 g, 91.0 mmol) in dichloromethane (125 mL) and tetrahydrofuran (125 mL) was added imidazole (9.27 g, 136 mmol) and TBDPS-C1 (25.6 mL. 100 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 2 h, was then diluted with water and extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography on silica gel, eluting with a gradient of 2-5% EtOAc in petroleum ether, to give 4-bromo-5-((lS.2 / ?)-2-(((tert-butyldiphenylsilyl)oxy)methyl)cyclopropyl)-6-chloro-l-(tetrahydro-2 / / -pyran-2-yl)-l / / -indazole (42.5 g, 68.4 mmol. 75% yield).

[00247] Step 2. rac-5-((lS,27?)-2-(((tert-Butyldiphenylsilyl)oxy)methyl)cyclopropyl)-6-chloro-l-(tetrahydro-2H-pyran-2-y 1)-4-(4,4,5,5-tetramethy 1-1,3,2-dioxaborolan-2-y 1 )-1 / / -indazole To the mixture of 4-bromo-5-((lS,2A)-2-(((tert-butyldiphenylsilyl)oxy)methyl)cyclopropyl)-6-chloro-l-(tetrahydro-2 / / -pyran-2-yl)-l / / -indazole (50.0 g, 80.0 mmol) in 1,4-dioxane (800 mL) and water (100 mL) was added 4,4,4',4'.5,5,5',5'-octamethyl-2,2'-bi(1.3,2-dioxaborolane) (92.0 g. 361 mmol), cesium carbonate (78.0 g, 240 mmol) and Pd(dppf)C12 (5.86 g, 8.0 mmol) under nitrogen. The reaction mixture was heated at 120 °C for 2 h. After cooling to room temperature, the mixture was diluted with water and extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4. filtered and concentrated. The crude product was purified by reversed phase MPLC (70-90% 25 min; 90% 20 min using CH3CN as eluent) to give ra<?-5-((LS',27?)-2-(((tert-butyldiphenylsilyl)oxy)methyl)cy clopropyl)-6-chloro-l-(tetr ahydro-2 / / -pyran-2-y 1)-4-(4,4.5.5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l / / -indazole (24.8 g, 37 mmol, 46% yield), m.z (ESI): 671.3 / 673.2 (M+H)+. 'HNMR (400 MHz, DMSO-do) 5 ppm 8.08 (m, 1 H), 7.88 (d, J=7.2 Hz, 1 H), 5.85-5.80 (m,l H), 3.85-3.83 (in, 1 H), 3.77-3.72 (m, 1 H), 3.58-3.56 (m, 1H), 2.91-2.81 (in, 1 H), 2.37-2.25(m, 2 H), 2.02 - 1.99 (m, 1 H), 1.91-1.88 (in, 1 H), 1.72-1.70 (m, 1 H), 1.56 (br s, 3 H), 1.401.34 (m, 12 H), 1.23-1.15 (m, 2 H), 0.84 (br s, 9 H). Intermediate L: (S)-4-(tert-Butoxy)-7-chloro-8-fluoro-2-((l-methylpyrrolidin-2-yl)methoxy)pyrido [4,3-i / | pyrimidine. O*Bu F Intermediate L

[00248] To a mixture of 4-(tert-butoxy)-2,7-dichloro-8-fluoropyrido[4,3-< / ]pyrimidme (Step 1 in Intermediate A, 14.0 g, 48.3 mmol) and 4A MS (2.5 g) in 1,4-dioxane (280 mL) was added (5)-(1-methylpyrrolidin-2-yl)methanol (8.34 g, 72.4 mmol) and CS2CO3 (39.3 g. 121 mmol) in sequence. The reaction mixture was stirred at room temperature for 10 h. then was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na2SO4. filtered, and concentrated. The crude product was triturated with MTBE for 2 h. The suspension was filtered, and the filter cake was washed with MTBE and concentrated under reduced pressure to give (5)-4-(tert-butoxy)-7-chloro-8-fluoro-2-((l-methylpyrrolidin-2-yl)methoxy)pyrido[4,3-J|pyrimidine (7.89 g, 21.4 mmol. 44% yield), m / z (ESI): 369.1 / 371.1. ’H NMR (400 MHz, CDCh) 5 ppm 8.86 (s. 1 H), 4.58 (br d. J= 3.2 Hz, 1 H), 4.41 - 4.47 (m, 1 H), 3.07 -3.28 (m. 1 H), 2.73 - 2.89 (m. 1 H), 2.55 (br s, 3 H), 2.28 - 2.45 (m, 1 H), 2.04 - 2.19 (m. 1 H), 1.78 -1.93 (m. 3 H), 1.76 (s, 9 H). 19F NMR (376 MHz, CDCI3) 8 ppm -135.34 (s). Intermediate M: 4-(6-Chloro-l-(tetrahydro-2H-pyran-2-yl)-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l / / -indazol-5-yl)butyl methanesulfonate. Intermediate M

[00249] Step 1: 4-(4-Bromo-6-chloro-l-(tetrahydro-277-pyran-2-yl)-177-indazol-5-yl)butanal. To a solution of 4-bromo-6-chloro-5-iodo-l-(tetrahydro-2H-pyran-2-y 1)-IH-indazolc (25.0 g, 56.6 mmol, Lab Network) in AJV-dimethylformamide (300 mL) was added NaHCOs (11.9 g. 142 mmol) and TBAC1 (14.8 g, 56.6 mmol) under N2. The reaction mixture was stirred at room temperature for 15 minutes, then but-3-en-l-ol (8.17 g, 113 mmol) and Pd(OAc)2 (1.27 g. 5.66 mmol) was added under N2. The mixture was stirred at 80 °C for 12 h under N2. After cooling to room temperature, the residue was diluted with water and extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel, eluting with a gradient of 5-10% ethyl acetate in petroleum ether, to give 4-(4-bromo-6-chloro-l-(tetrahydro-2H-pyran-2-yl)-lH-indazol-5-yl)butanal (15 g, 39 mmol, 70% yield), m'z (ESI): 385.1 / 387.1 (M+H)+.

[00250] Step 2. 4-(4-Bromo-6-chloro-l-(tetrahydro-2H-pyran-2-yl)-lH-indazol-5-yl)butan-l-ol. To a solution of 4-(4-bromo-6-chloro-l-(tetrahydro-2H-pyran-2-yl)-lH-indazol-5-yl)butanal (15 g, 39 mmol) in EtOH (300 mL) was added NaBH4 (4.41 g. 117 mmol) in portions at 0 °C. The mixture was stirred at room temperature for 2 h, then was quenched by addition of saturated NH4C1 and water. The aqueous layer was extracted with EtOAc, and the combined organic layers were washed with brine, dried over Na2SO4. filtered and concentrated. The residue was purified by column chromatography on silica gel. eluting with a gradient of 5-10% ethyl acetate in petroleum ether, to give 4-(4-bromo-6-chloro-l-(tetrahydro-2H-pyran-2-yl)-177-indazol-5-yl)butan-l-ol (11 g, 28 mmol, 73% yield), m / z (ESI): 387.0 / 389.0 (M+H)+.

[00251] Step 3. 4-(6-chloro-l-(tetrahydro-2 / / -pyran-2-yl)-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-17 / -indazol-5-yl)butan-l-ol. A vial was charged with tris(4-methoxyphenyl)phosphine (1.45 g, 4.13 mmol, Ambeed, Inc.), palladium acetate (0.46 g, 2.06 mmol, Combi-Blocks Inc.), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(l,3,2-dioxaborolane) (3.93 g, 15.5 mmol, Ambeed, Inc.), cesium carbonate (6.72 g, 20.6 mmol), 4-(4-bromo-6-chloro-l-(tctrahydro-2 / / -pyran-2-yl)-177-indazol-5-yl)butan-l-ol (4.00 g, 10.3 mmol) and ethyl acetate (10 mL), then sparged with nitrogen and heated to 80 °C for 12 h. The reaction mixture was cooled to room temperature then the crude material was fdtered through a plug of celite and concentrated. The crude material was purified by chromatography on silica gel, eluting with a gradient of 0-20% 3:1 EtOAc / EtOH (with 2% TEA) in heptane, to provide 4-(6-chloro-l-(tetrahydro-2H-pyran-2-yl)-4-(4,4.5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l / / -indazol-5-yl)butan-l-ol (3.05 g, 7.03 mmol, 68% yield), m z (ESI): 435.1 (M+H)+.

[00252] Step 4. 4-(6-Chloro-l-(tetrahydro-2H-pyran-2-yl)-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l / / -indazol-5-vl)butyl methanesulfonate. A vial was charged with 4-(6-chloro-l-(tetrahydro-2H-pyran-2-yl)-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l / / -indazol-5-yl)butan-l-ol (3.20 g, 7.36 mmol), triethylamine (1.24 mL, 8.83 mmol) and dichloromethane (36 mL), then cooled to 0 °C. Methanesulfonyl chloride (0.63 mL, 8.10 mmol) was added dropwise and upon completion, the mixture was allowed to wann to room temperature with stirring. The crude mixture was and purified by column chromatography on silica gel, eluting with a gradient of 0-50% (3:1 EtOAc / EtOH with 2% TEA) / heptane, to provide 4-(6-chloro-1-(tctrahydro-2 / / -pyran-2-y 1)-4-(4.4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-lH-indazol-5-yl)butyl methane sulfonate (3.25 g, 6.34 mmol, 86% yield), m z(ESI): 513.0 (M+H)+. Intermediate N: tert-Butyl 2-(2-(2-(6-chloro-l-(tetrahydro-2H-pyran-2-yl)-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-177-indazol-5-yl)ethoxy)ethyl)-2-hydroxy-6-azaspiro [3.5] nonane-6-carboxylate. VinylMgBr THF Step 1 TESCI, ImH DCM Step 2 MsCI, DIPEA DMAP,DCM Step 4 NaH, THF, DMF Step 5 9-BBN, THF H2O2, NaOH Step 3

[00253] Step 1. tert-Butyl (2S',47?)-2-hydroxy-2-vinyl-6-azaspiro[3.5]nonane-6-carboxylate. A 250 mL round-bottom flask was charged with tert-butyl 2-oxo-6-azaspiro|3.5 |nonanc-6-carboxylatc (18.0 g, 75.0 mmol, Pharmablock Inc.) in tetrahydrofuran (350 mL) and cooled to 0 °C. Vinylmagnesium bromide (0.7 M solution in THF, 114 mL, 80 mmol) was added and die reaction was stirred at room temperature for 1 h. The reaction was quenched with saturated aqueous ammonium chloride solution and extracted with EtOAc. The combined organic layers were dried over sodium sulfate, filtered, and concentrated. The crude was purified by column chromatography on silica gel, eluting with a gradient of 0-80% ethyl acetate in heptane, to yield tert-butyl (2S,4R)-2-hydroxy-2-vinyl-6-azaspiro[3.5]nonane-6-carboxylate (4.82 g, 18.0 mmol, 24% yield). ’H NMR (400 MHz, CDCl3) 5 ppm 5.99 - 6.20 (m, 1 H). 4.94 - 5.34 (m, 2 H). 3.47 - 3.58 (m, 2 H), 3.29 - 3.40 (m, 2 H), 2.01 (s, 4 H), 1.55 - 1.57 (m, 1 H), 1.45 - 1.52 (m, 13 H) and tert-butyl (2s,4r)-2-hydroxy-2-vinyl-6-azaspiro[3.5]nonane-6-carboxylate (5.25 g, 19.7 mmol, 26% yield). !H NMR (400 MHz, CDCI3) 5 ppm 6.14 (dd. / =17.2, 10.6 Hz. 1 H), 5.07 - 5.39 (m. 2 H), 3.20 - 3.39 (m, 4 H). 2.14 - 2.32 (m, 2 H). 1.84 - 1.94 (m, 2 H). 1.65 1.80 (m, 3 H). 1.45 - 1.52 (m, 11 H). Diastereoisomers have been determined by NOESY NMR spectrocopy.

[00254] Step 2. tert-Butyl (2S',41?)-2-((triethylsilyl)oxy)-2-vinyl-6-azaspiro[3.5]nonane-6-carboxylate. In a 100 mL round-bottom flask was charged with tert-butyl (2x,4r)-2-hydroxy-2-vinyl-6-azaspiro[3.5]nonane-6-carboxylate (5.25 g, 19.7 mmol), imidazole (3.48 g, 51.1 mmol) in dichloromethane (100 mL). The mixture was cooled to 0 °C and chlorotriethylsilane (4.3 mL, 25.5 mmol) was added. The mixture was allowed to warm to room temperature with stirring for 30 minutes. Water was added and the aqueous phase was extracted with EtOAc. The combined organic layers were dried over sodium sulfate, filtered, and concentrated. The crude was purified by column chromatography on silica gel, eluting with a gradient of 0-50% ethyl acetate (0.1% EtjN as an additive) in heptane, to yield tert-butyl (2S.4.R)-2-((triethylsilyl)oxy)-2-vinyl-6-azaspiro[3.5]nonane-6-carboxylate (7.40 g, 19.4 mmol, 99%yield). !H NMR (400 MHz, CDCl3) 5 ppm 5.97 - 6.27 (m, 1 H), 5.21 -5.46 (m, 1 H), 5.04-5.21 (m, 1 H), 3.20 - 3.36 (m. 4 H), 2.15 - 2.42 (m, 2 H), 1.83-2.04 (m, 2 H), 1.60 - 1.75 (m, 2 H), 1.46 - 1.57 (m, 11 H). 0.94 - 1.05 (m, 8 H). 0.57 - 0.65 (m, 6 H).

[00255] Step 3. tert-Butyl (2S,,47?)-2-(2-hydroxyethyl)-2-((triethylsilyl)oxy)-6-azaspiro[3.5]nonane-6-carboxylate. In a 150 mL flask under nitrogen was charged with tert-butyl (2s.4r)-2-((triethylsilyl)oxy)-2-vinyl-6-azaspiro[3.5]nonane-6-carboxylate (7.40 g, 19.4 mmol) in tetrahydrofuran (100 mL). The contents were cooled to 0 °C and 9-borabicyclo|3.3.1|nonane (80 mL, 40 mmol) was added slowly. The reaction mixture was allowed to warm to room temperature with stirring for 5 h. The mixture was cooled again to 0 °C and 3 N NaOH (42 mL, 14 mmol) and hydrogen peroxide (12.9 mL, 126 mmol) was added. The mixture was allowed to warm to room temperature with stirring for 3 h. The organic layer was separated, and the aqueous layer was extracted with EtOAc. The combined organic layers were dried over sodium sulfate, filtered, and concentrated. The crude was purified by column chromatography on silica gel, eluting with a gradient of 0-100% ethyl acetate in heptane, to give tert-butyl (2lS',47?)-2-(2-hydroxjethyl)-2-((triethylsilyl)oxy)-6-azaspiro[3.5]nonane-6-carboxylate (6.23 g, 15.6 mmol, 80%yield) 'HNMR (400 MHz, CDCh) 8 ppm 3.77 - 3.97 (m, 2 H), 3.20 - 3.40 (m, 4 H), 2.53 - 2.70 (m, 1 H), 2.10 - 2.22 (m, 2 H), 1.85 - 2.00 (m, 4 H), 1.61 - 1.68 (m, 2 H), 1.43 - 1.53 (m, 11 H), 0.92 - 1.02 (m, 9 H), 0.59 -0.71 (m, 6 H).

[00256] Step 4. tert-Butyl (2A',4 / ?)-2-(2-((methylsulfonyl)oxy)ethyl)-2-((triethylsilyl)oxy)-5-azaspiro[3.5]nonane-5-carboxylate. To a 100-mL round bottom flask was charged xvith tert-butyl (2S,4R)-2-(2-hydroxyethyl)-2-((triethylsilyl)oxy)-6-azaspiro[3.5]nonane-6-carboxylate (6.23 g, 15.6 mmol) and triethylamine (6.5 mL, 47 mmol) in dichloromethane (80 mL). Methanesulfonyl chloride (2.4 mL, 31 mmol) and A.A-dimcthylpyridinM-amine (0.38 g, 3.11 mmol) was added sequentially. After 2 h of stirring at room temperature, the mixture was quenched w ith water and extracted w ith CH2CI2. The combined organic layers were dried over Na2SO4, filtered, and concentrated. The crude material w as purified by column chromatography on silica gel, eluting with a gradient of 0-100% ethyl acetate in heptane, to provide tert-buty l (2>S',4R)-2-(2-((methylsulfonyl)oxy)ethyl)-2-((triethylsilyl)oxy)-5-azaspiro[3.5]nonane-5-carboxylate (6.66 g, 13.9 mmol, 90% yield). ’HNMR (400 MHz, CDCI3) 8 ppm 4.47 - 4.24 (in, 2H), 3.40 - 3.26 (m, 4H), 3.06 - 2.96 (m, 3H), 2.20 - 2.07 (m, 4H), 1.94- 1.86 (m, 2H), 1.67- 1.60 (m, 2H), 1.53 - 1.44 (m, 11H), 1.02- 0.94 (m, 9H), 0.720.52 (m, 6H).

[00257] Step 5. tert-Butyl (25,47?)-2-(2-(2-(4-bromo-6-chloro-l-(tetrahydro-2H-pyran-2-yl)-17T-indazol-5-yl)ethoxy)cthyl)-2-hydroxy-6-azaspiro[3.5]nonane-6-carboxylate. A 100 mL roundbottom flask w as charged with 2-(4-bromo-6-chloro-l -(tctrahydro-2 / / -pyran-2-y 1)-1 / / -indazol-5-yl)ethan-l-ol (Step 1 of Intermediate E, 5.08 g, 14.1 mmol), tetrahydrofuran (20 mL), and N,N-dimethylfonnamide (7 mL). Sodium hydride (60 wt% in mineral oil, 0.28 g, 7.08 mmol) w as added, and the reaction mixture was stirred at room temperature for 30 minutes. tert-Butyl (2S,4R)-2-(2-((methylsulfonyl)oxy)ethyl)-2-((triethylsilyl)oxy)-5-azaspiro[3.5]nonane-5-carboxylate (1.69 g, 3.54 mmol) in THF (5 mL) was added and the reaction mixture was wanned to 50 °C for 72 h. The mixture was quenched carefully with water and extracted with EtOAc. The combined organic layer was dried over sodium sulfate, filtered, and concentrated. The crude material was purified by column chromatography on silica gel, eluting with a gradient of 0-100% ethyl acetate in heptane, to give tertbutyl (25.4R)-2-(2-(2-(4-bromo-6-chloro-l-(tetrahydro-2 / 7-pyran-2-yl)-l / / -indazol-5-yl)ethoxy)ethyl)-2-hydroxy-6-azaspiro[3.5]nonane-6-carboxylate (0.68 g. 1.08 mmol. 31% yield), m / z (ESI): 648.0 (M+Na)+. *H NMR (400 MHz, CDCI3) 8 ppm 7.92 - 8.09 (m, 1 H), 7.65 - 7.76 (m, 1 H), 5.58 - 5.74 (m, 1 H), 3.98 - 4.07 (m, 1 H), 3.64 - 3.80 (m, 5 H), 3.27 - 3.44 (m. 4 H), 3.21 - 3.26 (m. 2 H), 2.42 - 2.55 (m, 1 H), 2.08 - 2.23 (m, 2 H), 1.90 - 2.04 (m. 4 H), 1.65 - 1.85 (m. 7 H), 1.42 - 1.53 (m, 11 H).

[00258] Step 6. tert-Butyl (25,47?)-2-(2-(2-(6-chloro-l-(tetrahydro-27 / -pyran-2-yl)-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l / / -indazol-5-yl)ethoxy)ethyl)-2-hydroxy-6-azaspiro[3.5]nonane-6-carboxylate. A vial was charged with tris(4-methoxyphenyl)phosphine (46 THP mg, 0.13 mmol), palladium acetate (24 mg, 0.11 mmol), bis(pinacolato)diboron (0.41 g, 1.62 mmol), cesium carbonate (0.71 g, 2.16 mmol), tert-butyl (2S,47?)-2-(2-(2-(4-bromo-6-chloro-l-(tetrahydro-2 / 7-pyran-2-yl)-l / / -indazol-5-yl)ethoxy)ethyl)-2-hydroxy-6-azaspiro[3.5]nonane-6-carboxylate (0.68 g. 1.08 mmol) and ethyl acetate (4 mL). The reaction mixture was then sparged with N2 for 3 min and heated to 80 °C for 1 h. After cooling to room temperature, the mixture was filtered through a pad of celite and and the filtrate was purified by column chromatography on silica gel, eluting with a gradient of 0-100% ethyl acetate in heptane, to provide tert-butyl (2S',47?)-2-(2-(2-(6-chloro-l-ftctrahy dro-2H-py ran-2-y 1)-4-(4,4,5,5 -tetramethyl-1,3,2-dioxaborolan-2-y 1)-1 W-indazol-5 -yl)ethoxy)ethyl)-2-hydroxy-6-azaspiro[3.5]nonane-6-carboxylate (0.49 g. 0.72 mmol, 67% yield, purity: 63%). m / z (ESI): 674.4 (M+H)1. Intermediate O: 5-(2-((ter / -ButyIdimethylsilyl) oxy)ethyI)-6-methyl-l-(tetrahydro-2H-pyran-2-yl)-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l / f-indazole. OH BugSri^                 I         NalO4, K2OsO4*H2O Pd(PPh3)4             ||            2,6-dimethylpyridine LiCI, 4A MS, toluene      A-jjJ        1,4-dioxane / H2O Step1          n-N              Step 2 THP

[00259] Step 1. 5-Allyl-4-bromo-6-methyl-l-(tetrahydro-2 / / -pyran-2-yl)-l / / -indazole. To a solution of 4-bromo-5-iodo-6-mcthyl-1-(tetrahydro-2W-pyran-2-yl)-1 / / -indazole (120 g, 285 mmol. Advanced ChemBlocks) in toluene (1.2 L) was added 4A MS (40 g, 285 mmol). LiCI (59.8 g, 1.43 mol) and Pd(PPh3)4 (32.9 g, 28.5 mmol) under N2. Then allyltributylstannane (132 g, 399 mmol) was added in one portion under N2. The mixture was stirred at 110 °C for 12 h. After cooling to room temperature, the reaction mixture was diluted with water and extracted with ethyl acetate. The combined organics were dried over Na2SO4, filtered and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel. eluting with a gradient of 1-100% ethyl acetate in petroleum ether, to give 5-allyl-4-bromo-6-methyl-l-(tetrahydro-27f-pyran-2-yl)-l / / -indazolc (80 g, 250 mmol, 87% yield).

[00260] Step 2. 2-(4-Bromo-6-methyl-l-(tetrahydro-2H-pyran-2-yl)-lH-indazol-5-yl)acetaldehyde. To a solution of 5-allyl-4-bromo-6-methyl-l-(tetrahydro-27f-pyran-2-y 1)-1 / / -indazole (40.0 g. 119 mmol) in 1,4-dioxane (800 mL) and water (400 mL) was added K2OsO4’H2O (1.98 g, 5.97 mmol) and 2,6-dimethylpyridine (38.4 g, 358 mmol), then sodium periodate (77.0 g, 358 mmol) was added and the reaction was stirred at room temperature for 2 h. The reaction mixture was quenched by addition of sat. Na2SO2 at 0 °C for 1 h. The reaction mixture was diluted with water and extracted with ethyl acetate. The combined organics were dried over Na2SO4, filtered and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel, eluting with a gradient of 1-100% ethyl acetate in petroleum ether, to give 2-(4-bromo-6-methyl-l-(tetrahydro-2 / / -pyran-2-yl)-17 / -indazol-5-yl)acetaldehyde (27.5 g, 82 mmol, 69% yield).

[00261] Step 3. 2-(4-Bi omo-6-methy 1-1-(tetrahydro-2H-pyran-2-yl)-l H-indaz(»l-5-yl)ethan-l-ol. To a solution of 2-(4-bromo-6-methyl-l-(tetrahydro-2H-pyran-2-yl)-17 / -indazol-5-yl)acetaldehyde (40.0 g, 119 mmol) in ethanol (800 mL) was added sodium tetrahydroborate (13.5 g, 356 mmol) in portions at 0 °C. Then the reaction was stirred at room temperature for 2 h under N2. The reaction mixture was quenched by addition of sat. NH4C1 (1 L) at 0 °C. The reaction mixture was diluted with water and extracted with ethyl acetate. The combined organics were dried over Na2SO4, filtered and die filtrate was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel, eluting with a gradient of 1-100% ethyl acetate in petroleum ether, to give 2-(4-bromo-6-methyl-l-(tetrahydro-2H-pyran-2-yl)-lH-indazol-5-yl)ethan-l-ol (36.2 g. 107 mmol, 90% yield), m / z (ESI): 339.0 / 341.0 (M+H)+. Intermediate P: tert-Butyl (2S,4^)-2-(2-(2-(4-bromo-6-methyl-l-(tetrahydro-2H-pyran-2-yl)-lH-indazol-5-yl)ethoxy)ethyl)-2-hydroxy-6-azaspiro[3.5]nonane-6-carboxylate. Intermediate O NaH, THF, DMF

[00262] tert-Butyl (25',47?)-2-(2-(2-(4-bromo-6-methyl-l-(tetrahydro-2f7-pyran-2-yl)-lf7-indazol-5-yl)ethoxy)ethyl)-2-hydroxy-6-azaspiro[3.5]nonane-6-carboxylate. A 150-mL round bottom flask was charged with 2-(4-bromo-6-methyl-l-(tetrahydro-2H-pyran-2-yl)-lLr-indazol-5-yl)ethan-l-ol (Step 3 in Intermediate O, 3.79 g, 11.2 mmol) and tetrahydrofuran (18 mL) at room temperature under N2. Then sodium hydride (60 wt% in mineral oil, 0.39 g, 9.70 mmol) was added and the reaction mixture was stirred at room temperature for 30 minutes. tert-Butyl (25,4A)-2-(2-((methylsulfonyl)oxy)ethyl)-2-((triethylsilyl)oxy)-6-azaspiro[3.5]nonane-6-carboxylate (Step 4 in Intermediate N, 2.32 g, 4.86 mmol) in A / V-dimethylfonnamide (6 mL) was added. The reaction mixture was stirred at 50 °C for 1.5 h, cooled to room temperature and was diluted with water and extracted with EtOAc. The combined organic layers were washed with brine, dried over MgSCU filtered and concentrated. The crude material was purified by column chromatography on silica gel, eluting with a graduent of 0-100% EtOAc in heptane, followed by reversed phase column chromatography using a C18 column, eluting with a gradient of 0-100% (0.1% formic acid in CH3CN / H2O), then basified with saturated Naf ICO;, solution and extracted with EtOAc. The combined organic layers were washed with brine, dried over MgSO4, filtered, and concentrated under reduced pressure to give tert-butyl (25,4A)-2-(2-(2-(4-bromo-6-methyl-l-(tetrahydro-27T-pyran-2-yl)-lH-indazol-5-yl)ethoxy)ethyl)-2-hydroxy-6-azaspiro[3.5]nonane-6-carboxylate (0.46 g, 0.76 mmol, 16% yield), m / z (ESI): 606.2 (M+H)+. 'HNMR (400 MHz, CDCI3) 5 ppm 7.94 (s. 1H), 7.35 (s, 1H), 5.65 (br d, J = 9.0 Hz, 1H). 4.01 (br d, J= 11.1 Hz, 1H), 3.71 (br t, J = 4.8 Hz, 3H), 3.61 (br t, J = 7.2 Hz, 2H), 3.30 (br s, 2H), 3.22 (s, 2H). 3.21-3.16 (m, 2H). 2.54 (s, 3H), 2.16 (br s, 1H), 2.06 (br d. J = 12.1 Hz, 1H), 1.99 (br d. J = 12.5 Hz. 2H), 1.95 - 1.90 (m. 2H), 1.78 (br d, J = 12.8 Hz, 3H). 1.68 -1.65 (m, 2H), 1.56 (s, 4H). 1.48 (br s. 2H), 1.46 (s, 9H). Intermediate Q: 2-(3-(4-Bromo-6-chloro-l-(tetrahydro-2 / 7-pyran-2-yl)-lH-indazol-5-yl)propyl) 6-(tert-butyl) 2-fluoro-6-azaspiro[3.5]nonane-2,6-dicarboxylate.

[00263] Step 1. 6-(tert-Butyl) 2-methyl 2-fluoro-6-azaspiro[3.5]nonane-2,6-dicarboxylate. To a vial containing dichloromethane (25 mL) purged with nitrogen was added bis(2-methoxyethyl)aminosulfur trifluoride (1.4 mL, 7.5 mmol) at -78 °C. To this was added 6-(tert-butyl) 2-methyl 2-hydroxy-6-azaspiro[3.5]nonane-2.6-dicarboxylate (2.05 g, 6.85 mmol) as a solution in dichloromethane (25 mL) dropwise. The reaction mixture was stirred at -78 °C for 2 h and then was allowed to warm to room temperature with stirring for 16 h. The reaction mixture was carefully quenched with saturated aqueous sodium bicarbonate and the dichloromethane layer was decanted, dried (NaeSCL), filtered and concentrated. The residue was purified by column chromatography on silica gel, eluting with a gradient of 0 45% ethyl acetate in heptane, to give 6-( / ert-buty 1) 2-methyl 2-fhioro-6-azaspiro[3.5]nonane-2,6-dicarboxylate (0.21 g, 0.69 mmol. 10% yield) as a mixture of diastereomers, m / z (ESI): 246.2 (M-lBu+H)+.

[00264] Step 2. 6-(tert-Butoxycarbonyl)-2-fluoro-6-azaspiro[3.5]nonane-2-carboxylic acid. To a 20-mL vial was charged with 6-(tert-butyl) 2-methyl 2-fluoro-6-azaspiro[3.5]nonane-2,6-dicarboxylate (0.21 g, 0.69 mmol), tetrahydrofuran (3.5 mL), water (3.5 mL), and lithium hydroxide, monohydrate (58 mg, 1.40 mmol). The reaction was wanned to 45 °C with stirring for 1 h. After cooling to room temperature, the mixture was frozen in a dry-ice acetone bath and lyophilized to give 6-(Zert-butoxycarbonyl)-2-fluoro-6-azaspiro[3.5]nonane-2-carboxylic acid (0.20 g, 0.69 mmol. 100% yield). Wz(ESI): 232.1 (M-‘Bu+H)+.

[00265] Step 3. 2-(3-(4-Bromo-6-chloro-l-(tetrahydro-2 / 7-pyran-2-yl)-l / 7-indazol-5-yl)propyl) 6-(tert-butyl) 2-fluoro-6-azaspiro[3.5]nonane-2,6-dicarboxylate. To a 40-mL vial was charged with 6-(te / -t-butoxy carbonyl)-2-fluoro-6-azaspiro[3.5]nonane-2-carboxy lie acid (0.11 g, 0.37 mmol), acetonitrile (1.8 mL), l,T-dimethyltriethylamine (0.3 mL, 1.8 mmol), and 2-chloro-l-methylpyridinium iodide (0.33 g, 1.30 mmol). The reaction mixture was stirred at room temperature and then 3 -(4-bromo-6-chloro-1 -(tetrahydro-2H-pyran-2-y 1)-1 / / -indazol-5 -yl)propan-1 -ol (Intermediate A, 0.21 g, 0.54 mmol) was added. The solution was heated to 60 °C for 20 h. After cooling to room temperature, the reaction mixture was filtered, and the filtrate was concentrated. The residue was purified by column chromatography on silica gel, eluting with a gradient of 0-60% ethyl acetate in heptane, to yield 2-(3-(4-bromo-6-chloro-l-(tetrahydro-2H-pyran-2-yl)-l / 7-indazol-5-yl)propyl) 6-(tert-butyl) 2-fluoro-6-azaspiro[3.5]nonane-2.6-dicarboxylate (0.17 g, 0.26 mmol. 72% yield), m / z (ESI): 664.0 (M+Na)+. Intermediate R: tert-Butyl (2 / ?,4A')-2-((3-(4-bromo-6-chloro-l-(tetrahvdro-2 / / -pyran-2-yl)-1 / / -indazol-5-yl)propyl)carbamoyl)-2-fluoro-6-azaspiro[3.5]nonane-6-carboxylate and tert-butyl (2A,4 / ?)-2-((3-(4-bromo-6-chloro-l-(tetrahydro-2 / / -pyran-2-yl)-l / / -indazol-5- yl)propyl)carbamoyl)-2-fluoro-6-azaspiro[3.5]nonane-6-carboxylate. 2-CI-1-methylpyridinium iodide iPr2EtN, CH3CN Step 4 Intermediate R

[00266] Step 1. 3-(4-Bromo-6-chloro-l-(tetrahydro-2H-pyran-2-y 1)-1 H-indazol-5-yl)propy 1 methanesulfonate. To a solution of 3-(4-bromo-6-chloro-l-(tetrahydro-2 / / -pyran-2-yl)-l / / -indazol-5-yl)propan-l-ol (Intermediate I, 8.00 g, 21.41 mmol) in dichlorometliane (80 mL) was added TEA (9.0 mL, 64 mmol) and MS2O (5.59 g, 32.1 mmol) at 0 °C. The mixture was stirred at room temperature for 2 h, was then diluted with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na2SO4. filtered, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel, eluting with a gradient of 0-15% EtOAc in petroleum ether, to provide 3-(4-bromo-6-chloro-1 -(tetrahydro-2H-pyran-2-v 1)-1 / 7-indazol-5-yl)propyl methanesulfonate (9.0 g, 20 mmol, 93% yield), m / z (ESI): 475.0 (M+Na)+.

[00267] Step 2. 5-(3-Azidopropyl)-4-bromo-6-chloro-l-(tetrahydro-2 / / -pyran-2-y 1)-1 / / -indazole. To a solution of 3-(4-bromo-6-chloro-l-(tetrahydro-2H-pyran-2-yl)-l / / -indazol-5-yl)propyl methanesulfonate (9.0 g, 20 mmol) in A,A-dirnethylformamide (90 mL) was added NaNs (1.51 g, 23.2 mmol) in portions. Then the mixture was stirred at 80 °C for 2 h. After cooling to room temperature, the reaction mixture was diluted with water and adjusted to pH 9 with 1 N NaOH solution, and then extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated. The crude product containing 5-(3-azidopropyl)-4-bromo-6-chloro-1 -(tetrahydro-2 / / -pyran-2-yl)-1 / / -indazole (8.0 g, 20 mmol) was used in the next step without further purification.

[00268] Step 3: 3-(4-Bromo-6-chloro-l-(tetrahydro-2 / 7-pyran-2-yl)-l / 7-indazol-5-yl)propan-l-amine. To a solution containing 5-(3-azidopropyl)-4-bromo-6-chloro-l-(tetrahydro-2 / 7-pyran-2-yl)-I / / -indazole (8.0 g, 20 mmol) in tetrahydrofuran (80 mL) was added H2O (2.2 mL, 120 mmol) and PPI13 (10.5 g, 40.1 mmol). The reaction mixture was stirred at 60 °C for 2 h, was then diluted with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel, eluting with a gradient of 0-100% EtOAc in petroleum ether, to provide 3-(4-bromo-6-chloro-l-(tetrahydro-2 / 7-pyran-2-yl)-l / 7-indazol-5-yl)propan-l-amine (6.8 g, 18.2 mmol, 91% yield), m / z (ESI): 374.0 (M+H)+. :H NMR (400 MHz, CDCh) 5 ppm 7.96 (s, 1 H), 7.64 (s, 1 H). 5.60 - 5.67 (m, 1 H), 3.94 - 4.06 (m, 1 H), 3.67 - 3.82 (m, 1 H), 3.09 (t.. / =8.0 Hz. 2 H), 2.85 (t, 7=7.2 Hz, 2 H). 2.38-2.57 (m, 1 H).2.11 -2.19(m, 1 H). 2.05-2.11 (m, 1 H). 1.74 - 1.82 (m, 7 H).

[00269] Step 4: tert-Butyl (2 / ?,45)-2-((3-(4-bromo-6-chloro-l-(tetrahydro-2 / 7-pyran-2-yl)-l / / -indazol-5-yl)propyl)carbamoyl)-2-fluoro-6-azaspiro[3.5]nonane-6-carboxylate and to7-butyl (2S,4 / ?)-2-((3-(4-bromo-6-chloro-l-(tetrahydro-2 / / -pyran-2-yl)-l / / -indazol-5-yl)propyl)carbamoyl)-2-fluoro-6-azaspiro[3.5]nonane-6-carboxylate. To a 40-mL vial was charged with 6-( / ert-butoxycarbonyl)-2-fluoro-6-azaspiro[3.5]nonane-2-carboxylic acid (0.20 g, 0.69 mmol), A.A-dimethylformamide (2.5 mL), and Hunig's base (0.42 mL, 2.4 mmol). The mixture was treated with HATU (0.52 g, 1.38 mmol) and stirred for 15 minutes. Then 3-(4-bromo-6-chloro-l-(tetrahydro-2 / / -pyran-2-yl)-lH-indazol-5-yl)propan-l-amine (0.31 g, 0.83 mmol) was added inN,N-dimethylformamide (2 mL). The reaction mixture was stirred for 2.5 h and upon completion directly injected onto a C18 column, and eluted with 5-100% acetonitrile (0.1% formic acid) in water (0.1% formic acid) to give tert-butyl (2 / L4.S)-2-((3-(4-bromo-6-cliloro-l-(lctrahvdro-2H-pvran-2-yl)-lH-indazol-5-yl)propyl)carbamoyl)-2-fluoro-6-azaspiro[3.5]nonane-6-carboxylate (0.12 g, 0.19 mmol. 28% yield). m'z (ESI): 641.0 (M+H)+ and / ert-butyl (2S,47?)-2-((3-(4-bromo-6-chloro-l-(tetrahydro-2H-pyran-2-yl)-IH-indazol-5-yl)propyl)carbamoyl)-2-nuoro-6-azaspiro|3.5|nonanc-6-carboxylatc (0.27 g, 0.43 mmol, 62% yield), m / z (ESI): 641.0 (M+H)+ (stereochemistry arbitrarily assigned). Intermediate S: tert-Butyl 2-((4-(6-chloro-l-(tetrahydro-2H-pyran-2-yl)-4-(4,4,5,5-tetramethyl-l,3,2-dioxaboroIan-2-yl)-177-indazoI-5-yl)butoxy)methyI)-l-oxa-6-azaspiro[3.5]nonane-6-carboxylate.

[00270] Step 1. tert-Butyl 3-hydroxy-3-(oxiran-2-ylmethyl)piperidine-l-carboxylate. To a 250 mL round-bottom flask was charged with 3-chloroperoxybenzoic acid (7.43 g, 33.1 mmol) and dichloromethane (90 mL). The solution was cooled to 0 °C and l-Boc-3-allyl-3-hydroxypiperidine (4.0 mL, 16.6 mmol) was added as a solution in dichloromethane (30 mL). The solution was allowed to warm to room temperature with stirring for 24 h. The reaction mixture was diluted with aqueous sodium thiosulfate solution until no peroxide was detected by peroxide test strips. The aqueous was extracted with dichloromethane, and the dichloromethane layer was washed with saturated aqueous sodium bicarbonate, dried over sodium sulfate, and concentrated. The crude oil was purified by flash column chromatograpghy on silica gel, eluting with 0-80% ethyl acetate in heptane, to give tert-butyl 3-hydroxy-3-(oxiran-2-ylmethyl)piperidine-l-carboxylate (2.68 g, 10.41 mmol. 62% yield). Wz(ESI): 202.1 (M-lBu+H)+.

[00271] Step 2. tert-Butyl 2-(hydroxymethyl)-l-oxa-6-azaspiro[3.5]nonane-6-carboxylate. To a 250 mL round-bottom flask was charged with tert-butyl 3-hydroxy-3-(oxiran-2-ylmethyl)piperidine-1-carboxylate (2.50 g, 9.72 mmol), dimethyl sulfoxide (29 mL), and water (10 mL) under nitrogen. To this was added 10 M aqueous sodium hydroxide (1.0 mL, 10 mmol) and the reaction was heated to 140 °C for 1 h. After cooling to room temperature, the reaction mixture was diluted with ethyl acetate and saturated aqueous sodium chloride. The aqueous layer was extracted with ethyl acetate, and the combined organic layer was washed with saturated aqueous sodium chloride, dried over sodium sulfate and concentrated. The crude oil was purified by column chromatography on silica gel, eluting with 0-80% 3:1 EtOAc / EtOH (with 2% tritethylamine) in heptane, to yield tert-butyl 2-(hydroxymethyl)-l-oxa-6-azaspiro[3.5]nonane-6-carboxylate (0.93 g, 3.60 mmol, 37% yield) as a mixture of diastereomers, m / z (ESI): 202.1 (M-‘Bu+H)+.

[00272] Step 3. tert-Butyl 2-((4-(6-chloro-1-(tetrahydro-2H-pyran-2-yl)-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lZ / -indazoI-5-yl)butoxy)methyI)-l-oxa-6-azaspiro[3.5]nonane-6-carboxylate. To a 40 mL vial was charged with tert-buty l 2-(hydroxymethyl)-l-oxa-6-azaspiro[3.5]nonane-6-carboxylate (0.86 g, 3.30 mmol), tetrahydrofuran (19 mL), and sodium hydride (60 wt% in mineral oil, 0.21 g, 5.30 mmol). The reaction was stirred at room temperature under nitrogen for 15 minutes. Upon completion 3-(4-bromo-6-chloro-1 -(tctrahydro-2H-pyran-2-y 1)-1 / / -indazol-5-yl)propyl methanesulfonate (Step 1 in Intermediate R, 2.25 g, 4.99 mmol) was added and the solution was heated to 55 °C for 20 h. After cooling to room temperature, the reaction was carefully quenched with saturated aqueous ammonium chloride and extracted with ethyl acetate. The organics were dried over sodium sulfate, concentrated, and the residue was purified by column chromatography on silica gel, eluting with 0^10% ethyl acetate in heptane, following by reversed phase column chromatography to yield tert-butyl 2-((3-(4-bromo-6-chloro-l-(tetrahydro-2H-pyran-2-yl)-l / / -indazol-5-yl)propoxy)methyl)-l-oxa-6-azaspiro[3.5]nonane-6-carboxylate (1.18 g. 1.92 mmol, 58% yield) as a mixture of diastereomers. Intermediate T: 2-(4-Bromo-6-ethyl-l-(tetrahydro-2 / T-pyran-2-yl)-l / 7-indazol-5-yl)ethan-l-ol. Fe, NH4CI, EtOH THE H2O Step 1 NBS DCM Step 2 HCI, NaNO2. KI ACN, H2O Step 3 LDA, DMF THF Step 4 N2H4 H2O DMSO Step 5 DHP,TsOH.H2O DCM Step 6 Pd(PPh3)4, LiCI Toluene Step 7 K2OsO4 h2o 2,6-dimethylpyridine NalO4 dioxane, H2O Step8 NaBH4 EtOH Step 9 OH Intermediate T

[00273] Step 1. 2-Ethyl-4-fluoroaniline. To a solution of 2-ethyl-4-fluoro-l-nitrobenzene (15 g, 89 mmol) in tetrahydrofuran (90 mL) and ethanol (90 mL) and water (18 mL) was added NH4C1 (7.11 g. 133 mmol) and iron (24.76 g. 443 mmol) under N: then the mixture was stirred at 90 °C for 2 h. The reaction mixture was combined with three other batches (15 g x 2, 5 g) and concentrated under reduced pressure. The residue was diluted with water and extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated to give 2-ethyl-4-fluoroaniline (40 g in total), m / z (ESI): 140.3 (M+H)+.

[00274] Step 2. 2-Bromo-6-ethyl-4-fluoroaniIine. To a solution of 2-ethyl-4-fluoroaniline (17.5 g. 126 mmol) in dichloromethane (180 mL) was added NBS (24.62 g, 138 mmol) at -10°C. Then the mixture was stirred at room temperature for 1.5 h. The reaction mixture was combined with two other batches (17.5 g, 5 g) and diluted with water and extracted with DCM. The combined organic layers were washed with brine, dried overNa2SO4. fdtered and concentrated. The residue was purified by column chromatography on silica gel, eluting with a gradient of 0-100% EtOAc in petroleum ether, to give 2-bromo-6-ethyl-4-fluoroaniline (33.5 g in total), m'z (ESI): 220.1 (M+H)+.

[00275] Step 3. l-Bromo-3-ethyl-5-fluoro-2-iodobenzene. To a solution of 2-bromo-6-ethyl-4-fluoroaniline (9.50 g. 43.6 mmol) in acetonitrile (100 mL) was added HC1 (37%, 11.6 mL, 139 mmol) and NaNOz (3.91 g, 56.6 mmol) in water (20 mL) dropwise at 0 °C. The mixture was stirred at 0 °C for 0.5 h, and then KI (9.40 g, 56.6 mmol) in water (20 mL) was added dropwise at 0 °C. The resulting mixture was stirred at room temperature for 2 h. The mixture was combined with three batches (9.5 g x 2, 5 g) and adjusted to pH 8 - 9 with 1 M aq. NaOH and diluted with water. The aqueous layer was extracted with EtOAc, and the combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel. eluting with a gradient of 0-10% EtOAc in petroleum ether, to give l-bromo-3-ethyl-5-fluoro-2-iodobenzene (45 g in total). 'HNMR (400 MHz, CDCI3) 5 ppm 7.27 - 7.31 (m, 1 H), 6.87-6.96 (m. 1 H), 2.85 (q, / =7.6 Hz, 2 H), 1.22 (t, / =7.2 Hz, 3 H).

[00276] Step 4. 2-Bromo-4-ethyl-6-fluoro-3-iodobenzaldehyde. To a solution of l-bromo-3-ethyl-5-fluoro-2-iodobenzene (17.5 g, 53.2 mmol) in tetrahydrofuran (180 mL) was added LDA (2 M in THF, 29.3 mL, 58.5 mmol) dropwise at -78 °C. The mixture was stirred at -78 °C for 0.5 h and then DMF (5.4 mL. 69 mmol) was added dropwise at -78 °C. The resulting mixture was stirred at -78 °C for 1.5 h. The reaction mixture was combined with two batches (17.5 g, 5 g) and quenched by sat. NH4CI at 0 °C, and then diluted water and extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SOi, filtered and concentrated. The residue was purified by column chromatography on silica gel, eluting with a gradient of 0-10% EtOAc in petroleum ether, to give 2-bromo-4-ethyl-6-fluoro-3-iodobenzaIdehyde (27 g in total). ’HNMR (400 MHz, CDCI3) 6 ppm 10.20 (s, 1 H). 7.11 (d. / =11.2 Hz, 1 H), 2.92 (q, / =7.6 Hz, 2 H), 1.26 (t, / =7.2 Hz, 3 H).

[00277] Step 5. 4-Bromo-6-ethyl-5-iodo-lH-indazole. To a solution of 2-bromo-4-ethyl-6-fluoro-3-iodobenzaldehyde (27 g, 76 mmol) in dimethyl sulfoxide (300 mL) was added hydrazine monohydrate (19.52 g, 382 mmol). Then the mixture was stirred at 110 °C for 12 h. After cooling to room temperature, the reaction mixture was poured into water. The solid was collected by filtration and the filter cake was concentrated under reduced pressure to give 4-bromo-6-ethyl-5-iodo-l / f-indazole (23 g, 65.5 mmol, 87% yield). ’H NMR (400 MHz, CDC72) 5 ppm 8.01 (s, 1 H), 7.33 (s, 1 H), 2.98 (q, / =7.6 Hz, 2 H), 1.29 (t, / =7.6 Hz, 3 H).

[00278] Step 6. 4-Bromo-6-ethyl-5-iodo-l-(tetrahydro-2H-pyran-2-yl)-lH-indazole. To a solution of 4-bromo-6-ethyl-5-iodo-lH-indazole (23.0 g, 65.5 mmol) in dichloromethane (300 mL) was added TsOH H2O (0.62 g, 3.30 mmol) and DHP (18 mL. 197 mmol) under N2. Then the mixture was stirred at room temperature for 1 h. The reaction mixture was diluted with water and extracted with DCM. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated to give 4-bromo-6-cthyl-5-iodo-l-(tctrahydro-27 / -pyran-2-yl)-177-indazolc (30 g in total).

[00279] Step 7.5-Allyl-4-bromo-6-ethyl-l-(tetrahydro-2H-pyran-2-yl)-lH-indazole. To a solution of 4-bromo-6-ethyl-5-iodo-l-(tetrahydro-277-pyran-2-yl)-lH-indazole (14.0 g. 32.2 mmol) in toluene (200 mL) was added LiCl (6.82 g. 161 mmol) and allyltributylstannane (22.95 g. 69.3 mmol) and Pd(PPh3)4 (3.72 g, 3.22 mmol) under N2. Then the mixture was stirred at 110 °C for 12 h. The reaction mixture was combined with another batch (14 g scale) and diluted with water and extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel, eluting with a gradient of 0-10% EtOAc in petroleum ether, to give 5-allyl-4-bromo-6-cthyl-l-(tctrahydro-2 / / -pyran-2-yl)-l / / -indazole (6.4 g in total), m / z (ESI): 349.2 (M+H)+.

[00280] Step 8. 2-(4-Biomo-6-ethvl-l-(tetrahydro-2W-pyran-2-vl)-lH-indazol-5- yl)acetaldehyde. To a solution of 5-allyl-4-bromo-6-ethyl-1 -(tetrahydro-2H-pyran-2-yl)-IH-indazole (5.9 g, 16.9 mmol) in 1,4-dioxane (100 mL) and water (20 mL) was added K2OsO42H2O (1.25 g, 3.38 mmol), 2,6-dimethylpyridine (3.62 g, 33.8 mmol) and NaIO4 (14.45 g, 67.6 mmol). Then the reaction mixture was stirred at 50 °C for 2 h. The reaction mixture was combined with two other batches (5.9 g, 1 g), diluted with water, and extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography on silica gel, eluting with a gradient of 0-10% EtOAc in petroleum ether, to give 2-(4-bromo-6-ethyl-l-(tetrahydro-2H-pyran-2-yl)-17 / -indazol-5-yl)acetaldehyde (3.9 g in total). 'H NMR (400 MHz, CDCl3) 5 ppm 9.75 (s, 1 H), 7.99 (s, 1 H), 7.41 (s, 1 H). 5.67 - 5.73 (m, 1 H), 4.08 (s, 2 H). 3.98 - 4.06 (m, 1 H), 3.71 - 3.80 (m, 1 H), 2.76 (q, / =7.6 Hz. 2 H), 2.50 - 2.62 (m, 1 H), 2.06 - 2.22 (m, 2 H), 1.65 - 1.83 (m, 3 H), 1.25 - 1.30 (m, 3 H).

[00281] Step 9. 2-(4-Bromo-6-ethyI-l-(tetrahydro-277-pyran-2-yI)-177-indazol-5-yl)ethan-l-oL To a solution of 2-(4-bromo-6-ethyl-l-(tetrahydro-2H-pyran-2-yl)-l / / -indazol-5-yl)acetaldehyde (3.9 g, 11 mmol) in ethanol (40 mL) was added NaBH4 (1.14 g, 30.1 mmol) in portion at 0 °C. Then the mixture was stirred at room temperature for 1 h. The reaction mixture was quenched by water at 0 °C, and then diluted with water and extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography on silica gel, eluting with a gradient of 0-20% EtOAc in petroleum ether, to give 2-(4-bromo-6-ethyl-l-(tetrahydro-2H-pyran-2-yl)-17 / -indazol-5-yl)ethan-l-ol (3.4 g, 9.6 mmol, 87% yield). m / z(ESI): 353.1 (M+H)+. Intermediate U: 4-(Benzyloxy)-7-chloro-8-fluoro-2-(((27?,7a7?)-2-fluorotetrahydro-lH-pyrrolizin-7a(5 / 7)-yl)methoxy)pyrido[4,3-< / ]pyrimidine. BnOH, t-BuOK 4A MS, THF Step 1 DIEA, Dioxane Step 2 OBn Intermediate U

[00282] Step 1. 4-(Benzyloxy)-2,7-dichloro-8-fluoropyrido[4,3-d]pyrimidine. To a solution of 2,4,7-trichloro-8-fluoropyrido[4,3-d]pyrimidine (50.0 g, 198 mmol) and 4A molecular sieves (20 g, 198 mmol) in tetrahydrofuran (1.5 L) was added phenylmethanol (20.4 g, 188 mmol) in t-BuOK (IM in THF , 188 mL, 188 mmol) dropwisc at -60 °C. The reaction mixture was stirred at -60 °C for 2 h, was then diluted with water and extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure. The crude product was triturated with petroleum ether at room temperature for 30 minutes, fdtered and concentrated under reduced pressure to give 4-(benzyloxy)-2,7-dichloro-8-fluoropyrido[4,3-d]pyrimidine (51.2 g, 158 mmol, 80% yield). ’H NMR (400 MHz, DMSO-rA) 5 ppm 9.20 (s, 1 H), 7.55 - 7.65 (m, 2 H), 7.39 - 7.48 (m, 3 H). 5.72 (s, 2 H).

[00283] Step 2. 4-(Benzyloxy)-7-chloro-8-fluoro-2-(((27?,7a7?)-2-fluorotetrahydro-lZ7-pyrrolizin-7a(5H)-yl)inethoxy)py rido[4,3-< / ]pyrimidine. A solution of 4-(bcnzyloxy)-2,7-dichloro-8-fluoropyrido[4,3-d]pyrimidine (1.0 g, 3.1 mmol) and ((2R,7aR)-2-fluorotetrahydro-lH-pyrrolizin-7a(577)-yl)methanol (0.69 g, 4.3 mmol) in DIPEA (5 mL, 29 mmol) and 1,4-dioxane (5 mL) was stirred at 100 °C for 1 h. The reaction mixture was diluted with water and extracted with EtOAc. The combmed organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by prep-HPLC (column: Waters Xbridge BEH C18 250 x 70 mm x 10 pm; mobile phase: [A: H2O (10 mM NH4HCO3); B: ACN]; B%: 50-80 %, 20 min) to give 4-(benzyloxy)-7-chloro-8-fluoro-2-(((2J?,7aR)-2-fluorotetr ahydro-lH-pyrrolizin-7a(5 / 7)-yl)methoxy)pyrido[4,3-<: / | pyrimidine (0.25 g, 36 mmol, 18% yield), m / z (ESI): 447.2 (M+H)+. Intermediate V & W: ( / ?)-7-Chloro-2-((l-((dimcthylamino)methyl)-2,2-difluorocyclopropyl)methoxy)-8-fluoropyrido[4,3-«7]pyrimidin-4-ol & (5)-7-chloro-2-((l-((dimethylamino)methyl)-2,2-difluorocyclopropyl)methoxy)-8-fluoropyrido[4,3-< / ]pyrimidin-4-ol. AcOH TEA Step 1 CICF2CO2Na diglyme Step 2 K2CO3 MeOH Step 3 MsCI, TEA DCM Step 5 F 1) Pd / C / Pd(OH)2, H2 TFE 2) 2M HCI / MeOH Step 7 BnBr, NaH DMF Step 4 F DIPEA, dioxane Me2NH in THF K2CO31 THF Step 6 SFC Step 10 Step 8 Intermediate V LiOH H20 THF, H20 Step 9 Me2N OH Intermediate W

[00284] Step 1. 2-Methylenepropane-l,3-diyl diacetate. To a solution of 3-chloro-2-(chloromethyl)prop-l-ene (60.0 g. 480 mmol) in triethylamine (146 g. 1.44 mol) was added acetic acid (72.1 g, 1.20 mol) dropwise. The resulting mixture was heated and stirred at 70 °C for 12 h under N2. After cooling to room temperature, the reaction mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried overNa2SO / i, filtered and concentrated. The residue was purified by column chromatography on silica gel. eluting with a gradient of 5-100% EtOAc in petroleum ether, to provide 2-methylenepropane-1,3 -diyl diacetate (56.4 g, 328 mmol. 67% yield). !H NMR (400 MHz, CDCI3) 5 ppm 5.21 (s, 2 H), 4.54 (s, 4 H). 2.02 (s, 6 H).

[00285] Step 2. (2,2-Difluorocyclopropane-l,l-diyl)bis(methylene) diacetate. To a solution of 2-methylenepropane-1.3-diyl diacetate (80.0 g. 465 mmol) in diglyme (640 mL) was added the solution of ClCF2CO2Na (353 g, 2.32 mol) in diglyme (640 mL) dropwise at 180 °C under nitrogen over 5 h. The resulting mixture was stirred at 180 °C for 1 h. After cooling to room temperature, the reaction mixture was diluted with water and extracted with petroleum ether. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated to give the crude containing (2,2- difluorocyclopropane-l,l-diyl)bis(methylene) diacetate (80 g) which was used directly without further purification.

[00286] Step 3. (2,2-Difluorocyclopropane-l,l-diyl)dimethanol. To a solution of (2,2-difluorocyclopropane-l,l-diyl)bis(methylene) diacetate (100 g, 450 mmol) in methanol (1.25 L) was added potassium carbonate (124 g, 900 mmol). The resulting mixture was stirred at room temperature for 12 h under N2, was then diluted with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography on silica gel, eluting with a gradient of 5-100% EtOAc in petroleum ether, to provide (2,2-difluorocyclopropanc-l,l-diyl)dimcthanol (43.0 g, 312 mmol, 69% yield).

[00287] Step 4. (1 -((Benzyloxy)methy])-2,2-difluorocyclopropyl)methanol. To a solution of (2,2-difluorocyclopropane-l,l-diyl)dimethanol (64.0 g. 463 mmol) in AJV-dimethylformamide (1.18 L) was added sodium hydride (60 wt% in mineral oil. 22.2 g, 927 mmol) in portions under N2 at 0 °C. The mixture was stirred at 0 °C for 1 h. Then the solution of (bromomethyl)benzene (95.0 g, 556 mmol) in A,A-dimethylformamide (100 mL) was added dropwise at 0 °C. The resulting mixture was stirred at 0 °C for 1 h under N2, was then diluted with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried overNa2SO4, filtered and concentrated. The residue was purified by column chromatography on silica gel, eluting with a gradient of 5-100% EtOAc in petroleum ether, to provide (l-((bcnzyloxy)mcthyl)-2,2-difluorocyclopropyl)mcthanol (47.75 g, 209 mmol, 45% yield).

[00288] Step 5. (l-((Benzyloxy)methyl)-2,2-difluorocyclopropyl)methyl methanesulfonate. To a 3-L three-neck bottle was added the solution of (1-((benzyloxy )methy 1)-2.2-difluorocyclopropyl)methanol (58.0 g, 254 mmol) in dichloromethane (1.2 L), TEA (142 mL, 1016 mmol) was added slowly at 0 °C, then methanesulfonyl chloride (57.7 g, 504 mmol) was added dropwise at 0 °C under N2. The resulting mixture was stirred at room temperature for 3 h, was then diluted with ice water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography on silica gel, eluting with a gradient of 5-100% EtOAc in petroleum ether, to provide (l-((benzyloxy)methyl)-2,2-difluorocyclopropyl)methyl methanesulfonate (70.0 g, 228 mmol, 90% yield).

[00289] Step 6. l-(l-((Benzyloxy)methyl)-2,2-difluorocyclopropyl)-A^V-dimethylmethanamine. To a solution of (l-((benzyloxy)methy 1)-2,2-difluorocyclopropyl)methyl methanesulfonate (40.0 g. 131 mmol) in tetrahydrofuran (400 mL) was added Me2NH in THF (326 mL, 653 mmol) and K2CO2 (36.1 g, 261 mmol) in sequence. The resulting mixture was stirred at 50 °C for 24 h under N2, was dien diluted with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography on silica gel, eluting with a gradient of 5-100% EtOAc in petroleum ether, to provide 1-(l-((benzyloxj)methyl)-2,2-difluorocyclopropyl)-A,Ar-dimethylmethanamine (24 g, 94 mmol, 72% yield).

[00290] Step 7. (l-((Dimethylamino)methyl)-2,2-difluorocyclopropyl)methanol. To a solution of 10% Pd / C (8 g) and 20% Pd(OH)2 (8 g) in 2,2,2-trifluoroethan-l-ol (1 L) was added 1-(1-((benzyloxy)methyl)-2,2-difluorocyclopropyl)-AyV-dimethylmethanamine (50 g, 196 mmol) under an Argon atmosphere. The suspension was degassed and purged with H2 for 3 times. The reaction mixture was stirred under H2 (15 psi) at room temperature for 12 h, was then filtered through a pad of cclitc and washed with methanol. To the combined filtrate was treated with HC1 (3 M in McOH, 100 mL, 300 mmol), then was concentrated under reduced pressure to give (l-((dimethylamino)methyl)-2,2-difluorocyclopropyl)methanol (20.49 g, 102 mmol, 52% yield, as its HC1 salt).

[00291] Step 8. l-(l-(((7-Chloro-8-fluoro-4-(2,2,2-trifluoroethoxy)pyrido[4,3-< / ]pyrimidin-2-yl)oxy)methyl)-2,2-difluorocyclopropyl)-A^V-dimethylmethanamine. To a solution of 2,7-dichloro-8-fluoro-4-(2,2,2-trifluoroethoxy)pyrido[4,3-d]pyrimidine (Step 1 in Intermediate C, 20.0 g, 63.3 mmol) in 1,4-dioxane (400 mL) was added (l-((dimethylamino)methyl)-2,2-difluorocyclopropyl) methanol hydrochloride (15.31 g, 76 mmol) and DIPEA (27.6 mL, 158 mmol) in sequence under N2 at 0 °C. The reaction mixture was stirred at room temperature for 3 h, was then diluted with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na2SO4, fdtered, and concentrated to give l-(l-(((7-chloro-8-fluoro-4-(2,2,2-trifluoroethoxy)pyrido[4,3-t / |pyrimidin-2-yl)oxj')methyl)-2,2-difluorocyclopropyl)-A,A-dimethylmethanamine (12.3 g, 27 mmol, 44% yield).

[00292] Step 9. 7-Chloro-2-((l-((dimethylamino)methyl)-2,2-difluorocyclopropyl)methoxy)-8-fluoropyrido[4,3-rf]pyrimidin-4-oL To a solution of l-(l-(((7-chloro-8-fluoro-4-(2.2,2-trifluoroethoxy)pyrido[4,3-6 / ]pyrimidin-2-yl)oxy)methyl)-2,2-difluorocyclopropyl)-A,A-dimethylmethanamine (32.3 g, 72.6 mmol) in tetrahydrofuran (640 mL) and water (128 mL) was added LiOHH2O (12.2 g, 290 mmol). The reaction mixture was stirred at 60 °C for 2 h. After cooling to room temperature, the mixture was combined with another batch (10 g) and diluted with H2O and extracted with ethyl acetate. The combined organic layers were dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography on silica gel, eluting with a gradient of 5-100% EtOAc in petroleum ether, to provide 7-chloro-2-((l-((dimethylamino)methyl)-2.2-difluorocyclopropyl)methoxy)-8-fluoropyrido[4.3-J]pyrimidin-4-ol (25.5 g, 70 mmol, 74% yield).

[00293] Step 10. (7?)-7-Chloro-2-((l-((dimethylamino)methyl)-2,2-difluorocyclopropyl)methoxy)-8-fluoropyrido[4,3-< / ]pyrimidin-4-ol & (5)-7-chloro-2-((l-((dimethylamino)methyl)-2,2-difluorocyclopropyl)methoxy)-8-fluoropyrido[4,3-< / |pyrimidin-4-ol. 7-Chloro-2-((l-((dimcthylamino)mcthyl)-2,2-difluorocyclopropyl)mcthoxy)-8-fluoropyrido[4,3- <7]pyrimidin-4-ol (33 g, 91 mmol) was separated by SFC (Column: Chiralpak IG 250 x 50 mm, 10 pm, Mobile phase: A for CO2 and B for EtOH (0. 1%NHj H2O), Gradient: B%=60% isocratic, Flow rate: 200 mL / min) to give two compounds (the structures were temporary assigned) as follows: Peak 1: (7?)-7-chloro-2-((l-((dimethylamino)methy 1)-2,2-difluorocyclopropyl)methoxy)-8-fluoropyrido[4,3-<7]pyrimidin-4-ol (13.8 g, 38.1 mmol, 42% yield), m / z (ESI): 363.1 / 365.0 (M+H)+. ’HNMR (400 ^Rz^METHANOL-d^ 5 ppm 8.72 (s, 1 H), 4.48 - 4.59 (m, 2 H), 2.98 (d, J= 13.6 Hz, 1 H), 1.T1 (d, J= 12.8 Hz, 1 H), 2.52 (s, 6 H), 1.76- 1.79 (m, 1 H), 1.51 - 1.54 (m, 1 H). ,9FNMR (376 MHz, METHANOL-dJ) 5 ppm -136.99 - -137.42 (m, 1 F). -138.84 -139.55 (m, 2 F). SFC: ee % = 99.9% Peak 2: (S)-7-chloro-2-((l-((dimethylamino)methy 1)-2,2-difluorocyclopropyl)methoxy)-8-fluoropyrido[4,3-<7]pyrimidin-4-ol (16.7 g, 47.7 mmol, 52% yield), m'z (ESI): 363.1 / 365.0 (M+H)+. 'HNMR (400 MR^METHANOL-d^ 5 ppm 8.74 (s, 1 H), 4.50 (s, 2 H), 2.86 (d, J= 16.4 Hz, 1 H), 2.40 (d, J= 14.4 Hz, 1 H), 2.26(s, 6 H), 1.64 - 1.65 (m, 1 H), 1.32 - 1.33 (m, 1 H). ”FNMR (400 MHz, MEIHANOL-d4) 5 ppm-137.31 - -137.73 (m, 1 F), -138.94 -139.70 (m, 2 F). SFC: ee% = 99.7%. Intermediate X: 3-(4-Bromo-6-methvl-1-(tctrahvdro-2 / 7-pyran-2-vl)-l / 7-indazol-5-yl)propan-l-ol.

[00294] The title compound was synthesized analogous to Intermediate A using 4-bromo-5-iodo-6-methyl-l-(tetrahydro-2H-pyran-2-yl)-lH-indazole (Advanced ChemBlocks) in Step 1. m / z (ESI): 353.0 (M+H)+. 'H NMR (400 MHz. CDCh) 5 ppm 7.95 (s, 1 H), 7.35 (s, 1 H), 5.58 - 5.76 (m, 1 H), 3.97 - 4.08 (m. 1 H), 3.68 - 3.884 (in, 3 H), 2.91 - 3.07 (in, 2 H), 2.47 - 2.64 (m, 4 H), 2.12 - 2.25 (m, 1 H), 2.06 - 2.12 (m, 1 H), 1.63 - 1.91 (m, 5 H). Intermediate Y: 2-(3-(4-Bromo-6-methyl-l-(tetrahydro-2H-pyran-2-yl)-lH-indazol-5-yl)propyl) 6-(h?rt-butyl) 6-azaspiro[3.5]nonane-2,6-dicarboxylate. Intermediate Y

[00295] A 40-mL vial was charged with HATU (1.86 mg, 4.90 mmol, AA BLOCKS LLC), 1,1'-dimethyltriethylamine (2.1 mL, 12 mmol), 6-( / ert-butoxycarbonyl)-6-azaspiro[3.5]nonane-2-carboxylic acid (1.10 g, 4.08 mmol, Aurum Pharmatech LLC), 3-(4-bromo-6-methyl-l-(tetrahydro-2 / / -pyran-2-yl)-IH-indazol-5-yl)propan-l-ol (Intermediate X, 2.16 g, 6.13 mmol) and N.N-dimethylformamide (20 mL). The reaction mixture was stirred at room temperature for 16 h. the crude mixture was purified by column chromatography on silica gel, eluting with a gradient of 0-85% EtOAc in heptane, to yield 2-(3-(4-bromo-6-methyl-l-(tetrahydro-2H-pyran-2-yl)-lH-indazol-5-yl)propyl) 6-( / ert-butyl) 6-azaspiro[3.5]nonane-2,6-dicarboxylate (Intermediate Y, 2.16 g. 3.57 mmol. 87% yield), m / z (ESI): 606.2 (M+H)+. Intermediate Z: rac-((17?,25)-2-(4-Bromo-6-methyl-l-(tetrahydro-2H-pyran-2-yl)-lH-indazol-5-yl)cyclopropyl) methanol. Pd(dppf)CI2, K3PO4 CH3CN, H2O Intermediate Z

[00296] To a solution of 4-bromo-5-iodo-6-methyl- l-(tetrahydro-2H-pyran-2-yl)- IH-inda / olc (45 g, 107 mmol, Advanced ChcmBlocks) in acetonitrile (1 L) and water (250 mL) was added potassium trifluoro ((LS',27?)-2-(hydroxymethyl)cyclopropyl) borate (38.0 g, 214 mmol, Lab Network), K3PO4 (113 g, 534 mmol) and Pd(dppf)C12 (15.64 g, 21.37 mmol) in sequence under nitrogen. The mixture was stirred at 80 °C for 12 h. After cooling to room temperature, the reaction mixture was diluted with water and extracted with EtOAc. The combined organic layers were dried over Na2SO4, filtered and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel, eluting with 10-35% EtOAc in petroleum ether, to give rac-((lR,2S)-2-(4-bromo-6-methyl-l-(tetrahydro-2H-pyran-2-yl)-l / 7-indazol-5-yl)cyclopropyl) methanol (Intermediate Z, 12.9 g, 35.6 mmol, 33% yield), m / z (ESI): 365.0 / 367.0 (M+H)+. Intermediate AA. ((17?,2A)-2-(4-Bromo-6-chloro-2-trityl-2Z7-indazol-5-yl)cyclopropyl)methanol.

[00297] Total 115 g of rac-(2-(4-bromo-6-chloro-2-trityl-2H-indazol-5-yl)cyclopropyl)methanol was separated by SFC [Instrument: Waters SFC350; Column: DAICEL CHIRALPAK IE (250 mm x 50 mm, 10 pm); Mobile phase: A for CO? and B for EtOH; Gradient: B%=55% isocratic elution mode; Flow rate: 200 mL / min; Wavelength: 220 nm; Column temperature: 40 °C; System back pressure: 100 bar]. The eluent was concentrated to remove organic solvents.

[00298] Compound ((lA.25)-2-(4-bromo-6-chloro-2-trityl-2 / f-indazol-5-yl)cyclopropyl)methanol (44 g as Pl. 100% ee, the structure was temporary assigned) was obtained, m / z (ESI): 243.3 (M+H)+.

[00299] Compound ((lS,2R)-2-(4-bromo-6-chloro-2-trityl-2H-indazol-5-yl)cyclopropyl)methanol (45 g as P2, 98% ee, the structure was temporary assigned) was obtained, m / z (ESI): 243.3 (M+H)+. Intermediate BB: tert-Butyl (2A,4S)-2-((((17?,2A)-2-(4-bromo-6-chloro-2-trityl-2H-indazol-5-yl)cycIopropyI)methoxy)methyl)-l-oxa-6-azaspiro[3.5]nonane-6-carboxylate.

[00300] Step 1. tert-Butyl (3A)-3-(3-(((l / ?,25)-2-(4-bromo-6-chloro-2-trityl-2 / / -indazol-5- yl)cyclopropyl)methoxy)-2-hydroxypropyl)-3-hydroxypiperidine-l-carboxylate. To a stirred mixture of ((lJ?,2S)-2-(4-bromo-6-chloro-2-trityl-2H-indazol-5-yl)cyclopropyl)methanol (Intermediate AA, 1.78 g, 3.26 mmol) in tetrahydrofuran (12 mL) at 0 °C under nitrogen, was added potassium tert-butoxide (0.40 g, 3.54 mmol, Sigma Aldrich). This was stirred at 0 °C for 10 minutes, then tert-butyl (35)-3-hydroxy-3-(oxiran-2-yhnethyl)piperidine-l-carboxylate (Step 1 in Example 1.038, 0.70 g, 2.72 mmol,) was added a solution in tetrahydrofuran (6 mL). The resulting mixture was stirred at 50 °C for 2 h. The reaction was concentrated and the crude material purified by column chromatography on silica gel, eluting with a gradient of 0-100% EtOAc in heptane to provide tertbutyl (35)-3-(3-(((17?,25)-2-(4-bromo-6-chloro-2-trityl-2H-indazol-5-yl)cyclopropyl)methoxy)-2-hydroxypropyl)-3-hydroxypiperidine-l-carboxylate (0.82 g, 1.03 mmol, 37% yield), m / z (ESI): 821.6 (M+Na)+.

[00301] Step 2. tert-Butyl (25,45)-2-((((17?,25)-2-(4-bromo-6-chloro-2-trityl-2 / T-indazol-5-yl)cyclopropyl)methoxy)methyl)-l-oxa-6-azaspiro[3.5]nonane-6-carboxylate. To a stirred mixture of tert-butyl (35)-3-(3-(((17?,25)-2-(4-bromo-6-chloro-2-trityl-2H-indazol-5-yl)cyclopropyl)methoxy)-2-hydroxypropyl)-3-hydroxypiperidine-l-carboxylate (1.38 g, 1.72 mmol) in tetrahydrofuran (17 mL) at 0 °C under nitrogen, was added potassium tert-butoxide (0.43 g, 3.79 mmol). The resulting mixture was stirred at 0 °C for 30 minutes. To this was added 2-nitrobenzenesulfonyl chloride (0.53 g, 2.41 mmol) and the reaction was warmed to room temperature over 16 h. Upon completion the reaction was diluted with water and extracted with ethyl acetate. The ethyl acetate was dried over sodium sulfate and concentrated. The crude material was purified by column chromatography on silica gel. eluting with a gradient of 0-70% EtOAc in heptane to provide tert-butyl (27?,45)-2-((((U?.25)-2-(4-bromo-6-chloro-2-trityl-2rt-indazol-5-yl)cyclopropyl)methoxy)methyl)-l-oxa-6-azaspiro[3.5]nonane-6-carboxylate (0.35 g, 0.44 mmol, 25% yield), m / z (ESI): 804.0 (M+Na)+ and tert-butyl (25.45)-2-((((17?,25)-2-(4-bromo-6-chloro-2-trityl-2H-indazoI-5-yl)cyclopropyl)methoxy)methyl)-l-oxa-6-azaspiro[3.5]nonane-6-carboxylate (0.26 g, 0.33 mmol. 19% yield), m / z (ESI): 804.0 (M+Na)+. Intermediate CC: tert-Butyl (31?,57?)-l,7-dioxa-10-azadispiro[2.1.65.l3]dodecane-10-carboxylate and Intermediate DD: tert-butyl (35,55)-1,7-dioxa-10-azadispiro[2.1.65.l3]dodecane-10-carboxylate.

[00302] Step 1. tert-Butyl 2-oxo-6-oxa-9-azaspiro[3.6]decane-9-carboxylate. To a 250-inL round-bottom flask was added tert-butyl 2-hydroxy-6-oxa-9-azaspiro[3.6]decane-9-carboxylate (2.50 g. 9.72 mmol, Enamine) in dichloromethane (50 mL). The mixture was cooled to 0 °C and Dess Martin periodinane (4.94 g, 11.7 mmol) was added. The reaction mixture was stirred at 0 °C for 1 h and then at room temperature for 1 h. The reaction mixture was quenched with a mixture of 0.1 N sodium thiosulfate solution and saturated sodium bicarbonate solution (1:1). The aqueous layer was extracted with dichloromethane and tire combined organic layers were dried over sodium sulfate, filtered, and concentrated. The crude material was purified by column chromatography on silica gel, eluting with a gradient of 5-80% EtOAc in heptane, to give tert-butyl 2-oxo-6-oxa-9-azaspiro[3.6]decane-9-carboxylate (2.6 g, 10 mmol, crude), m / z (ESI): 200.0 (M-‘Bu+H)+. 1H NMR (400 MHz, CDCh) 5 ppm 3.89 - 3.69 (in. 6H), 3.65 - 3.50 (m. 2H), 3.11 - 2.78 (m, 4H), 1.49 (s, 9H).

[00303] Step 2. tert-Butyl l,7-dioxa-10-azadispiro[2.1.65.l3]dodecanc-10-carboxylate. To a solution of potassium tert-butoxide (2.69 g, 23.9 mmol) in dimethyl sulfoxide (50 mL) was added trimethylsulfoxonimn iodide (5.87 g, 26.7 mmol) under nitrogen. The reaction mixture was stirred at room temperature for 1.5 h, 1,2-dimethoxyethane (10 mL) was added at 0 °C. Then tert-butyl 2-oxo-6-oxa-9-azaspiro[3.6]decane-9-carboxylate (4.7 g, 18 mmol) in 1,2-dimethoxyethane (10 mL) and dimethyl sulfoxide (2.5 mL) was added at 0 °C. The mixture was stirred at 0 °C for 2 h and at room temperature for 1 h. The mixture was quenched by addition of water at 0 °C, and then extracted with EtOAc. The combined organic layers were washed with water and brine, dried over Na2SO4. filtered and concentrated. The crude material was purified by column chromatography on silica gel, eluting with a gradient of 5-80% EtOAc in heptane, to give tert-butyl l,7-dioxa-10-azadispiro[2.1.6'’.l3]dodecane-10-carboxylate (3.15 g, 11.7 mmol, 64% yield), m / z (ESI): 214.0 (M-lBu+H)+. ]H NMR (400 MHz, CDCI3) 5 ppm 3.78 - 3.50 (in. 8H), 2.80 - 2.68 (in. 2H), 2.48 - 2.21 (m. 4H), 1.51-1.48 (m. 9H).

[00304] Step 3. tert-Butyl (3 / ?,5 / ?)-l,7-dioxa-10-azadispiro[2.1.65.l3]dodecane-10-carboxylate and tert-butyl (35,55)-1,7-dioxa-10-azadispiro[2.1.65.l3]dodecane-10-carboxylate. tert-Butyl 1,7-dioxa-10-azadispiro[2.1.65.l3]dodecane-10-carboxylate (3.12 g, 11.6 mmol) was purified via SFC using a ChiralPak IG, 3 x 25 cm, 5 pm column with a mobile phase of 10% EtOH using a flowrate of 200 mL / min to generate 0.98 g of tert-butyl (3R,5R)-l,7-dioxa-10-azadispiro[2.1.65. l3]dodecane-10-carboxylate with an ee of 99%. m / z (ESI): 214.0 (M-lBu+H)+. ’H NMR (400 MHz, CDCI3) 6 ppm 3.81 - 3.63 (m, 5H). 3.61 (s, 1H), 3.58 - 3.45 (m, 2H). 2.76 - 2.70 (m, 2H). 2.48 - 2.36 (m, 2H). 2.29 - 2.22 (m. 2H), 1.52 - 1.47 (in. 9H) and 1.7 g of tert-butyl (35.55)-1.7-dioxa-10-azadispiro[2.1.65.l3]dodecane-10-carboxylate with an ee of 99%. m / z (ESI): 214.0 (M-lBu+H)+. ’H NMR (400 MHz. CDCI3) 8 ppm 3.81 - 3.67 (in, 6H), 3.60 - 3.50 (m, 2H), 2.76 (d, J = 9.0 Hz, 2H), 2.39-2.14 (m. 4H), 1.48 (d, J = 6.5 Hz. 9H). Intermediate EE: rac-tert-Butyl 2-((2-((15,25)-2-(4-bromo-6-chloro-l-(tetrahydro-2H-pyran-2-yl)-l / 7-indazol-5-yl)cyclopropyl)ethyl)carbamoyl)-6-azaspiro[3.5]nonane-6-carboxylate. Ms2O, tea DMAP, DCM Step 1 NaN3 DMF Step 2 PPh3 thf / h2o Step 3 DIPEA, DMF Step 4

[00305] Step 1. rac-2-((lS,2S)-2-(4-Bromo-6-chloro-l-(tetrahydro-2H-pyran-2-yl)-l / 7-indazol-5-yl)cyclopropyl)ethyl methanesulfonate. To a solution of rac-2-((LS'.2tS)-2-(4-bromo-6-chloro-l-(tetrahydro-2H-pyran-2-yl)-lH-indazol-5-yl)cyclopropyl)ethan-l-ol (Step 4 in Intermediate LL, 2.0 g, 5.0 mmol) in dichloromethane (20 mL) was added TEA (2.0 mL. 14.3 mmol) and DMAP (61 mg, 0.50 mmol). The contents were cooled to 0 °C, then Ms2O (1.31 g, 7.51 mmol) was added. The reaction mixture was stirred at room temperature for 2 h, then was combined with three other batches (3 g), diluted with water, and extracted with DCM. The combined organic layers were dried over Na2SO4. filtered and the filtrate concentrated under reduced pressure. The residue was purified by column chromatography on silica gel, eluting with a gradient of 5-25% EtOAc in petroleum ether, to yield rac-2-((lS,2S)-2-(4-bromo-6-chloro-l-(tctrahydro-2 / 7-pyran-2-yl)-l A / -indazol-5-yl)cyclopropyl)ethyl methanesulfonate (total 8 g). m z(ESI): 501.1 (M+Na)+.

[00306] Step 2. rac-5-((lS,25)-2-(2-Azidoethyl)cyclopropyl)-4-bromo-6-chloro-l-(tetrahydro-2 / / -pyran-2-yl)-1 W-indazole. To a solution of rac-2-((lS,2<S)-2-(4-bromo-6-chloro-l-(tetrahydro-27f-pyran-2-yl)-lH-indazol-5-yl)cyclopropyl)ethyl methanesulfonate (2.0 g, 4.2 mmol) in N.N-dimethylformamide (20 mL) was added NaN3 (0.23 g, 3.50 mmol). The reaction mixture was stirred at 80 °C for 1 h. After cooling to room temperature, the mixture was diluted with water and adjusted to pH 9 with sat. NaOH. The aqueous layer was extracted with EtOAc and the combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated to give crude product of rac-5-((lS, 25)-2-(2 -azidoethyl)cyclopropyl)-4-bromo-6-chloro-l-(tetrahydro-2H-pyran-2-yl)-lH-indazole (1.8 g). m'z (ESI): 424.1 (M+H)+.

[00307] Step 3. rac-2-((lS,25)-2-(4-Bromo-6-chloro-l-(tetrahydro-2 / 7-pyran-2-yl)-l / 7-indazol-5-yl)cycIopropyI)ethan-l-amine. To a solution of rac-5-((15,25)-2-(2-azidoethyl)cyclopropyl)-4-bromo-6-chloro-1 -(tetrahydro-2H-pyran-2-yl)-1 H-indazole (1.8 g, 4.2 mmol) in tetrahydrofuran (20 mL) was added water (0.5 mL) and PPh3 (2.22 g, 8.48 mmol). The mixture was stirred at 60 °C for 1 h. The reaction mixture was purified by column chromatography on silica gel, eluting with a gradient of 0-10% MeOH in DCM, to give rac-2-((lS,25)-2-(4-bromo-6-chloro-l-(tetrahydro-27f-pyran-2-yl)-lH-indazol-5-yl)cyclopropyl)cthan-l -amine (1.2 g). m'z (ESI): 400.2 (M+H)+.

[00308] Step 4. r«c-tert-Butyl 2-((2-((15,25)-2-(4-bromo-6-chloro-l-(tetrahydro-2Z / -pyran-2-yl)-lf / -indazol-5-yl)cyclopropyl)ethyl)carbamoyl)-6-azaspiro[3.5]nonane-6-carboxylate. To a solution of 6-(tert-butoxycarbonyl)-6-azaspiro[3.5]nonane-2-carboxylic acid (0.74 g, 2.8 mmol) in A,A-dimethylformamide (10 mL) was added HATU (1.43 g, 3.76 mmol), DIPEA (1.5 mL. 8.6 mmol) and rac-2-((15,2S)-2-(4-bromo-6-chloro-l-(tctrahydro-27 / -pyran-2-yl)-lW-indazol-5-yl)cyclopropyl)ethan-l-amine (1.0 g, 2.5 mmol) in A,A-dimethylformamide (2 mL) at 0 °C. The reaction mixture was stirred at room temperature for 1 h, was then combined with another 0.2 g batch, diluted with water, and extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel, eluting with a gradient of 10-100% EtOAc in petroleum ether, to yield rac-tert-butyl 2-((2-((15,25)-2-(4-bromo-6-chloro-l-(tetrahy dro-2H-pyran-2-y 1)-IH-indazol-5-yl)cyclopropyl)ethyl)carbamoyl)-6-azaspiro[3.5]nonane-6-carboxylate (1.6 g). m / z (ESI): 673.3 (M+Na)+. Intermediate FF: (25,45)-8-(tert-Butoxycarbonyl)-2-fluoro-5-oxa-8-azaspiro[3.5]nonane-2-carboxylic acid. Boc fBuOK DMSO, DME, rt Step 1 Boc 1) HF-pyridine, CH2CI2 2) Boc2O, H2O, Na2CO3 Step 2 Phl(OAc)2, TEMPO CH3CN, H2O SteP 2           Intermediate FF

[00309] Step 1. tert-Butyl (31?,51?)-l,6-dioxa-9-azadispiro[2.1.5s.l3]undecane-9-carboxylate. To a solution of potassium tert-butoxide (2.84 g, 25.3 mmol) in dimethyl sulfoxide (50 mL) was added trimethylsulfoxonium iodide (6.22 g, 28.2 mmol) under nitrogen atmosphere. The mixture was stirred at room temperature for 1.5 h, then 1.2-dimethoxyethane (10 mL) was added at 0 °C, followed by tert-butyl 2-oxo-5-oxa-8-azaspiro[3.5]nonane-8-carboxylate (4.70 g, 19.5 mmol, Phannablock Inc.) in 1,2-dimethoxy ethane (10 mL) and dimethyl sulfoxide (2.5 mL). The mixture was stirred at 0 °C for 1 h and room temperature for 1 h. The mixture was quenched by the addition of water at 0 °C, and then extracted with EtOAc. The combined organic layers were washed with water and brine, dried over Na2SO4, fdtered, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel, eluting with 0-100% EtOAc in heptane, to provide tert-butyl (3R,5R)-1.6-dioxa-9-azadispiro[2.1.55.l3]undecane-9-carboxylate (0.82 g. 3.20 mmol, 16% yield), m / z (ESI): 200.0 (M-‘Bu+H)+.

[00310] Step 2. tert-Butyl (25,45)-2-fluoro-2-(hydroxymethyl)-5-oxa-8-azaspiro[3.5]nonane-8-carboxylatc. In a 250-mL round-bottom flask was added hydrogen fluoride (70% in 30% pyridine, (0.90 g, 9.1 mmol) and the flask was cooled to -78 °C. tert-Buty l (37?,5R)-l,6-dioxa-9-azadispiro[2.1.55.l3]undecane-9-carboxylate (0.82 g, 3.20 mmol) in dichloromethane (3 mL) was added dropwise, and the reaction mixture was stirred at -78 °C for 6 h. To the mixture was added 1 M Na2COs solution (70 mL) and dichloromethane (50 mL), and the mixture was allowed to warm to 0 °C. di- / ert-Butyl dicarbonate (0.70 g, 3.20 mmol) was added and the mixture was gradually warmed to room temperature with stirring for 16 h. The resulting mixture was extracted by CH2Q2. The combined organic layers were dried over Na2SO4, filtered, and concentrated. The crude was purified by column chromatography on silica gel, eluting with 0-100% EtOAc in heptane, to provide tertbutyl (2S,4S)-2-fluoro-2-(hydroxymethyl)-5-oxa-8-azaspiro[3.5]nonane-8-carboxylate (0.28 g. 1.00 mmol, 32% yield), m / z (ESI): 298.1 (M+Na)+. !H NMR (400 MHz. CDCI3) 8 ppm 3.70 - 3.60 (m, 2H), 3.59 - 3.54 (m. 2H), 3.34 (br s, 2H). 3.28 (s, 2H). 3.00 (br s, 1H), 2.44 - 2.33 (m, 2H), 2.33 -2.20 (m, 2H), 1.42 (s, 9H).

[00311] Step 3. (25,45)-8-( / t?rt-Butoxycarbonyl)-2-fluoro-5-oxa-8-azaspiro[3.5]nonane-2-carboxylic acid. To a 40-mL vial was dissolved tert-butyl (25.45)-2-fluoro-2-(hydroxymethyl)-5-oxa-8-azaspiro[3.5]nonane-8-carboxylate (0.73 g, 2.70 mmol) in water (8 mL) and acetonitrile (12 mL). TEMPO (83 mg, 0.53 mmol) and (diacetoxyiodo)benzene (2.15 g, 6.66 mmol) was added, and the mixture was heated at 60 °C for 3 h. Acetonitrile was removed, and the resulting aqueous mixture was basified with saturated NaHCO3 solution and extracted with EtOAc. The aqueous phase was acidified by 1 M K.HSO4 solution and extracted by EtOAc. The combined organic layers were dried over Na2SO4, filtered, and concentrated to provide (25.45)-8-(tert-butoxycarbonyl)-2-fluoro-5-oxa-8-azaspiro[3.5]nonane-2-carboxylic acid (0.69 g, 2.40 mmol, 89% yield), m / z (ESI): 312.1 (M+Na)+. 'H NMR (500 MHz, DMSO-dd) 8 ppm 13.87 -13.13 (m, 1H), 3.56 - 3.52 (m, 2H), 3.34 - 3.30 (m, 2H), 3.30 - 3.26 (m. 2H), 2.69 (br d, J = 2.6 Hz. 2H), 2.42 - 2.31 (m. 2H), 1.42 - 1.38 (m. 9H). 19FNMR (471 MHz. DMSO-da) 8 ppm -142.59 - -144.38 (m, IF). Intermediate GG: 4-(tert-Butoxy)-7-chloro-8-fluoro-2-(((2I?,7aS)-2-fluorotetrahydro-177-pyrrolizin-7a(5H)-yl)methoxy-d2)pyrido[4,3-rf]pyrimidine.

[00312] Step 1. ((27?,7a5)-2-Fluorotetrahydro-lH-pyrrolizin-7a(5 / / )-yl)methan-rf2-oL To a solution of methyl (2R.7aS)-2-fluorotetrahydro-lLf-pyrrolizine-7a(5 / 7)-carboxylate (9.00 g, 48.1 mmol) in tetrahydrofuran (200 mL) was added LiAlD4 (2.0 M in THF, 3.74 g. 89 mmol) slowly. The mixture was stirred at 0 °C for 1 h under a N2 atmosphere. Then sodium sulfate decahydrate (45 g) was added to quench the reaction followed by ethyl acetate. The reaction mixture was stirred at room temperature for 1 h, then filtered and the filtrate was concentrated under reduced pressure. The residue was combined with two other 9 g batches and purified by column chromatography on silica gel, eluting with a gradient of 50-100% EtOAc in petroleum ether, to provide ((2R,7aS)-2-fluorotctrahydro- l / / -pvrrolizin-7a(5 / / )-vl)mcthan-<A-ol (22.0 g, 136 mmol, 88% yield). !H NMR (400 MHz, CDCli) 5 ppm 5.13 (d,7=3.2 Hz, 1 H), 2.99 - 3.26 (m, 4 H), 2.87 - 2.96 (m, 1 H), 2.00 - 2.16 (m, 2H), 1.74 - 1.98 (m, 4 H).

[00313] Step 2. 4-( / ert-Butoxy)-7-chloro-8-fluoro-2-(((2I?,7a5)-2-fluorotetrahydro-lH-pyrrolizin-7a(5H)-yl)methoxy-d2)pyrido[4,3-< / ]pyrimidine. To a solution of ((2R,7aS)-2-fluorotetrahydro-lH-pyrrolizin-7a(5.H)-yl)methan-<72-ol (2.89 g, 17.9 mmol) in 1,4-dioxane (40 mL) was added 4-(tert-butoxy)-2,7-dichloro-8-fluoropyrido[4,3-<5?|pyrimidine (Step 1 in Intermediate A, 4.00 g, 13.8 mmol), DIPEA (7.2 mL, 41 mmol) and 4A MS (4 g). The reaction mixture was stirred at 80 °C for 2 h. After cooling to room temperature, the reaction mixture was concentrated under reduced pressure and the residue was diluted with water and extracted with ethyl acetate. The combmed organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure. The crude product was triturated with MTBE for 30 minutes to give 4-(ZerZ-butoxy)-7-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-lH-pyrrolizin-7a(5.H)-yl)methoxy-d2)pyrido[4,3 -d\ pyrimidine (3.0 g, 7.2 mmol, 52% yield), m / z (ESI): 415.1 (M+H)+. *H NMR (400 MHz, CDCh) 5 ppm 8.86 (s, 1 H), 5.23 - 5.40 (m. 1 H), 3.28 - 3.38 (m, 1 H), 3.14 - 3.28 m, 2 H), 2.98 - 3.06 (m, 1 H), 2.29 (s, 1 H), 2.11 -2.24(m, 2H). 1.90 - 2.02 (m, 3 H). 1.75 (s, 9 H). Intermediate HH: l-Azido-4-(4-bromo-6-methyl-l-(tetrahydro-2 / 7-pyran-2-yl)-l / T-indazol-5-yl)butan-2-one. Intermediate HH

[00314] Step 1. 4-(4-Bromo-6-methyl-l-(tetrahydro-2H-pyran-2-yl)-lH-indazol-5-yl)butan-2-one. To a 40-mL vial was charged with 4-bromo-5-iodo-6-methyl-l-(tctrahydro-2A-pyran-2-yl)-IH-indazole (2.0 g, 4.8 mmol, Advanced ChemBlocks), sodium bicarbonate (1.0 g, 12 mmol), TBAC1 (1.37 g, 4.94 mmol), palladium(II) acetate (54 mg, 0.24 mmol). 3-buten-2-ol (0.62 mL, 7.2 mmol) and N,A-dimethylformamide (10 mL). The reaction mixture was heated at 65 °C for 16 h. After cooling to room temperature, the reaction was diluted with saturated aqueous ammonium chloride and extracted with ethyl acetate. The combined organics were washed with water and brine, dried over sodium sulfate, filtered, and concentrated. The crude material was purified by column chromatography on silica gel, eluting with a gradient of 0-50% EtOAc in heptane, to yield 4-(4-bromo-6-methyl-l-(tctrahydro-2H-pyran-2-yl)-lH-indazol-5-yl)butan-2-onc. m / z (ESI): 365.0 (M+H)+.

[00315] Step 2. l-Bromo-4-(4-bromo-6-methyl-l-(tetrahydro-2H-pyran-2-yl)-lH-indazol-5-yl)butan-2-one. To a 250-mL round-bottom flask was charged with lithium diisopropylamide (1 M solution in THF / hexanes. 4.9 mL. 4.9 mmol) in anhydrous tetrahydrofuran (35 mL). The mixture was cooled to -78 °C and 4-(4-bromo-6-methyl-l -(tetrahy dro-2H-pyran-2-y 1)-1 A-indazol-5-yl)butan-2-one (1.50 g, 4.11 mmol) in THF (8 mL) was added dropwise under a nitrogen atmosphere. The reaction mixture was stirred at -78 °C for 30 minutes. Chlorotrimethylsilane (0.78 mL, 6.2 mmol) was then added dropwise at -78 °C and the reaction mixture was stirred at -78 °C for 30 minutes. The reaction was quenched with saturated NaHCOj solution, and the mixture was allowed to warm to room temperature and extracted with EtOAc. The organic layer was washed with brine, dried over Na2SO4, filtered, and concentrated.

[00316] The crude oil was diluted in anhydrous THF (10 mL) and cooled to 0 °C. Sodium bicarbonate (0.52 g, 6.20 mmol) and A-bromosuccinimide (0.73 g, 4.10 mmol) was added and the mixture was stirred at room temperature for 15 h. The reaction mixture was filtered and concentrated. The crude material was purified by column chromatography on silica gel, eluting with a gradient of 050% EtOAc in heptane, to give 1 -bromo-4-(4-bromo-6-methy 1-1 -(tetrahydro-2A-pyran-2-y 1)-1 H-indazol-5-yl)butan-2-one (0.74 g, 1.60 mmol, 40% yield), m / z (ESI): 444.2 (M+H)+.

[00317] Step 3.1 -Azido-4-(4-bromo-6-methyl-l -(tetrahydro-2H-pyran-2-yl)-l H-indazol-5-yl)butan-2-one. To a 250-mL flask was added l-bromo-4-(4-bromo-6-methyl-1 -(tetrahydro-2H-pyran-2-yl)-lH-indazol-5-yl)butan-2-one (5.00 g, 11.3 mmol) in acetone (50 mL). Sodium azide (0.95 g, 14.6 mmol) was then added, and the mixture was stirred at room temperature for 16 h. The mixture was filtered over a pad of celite, and the filtrate was concentrated in vacuo to provide l-azido-4-(4-bromo-6-mctliyl-l-(tctraliydro-2 / / -pyran-2-yl)-l / / -indazol-5-yl)butan-2-onc (4.51 g, 11.1 mmol, 99% yield), m / z (ESI): 406.2. 'H NMR (500 MHz, CDCls) 5 ppm 7.96 (d, / =0.8 Hz, 1 H), 7.38 (s, 1 H), 5.68 (dd, / =9.1, 2.8 Hz, 1 H), 4.01 - 4.05 (m, 1 H), 4.00 (s, 2 H), 3.76 (ddd, / =11.5, 10.4, 2.9 Hz, 1 H), 3.20 - 3.25 (m. 2 H), 2.68 - 2.74 (m, 2 H), 2.53 - 2.59 (m, 1 H), 2.53 (d, / =0.8 Hz, 3 H), 2.15 -2.21 (m, 1 H), 2.05 - 2.13 (m, 1 H), 1.73 - 1.82 (m, 2 H). 1.65 - 1.72 (m, 1 H). Intermediate II: 4-(terr-Butoxy)-7-chloro-8-fluoro-2-(((25,4 / ?)-4-fluoro-l-methyl pyrrol idin-2-yl)methoxy)pyrido [4,3- / ] pyrimidine. Intermediate II

[00318] The title compound was synthesized analogous to Intermediate C using ((25,4R)-4-fluoro-l-methylpyrrolidin-2-yl)methanol (CAS#: 2206737-78-0, PharmaBlock) in step 2. m / z (ESI): 387.0 (M+H)+. ]H NMR (400 MHz, CDCls) 8 ppm 8.87 (s, 1H), 5.1-5.3 (m, 1H), 4.5-4.6 (m, 2H), 3.5-3.6 (m, 1H), 3.12 (brd, 1H, / =4.8 Hz), 2.6-2.7 (m, 1H), 2.5-2.6 (m, 3H), 2.3-2.4 (m, 1H), 1.9-2.1 (m, 1H), 1.7-1.8 (m, 9H). Intermediate JJ: (25,45)-8-(tert-Butoxycarbonyl)-2-hydroxy-5-oxa-8-azaspiro[3.5]nonane-2-carboxylic acid. Step 1

[00319] Step 1. tert-Butyl (25,45)-2-((tert-butyldimethylsilyl)oxy)-2-cyano-5-oxa-8- azaspiro[3.5]nonane-8-carboxylate. To a 40-mL vial was added tert-butyldimethylsily 1 cyanide (1.23 g, 8.70 mmol, AbovChem) and / er / -butyl 2-oxo-5-oxa-8-azaspiro[3.5]nonane-8-carboxylate (2.0 g, 8.3 mmol. AA BLOCKS LLC) in tetrahydrofuran (15 mL). 2,8,9-Triisopropyl-2,5,8,9-tetraaza-l-phosphabicyclo[3,3,3]undercane (0.10 g, 0.33 mmol) was added and the reaction mixture was stirred at room temperature for 3 h. The resulting mixture was concentrated and directly purified by column chromatography on silica gel, eluting with a gradient of 0-100% EtOAc in heptane, to give tert-butyl (2S,4S)-2-((tert-butyldimethylsilyl)oxy)-2-cyano-5-oxa-8-azaspiro[3.5]nonane-8-carboxylate (2.63 g, 6.87 mmol, 83% yield), m / z (ESI): 327.1 (M-‘Bu+H)+. ]H NMR (500 MHz, CDCI3) 3 ppm 3.62 - 3.57 (m, 4 H), 3.46 - 3.41 (m, 2 H), 2.89 - 2.81 (m, 2 H), 2.38 - 2.33 (m, 2 H), 1.52 (s, 9 H), 0.94 - 0.92 (m, 9 H), 0.24 (s, 6 H).

[00320] Step 2. (2\,4A')-8-(tert-Butoxycarbonyl)-2-hydroxy-5-oxa-8-azaspiro[3.5|nonane-2-carboxylic acid. To a 250-mL round-bottom flask was added tert-butyl (2S,4S)-2-((tert-butyldimcthylsilyl)oxy)-2-cyano-5-oxa-8-azaspiro[3.5]nonanc-8-carboxylatc (2.63 g, 6.87 mmol) in hydrochloric acid (37%, 10 mL, 122 mmol). The mixture was heated to reflux for 1 h, dien concentrated. The residue was redissolved in water (30 mL) and basified to pH 11 by solid Na2COs. THF (30 mL), sodium bicarbonate (1.16 g, 13.8 mmol) and di-tert-butyl dicarbonate (1.65 g, 7.56 mmol) was then sequentially added. The mixture was stirred at room temperature for 1 h, then diluted with water and washed with EtOAc. The aqueous phase was then acidified to pH 1.5 with 1 M KHSO4 solution and extracted with EtOAc. The combined organic layers were dried over Na2SO4, filtered, and concentrated to provide (2S',4S)-8-(tert-butoxycarbonyl)-2-hydroxy-5-oxa-8-azaspiro[3.5]nonane-2-carboxylic acid (1.35 g, 4.70 mmol, 68% yield), m / z (ESI): 310.0 (M+Na)+. Intermediate KK: 4-(4-Bromo-6-chIoro-l-(tetrahydro-2 / / -pyran-2-yl)-l / / -indazol-5-yl)butanehy d razide Intermediate KK

[00321] Step 1. 4-(4-Bromo-6-chloro-l-(tetrahydro-277-pyran-2-yl)-177-indazol-5-yl)butanoic acid. To a 40 mL vial was charged with 4-(4-bromo-6-chloro-l-(telrahvdro-2H-pyran-2-yl)-lH-indazol-5-yl)butan-l-ol (Step 2 in Intermediate M, 0.61 g. 1.58 mmol) and tert-butanol (9 mL). To this was added 2-methyl-2-butene (0.18 mL. 1.58 mmol), and then sodium chlorite (0.60 g. 6.6 mmol) and sodium phosphate monobasic (0.19 g. 1.58 mmol) in xvater (18 mL) at 0 °C. The reaction mixture was allowed to xvann to room temperature xvith stirring for 1 h, xvas then concentrated and dissolved in MeOH. The crude xvas injected onto a C18 column and eluted with 5-100% acetonitrile (with 0.1% formic acid) in water (with 0.1% formic acid) to give 4-(4-bromo-6-chloro-l-(tetrahydro-2J / -pyran-2-yl)-l / / -indazol-5-yl)butanoic acid (0.38 g, 0.95 mmol, 60% yield). m,'z (ESI): 401.8 (M+H)+.

[00322] Step 2. 4-(4-Bromo-6-chloro-l-(tetrahydro-2Z / -pyran-2-y 1)-1 H-indazol-5-yl)butanehydrazide. In a 250-mL round-bottom flask, to a solution of 4-(4-bromo-6-chloro-l-(tetrahydro-27 / -pyran-2-yl)-lH-indazol-5-yl)butanoic acid (2.04 g, 5.08 mmol) in N.N-dimethylformamide (10 mL) was added diisopropylethylamine (2.0 mL, 11 mmol) and HATU (2.12 g, 5.59 mmol). The mixture was stirred at room temperature for 20 minutes, then the solution was added dropwise to the solution of anhydrous hydrazine (0.65 mL, 20.3 mmol) and diisopropylethylamine (2.0 mL, 11 mmol) in DMF (10 mL) at 0 °C over 20 minutes. The reaction mixture was stirred at room temperature for 2 h, was then quenched by the addition of water and filtered. The filter cake was washed with water and triturated in EtOAc. The solid was collected by filtration to provide 4-(4-bromo-6-chloro-l-(tetrahydro-2 / 7-pyran-2-yl)-lH-indazol-5-yl)butanehydrazide (1.51 g, 3.63 mmol, 72% yield), m / z (ESI): 415.0 / 417.1 (M+H)+. ’HNMR (400 MHz, DMSO-d6) 5 ppm 8.96 (s, 1H), 8.06 (s, 1H), 8.00 (s, 1H), 5.88 (dd, J= 9.5, 2.4 Hz, 1H), 4.15 (br s, 2H). 3.91 - 3.84 (m, 1H). 3.80 - 3.73 (m, 1H), 3.01 - 2.96 (m, 2H), 2.40 - 2.30 (m, 1H), 2.15 (t, J = 7.6 Hz, 2H), 2.06 - 1.94 (m, 2H), 1.82 - 1.71 (m, 3H), 1.63 - 1.56 (m, 2H). Intermediate LL: rac-2-((17?,2 / ?)-2-(4-Bromo-6-chloro-l-(tetrahydro-277-pyran-2-yl)-l / / -indazol-5-yl)cyclopropyl)acetohydrazide. DMP DCM Stepl MeO^ Phz PfPh Ph t-BuOK, THF Step 2 PPTS dioxane / H2O Step 3 NaBH4 EtOH Step 4 H2SO4, CrO3 Acetone Step 5 NH2NH2, HATU DMF Step 6 Intermediate LL

[00323] Step 1. rac-(17?,25)-2-(4-Bromo-6-chloro-l-(tetrahydro-27T-pyran-2-yl)-l / T-indazol-5- yl)cyclopropane-l-carbaldehyde. To a solution of rac-((lA,2S)-2-(4-bromo-6-chloro-l-(tetrahydro- 2H-pyran-2-yl)-IH-indazol-5-yl)cyclopropyl)mcthanol (Intermediate D, 5.00 g, 13 mmol) in dichloromethane (75 mL) was added Dess-Martin periodinane (11.0 g, 25.9 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 2 h. The mixture was filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel, eluting with a gradient of 5-10% EtOAc in petroleum ether, to give rac-(17?,2S)-2-(4-bromo-6-chloro-1 -(tetrahydro-2H-pyran-2-yl)-1 H-indazol-5-yl)cyclopropane-1 -carbaldehyde (4.16 g, 10.9 mmol, 85% yield).

[00324] Step 2. rac-4-Bromo-6-chloro-5-((15',27?)-2-((Z)-2-methoxyvinyl)cyclopropyl)-l-(tctrahydro-2H-pyran-2-yl)-lH-indazolc. To the mixture of (mcthoxymcthyl)triphcnylphosphonium (24.0 g, 78.0 mmol) in tetrahydrofuran (200 mL) was added t-BuOK (1 M in THF, 78 mL, 78 mmol) dropwise at 0 °C. The reaction mixture was stirred at 0 °C for 30 minutes, then the solution of rac-(lA,2>S)-2-(4-bromo-6-chloro-l-(tetrahydro-277-pyran-2-yl)-lH-indazol-5-yl)cyclopropane-l-carbaldehyde (10.0 g, 26.1 mmol) in tetrahydrofuran (200 mL) was added dropwise at 0 °C to the mixture. The reaction mixture was stirred at room temperature for 30 minutes, then was diluted with water and extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated. The residue was purified by column chromatography on silica gel, eluting with a gradient of 5-10% EtOAc in petroleum ether, to give rac-4-bromo-6-chloro-5-(( 1S,2R)-2-((Z)-2-methoxyvinyl)cyclopropyl)-l-(tetrahydro-2H-pyran-2-yl)-l / f-indazole (9.62 g, 23.0 mmol, 90% yield).

[00325] Step 3. rac-2-((15',25)-2-(4-Bromo-6-chloro-l-(tetrahydro-2 / 7-pyran-2-yl)-l / 7-indazol-5-yl)cyclopropyl)acetaldehyde. To the mixture of rac-4-bromo-6-chloro-5-((LS',2A)-2-((Z)-2-methoxyvinyl)cyclopropyl)-l-(tetrahydro-2H-pyran-2-yl)-l / f-indazole (33 g, 80 mmol) in 1.4-dioxane (790 mL) and water (130 mL) was added pyridine 4-methylbenzenesulfonate (32.4 g, 128 mmol). The reaction mixture was stirred at 70 °C for 12 h. After cooling to room temperature, the reaction mixture was quenched by addition of water and extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated. The residue was purified by column chromatography on silica gel, eluting with a gradient of 5-10% EtOAc in petroleum ether, to give rac-2-((15.25)-2-(4-bromo-6-chloro-l-(tetrahydro-2 / / -pyran-2-yl)-l / 7-indazol-5-yl)cyclopropyl)acetaldehyde (20.0 g, 50.3 mmol, 63% yield).

[00326] Step 4. rac-2-((15',25)-2-(4-Bromo-6-chloro-l-(tetrahydro-2 / / -pyran-2-yl)-l / / -indazol-5-yl)cyclopropyl)ethan-l-ol. To the mixture of rac-2-((lS,2S)-2-(4-bromo-6-chloro-l-(tetrahydro-2H-pyran-2-yl)-lH-indazol-5-yl)cvclopropyl)acctaldchvdc (20.0 g. 50.3 mmol) in ethanol (200 mL) was added NaBH4 (3.23 g, 85 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 1 h, was then quenched by addition of saturated NH4C1 solution and extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4. filtered, and concentrated. The residue was purified by column chromatography on silica gel, eluting with a gradient of 20-35% EtOAc in petroleum ether, to give rac-2-((15,2S)-2-(4-bromo-6-chloro-l-(tetraliydro-27 / -pyran-2-yl)-lH-indazol-5-yl)cyclopropyl)ethan-l-ol (19.1 g, 48.0 mmol, 95% yield), m / z (ESI): 401.0 / 399.0 (M+H)+. 'HNMR (400 MHz, DMSO-do') 5 ppm 8.06 (s, 1 H), 7.99 (s, 1 H), 5.87 (dd, J = 9.6, 2.4 Hz, 1 H), 4.29 - 4.33 (m, 1 H), 3.85 - 3.88 (m, 1 H), 3.76 - 3.77 (m. 1 H), 3.36 - 3.41(m, 2 H), 2.29 - 2.38 (m, 1 H), 1.97-2.03 (m. 3 H), 1.84 - 1.86 (m, 1 H), 1.69 - 1.73 (m, 1 H), 1.54 - 1.60 (m, 2 H), 1.38 -1.48 (m, 1 H), 1.31 -1.37 (m, 1 H), 0.80 - 0.92 (m, 1 H). 0.20 - 0.26 (m, 1 H).

[00327] Step 5. r«c-2-((15,25)-2-(4-Bromo-6-chloro-l-(tetrahydro-277-pyran-2-yl)-l / 7-indazol-5-yl)cyclopropyI)acetic acid. To a 250-mL round-bottom flask was charged rac-2-((15,25)-2-(4-bromo-6-chloro-1 -(tctrahydro-2H-pyran-2-y 1)-I A-indazol-5-y I )cyclopropyl)cthan-1 -ol (4.0 g, 10 mmol) in acetone (100 mL). At 0 °C, chromium trioxide solution in sulfuric acid (7.5 mL, 15.0 mmol) was added dropwise. The mixture was allowed to warm to room temperature with stirring for 1.5 h. Upon completion of the reaction, 0.1 M sodium thiosulfate solution (100 mL) was added to quench the reaction. The mixture was extracted by EtOAc, and the combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated to provide rac-2-((lS,2S)-2-(4-bromo-6-chloro-l-(tctrahydro-2A-pyran-2-yl)-IH-indazol-5-yl)cyclopropyl)acctic acid (4.35 g, 10.5 mmol, crude), m / z (ESI): 412.9 / 415.0 (M+H)+. !H NMR (400 MHz. CDC / j) 5 ppm 10.05 (br s, 1H), 8.00 (d, / = 0.8 Hz, 1H), 7.68 (s, 1H). 5.66 (dd, / =8.9, 2.4 Hz, 1H), 4.03 (br dd, J= 9.8, 2.1 Hz. 1H), 3.813.72 (m, 1H), 2.90-2.79 (m, 1H), 2.55-2.44 (m. 1H), 2.21-2.09 (m. 3H), 1.85 - 1.70 (m. 4H), 1.63 - 1.52 (m, 1H). 1.38 (dd, / = 16.5. 10.5 Hz, 1H), 1.11 (q, / =6.3 Hz. 1H).

[00328] Step 6. rac-2-((15,25)-2-(4-Bromo-6-chloro-l-(tetrahydro-2 / 7-pyran-2-yl)-l / 7-indazol-5-yl)cyclopropyl)acetohydrazide. In a 250-mL round-bottom flask, rac-2-((lS,2>S)-2-(4-bromo-6-chloro-1 -(tetrahydro-2H-pyran-2-yl)-lH-indazol-5-yl)cyclopropyl)acetic acid (4.35 g, 10.5 mmol) was dissolved in N,A-dimethy 1 formamide (20 mL) and the solution was cooled to 0 °C. HATU (4.80 g. 12.6 mmol) and A,A-diisopropylethylamine (4.0 mL, 23 mmol) was sequentially added and the mixture was stirred at room temperature for 30 minutes. The resulting solution was added dropwise to a separate flask containing a solution of anhydrous hydrazine (1.3 mL, 42 mmol) and AA-diisopropylethylamine (4.0 mL, 23 mmol) in A,A-dimethylformamide (20 mL) at 0 °C. The resulting mixture was stirred at room temperature for 1.5 h. was then quenched by the addition of water, and extracted by EtOAc. The combined organic layers were dried over Na2SO4. filtered, and concentrated to provide rac-2-(( 15,2S)-2-(4-bromo-6-chloro-l-ttclrahydro-2H-pyran-2-yl)-IH-indazol-5-yl)cyclopropyl)acetohydrazide (4.50 g, 10.5 mmol. 100% yield), m / z (ESI): 427.0 / 429.0 (M+H)+.1H NMR (400 MHz. CDCh) 5 ppm 7.99 (s. 1H), 7.67 (s. 1H), 6.92 (br s, 1H). 5.69 - 5.62 (m, 1H). 4.06 -3.98 (m. 1H), 3.78 - 3.73 (m, 1H), 2.70 (dt, / = 15.6. 4.0 Hz, 1H). 2.55 - 2.43 (m, 1H). 2.21 - 2.08 (m, 3H). 1.82- 1.74 (m, 3H). 1.60- 1.54 (m, 1H). 1.49-1.44 (m, 3H), 1.24- 1.07 (m, 2H). Intermediate MM: 4-(terLButoxy)-8-fluoro-2-(((2 / ?,7aN)-2-fluorotetrahydro-l / / -pyrrolizin- 7a(5 / 7)-yl)methoxy)-7-(tributylstannyl)pyrido[4,3-< / |pyrimidine. O’Bu PCy3Pd G2 LiCI, 1,4-dioxane bis(tributyltin) O‘Bu Intermediate MM

[00329] To a solution of 4-(tert-butoxy)-7-chloro-8-fluoro-2-(((2A.7a>S)-2-fluorotetrahydro-lH-pyrrolizin-7a(57f)-yl)methoxy)pyrido[4.3-J|pyrimidine (Intermediate C, 34 g, 82 mmol.) in 1.4-dioxane (680 mL) was added PCy3 Pd G? (19.5 g, 32.9 mmol) and LiCI (17.5 g, 412 mmol), then bis(tributyltin) (177 g, 305 mmol) was added in one portion under N2. The mixture was stirred at 80 °C for 36 h under N2. After cooling to room temperature, the reaction was fdtered and the filtrate was diluted with water and extracted with ethyl acetate. The combined organic layers were dried over Na2SO4. filtered and concentrated. The residue was purified by column chromatography on silica gel. eluting with 0-7% ethyl acetate in petroleum ether, to provide 4-(ter / -butoxy)-8-fluoro-2-(((2A,7a.S)-2-fluorotetrahydro-177-pyrrolizin-7a(5 / 7)-yl)methoxy)-7-(tributylstannyl)pyrido[4,3-^pyrimidine (29.8 g, 44.7 mmol, 54% yield), m / z (ESI): 667.4 / 669.4 (M+H)+. !H NMR (400 MHz, CDCl3) 5 ppm 9.21 (s, 1H), 5.21-5.36 (m, 1H), 4.20-4.29 (m, 2H), 3.24-3.28 (m, 2H), 2.05-2.30 (m, 3H), 1.80-2.05 (m, 4H), 1.34-1.60 (m, 9H), 1.20-1.32 (m, 18H), 0.86-0.93 (m, 9H). Intermediate NN: tert-Butyl (2N,47?)-2-cyano-2-fhioro-6-azaspiro[3.5]nonane-6-carboxylate. HATU, NH4OH DMF Step 1 CI3COCI, TEA DCM Step 2

[00330] Step 1. tert-Butyl (2N,47?)-2-carbamoyl-2-fluoro-6-azaspiro[3.5]nonane-6-carboxylate. To a 40-mL vial was charged with (2S',47?)-6-(tert-butoxycarbonyl)-2-fluoro-6-azaspiro[3.5]nonane-2-carboxylic acid (Intermediate G, 1.04 g, 3.62 mmol). AUV-dimethylformamide (15 mL), N,N-diisopropylethylamine (1.9 mL, 10.9 mmol), and HATU (1.51 g. 3.98 mmol) at 0 °C. The contents were stirred for 35 minutes and then ammonium hydroxide (2.3 mL, 18 mmol) was added. The reaction mixture was stirred at 0 °C for 30 minutes, was then diluted with ethyl acetate and saturated aqueous sodium bicarbonate. The aqueous layer was extracted with ethyl acetate and the combined organics were washed with water and brine, dried over sodium sulfate, filtered, and concentrated to yield tert-butyl (25,4 / / )-2-carbamoyl-2-fluoro-6-azaspiro[3.5]nonane-6-carboxylate (1.0 g, 3.5 mmol, 96% yield), m / z (ESI): 309.2 (M+Na)+.

[00331] Step 2. tert-Butyl (25,47?)-2-cyano-2-fluoro-6-azaspiro[3.5]nonane-6-carboxylate. To a 40-mLvial was charged with tert-butyl (2S,47?)-2-carbamoyl-2-fluoro-6-azaspiro[3.5]nonane-6-carboxylate (1.0 g, 3.5 mmol), dichloromethane (30 mL), and triethylamine (0.98 mL, 6.98 mmol) under a nitrogen atmosphere. The contents were cooled to 0 °C and 2,2.2-trichloroacetyl chloride (0.8 mL, 7 mmol) was added dropwise. The reaction mixture was allowed to warm to room temperature with stirring for 1 h, was then diluted with water, and extracted with dichloromethane. The combined organics were dried with sodium sulfate, filtered, and concentrated. The residue was purified by column chromatography on silica gel, eluting with 0-60% ethyl acetate in heptane, to provide tertbutyl (2S,4A)-2-cyano-2-fluoro-6-azaspiro[3.5]nonane-6-carboxylate (0.86 g, 3.20 mmol, 91% yield). / ^(ESI): 213.2 (M-Boc+H)+. Intermediate OO: tert-Butyl 2-((tert-butyldiphenylsilyl)oxy)-2-cyano-6-azaspiro[3.5]nonane-6-carboxylate.

[00332] To a 40-mL vial was added tert-butyl 2-oxo-6-azaspiro[3.5]nonane-6-carboxylate (2.5 g, 10.5 mmol,) and tert-butyldiphenylsilanecarbonitrile (2.91 g, 11 mmol) in tetrahydrofuran (15 mL). 2.8.9-Triisopropyl-2,5.8.9-tetraaza-l-phosphabicyclo[3.3,3]undercane (0.13 g, 0.42 mmol) was added and the reaction mixture was stirred at room temperature for 2.5 h. The resulting mixture was concentrated, and the residue was purified by column chromatography on silica gel, eluting with a gradient of 0-60% EtOAc in heptane, to provide tert-butyl 2-((tert-butyldiphenylsilyl)oxy)-2-cyano-6-azaspiro[3.5]nonane-6-carboxylate (5.10 g, 10.1 mmol. 97% yield) as a mixture of diastereomers. m / z (ESI): 449.2 (M+H)+. ’H NMR (400 MHz, CDCh) 8 ppm 7.73 - 7.77 (m, 5 H), 7.44 - 7.51 (m. 5 H), 3.35 - 3.42 (m. 2 H), 3.18 - 3.30 (m, 3 H). 2.17 - 2.40 (m, 3 H), 1.94 - 2.08 (m, 2 H), 1.57 - 1.69 (m, 1 H), 1.42 - 1.44 (m, 9 H), 1.32 - 1.36 (m, 1 H), 1.09 (s, 9 H). Intermediate PP: (25,45)-9-(tert-Butoxycarbonyl)-2-fluoro-6-oxa-9-azaspiro[3.6]decane-2-carboxylic acid. Intermediate CC                                                                       Intermediate PP

[00333] Step 1. tert-Butyl (25',45)-2-fluoro-2-(hydroxymethyl)-6-oxa-9-azaspiro[3.6]decane-9-carboxylate. In a 100-mL plastic round-bottom flask was added hydrogen fluoride (70% in 30% pyridine, 1.02 g, 10.3 mmol) and the contents were cooled to -78 °C. tert-Butyl (3R,5R)-l,7-dioxa-10-azadispiro[2.1.65.l3]dodecane-10-carboxylate (Intermediate CC, 0.98 g, 3.60 mmol) in dichloromethane (5 mL) was added dropwise, and the mixture was stirred at -78 °C for 3 h. The resulting mixture was poured into a mixture of 1 M NazCOs solution and DCM at 0 °C. The resulting mixture was extracted with DCM and tire combined organic layers were dried over Na2SO4, filtered, and concentrated. The crude was purified by column chromatography on silica gel, eluting with a gradient of 0-100% EtOAc in heptane, to give tert-butyl (2S.4.S)-2-fluoro-2-(hydroxymethyl)-6-oxa-9-azaspiro[3.6]dccanc-9-carboxylatc (0.52 g, 1.80 mmol, 50% yield), m / z (ESI): 312.1 (M+Na)+. ’H NMR (400 MHz, CDCI^ 5 ppm 3.83 - 3.65 (m, 6H), 3.64 - 3.45 (in, 4H), 2.63 (t, J = 7.1 Hz, 1H), 2.31 - 2.02 (m, 4H), 1.54 - 1.46 (m, 9H). 19F NMR (376 MHz, CDCI3) 5 ppm -143.08 - -147.71 (m, IF).

[00334] Step 2. (2A',4A')-9-(tert-Butoxycarhonyl)-2-fluoro-6-oxa-9-azaspiro[3.6|decane-2-carboxylic acid. To a stirred mixture of tert-butyl (2S,4.S)-2-fluoro-2-(liydroxymethyl)-6-oxa-9-azaspiro[3.6]decane-9-carboxylate (0.52 g, 1.80 mmol) and (diacetoxyiodo)benzene (1.46 g, 4.52 mmol) in water (4 mL) and acetonitrile (6 mL) was added TEMPO (57 mg, 0.36 mmol) under nitrogen. The resulting mixture was stirred at 60 °C for 2 h. The acetonitrile was removed, and the resulting aqueous mixture was basified with saturated NaHCOs solution and washed with EtOAc. The aqueous phase was acidified by 1 M KHSO4 solution, and extracted by EtOAc. The combined organic layers were dried over Na2SO4, filtered and concentrated to give (2S,4S)-9-(tert-butoxycarbonyl)-2-Huoro-6-oxa-9-azaspiro[3.6]decane-2-carboxylic acid (0.42 g, 1.30 mmol, 77% yield), m / z (ESI): 326.1 (M+Na)+. ’H NMR (400 MHz, CDCl / ) 5 ppm 3.87 - 3.64 (m, 6H), 3.57 - 3.45 (m, 2H), 2.84 -2.65 (m, 2H), 2.41 - 2.28 (m, 2H), 1.49 (d, J = 4.4 Hz. 9H). 19F NMR (376 MHz, CDCI3) 5 ppm -151.90 (s, IF). Intermediate QQ: (2.S’,4.S’)-6-(7-Chloro-2-(((.S')-l,2-dimethylpyrrolidin-2-yl)methoxy)-8-fluoropy rido [4,3-rf] py rimidin-4-yl)-6-azaspiro [3.5] nonan-2-ol. Intermediate QQ

[00335] Step 1. (2R,45)-6-(2,7-Dichloro-8-fluoropyrido [4,3-d\ pyrimidin-4-yl)-6-azaspiro[3.5]nonan-2-ol. A 100-mL round bottom flask was charged with 2,4,7-trichloro-8-fluoropyrido|4,3-r / |pyrimidine tert-butyl 6-hydroxy-1.4-thiazepane-4-carboxylate (3.00 g, 11.8 mmol, LabNetwork Inc.) and acetonitrile (40 mL). The reaction mixhire was cooled to 0 °C and (27?,45)-6-azaspiro[3.5]nonan-2-ol hydrochloride (Step 3 in Intermediate J, 1.66 g, 10.8 mmol) and DIPEA (6.2 mL, 36 mmol) were added. The reaction mixture was stirred at 0 °C for 30 minutes, was then concentrated. The residue was purified by column chromatography on silica gel. eluting with 0-50% 3:1 EtOAc / EtOH (with 2% triethylamine) in heptane, to yield (27?,45)-6-(2,7-dichloro-8-fluoropyrido[4,3-J|pyrimidin-4-yl)-6-azaspiro[3.5]nonan-2-ol (2.50 g, 7.00 mmol. 59% yield). Wz (ESI): 356.9 (M+H)+.

[00336] Step 2.4-((27?,45)-2-((tert-Butyldimethylsilyl)oxy)-6-azaspiro[3.5]nonan-6-yl)-2,7-dichloro-8-fluoropyrido [4,3-< / | pyrimidine. A 100 mL round bottom flask was charged with (27?,45)-6-(2,7-dichloro-8-fluoropyrido[4.3-J|pyrimidin-4-yl)-6-azaspiro[3.5]nonan-2-ol (1.50 g. 4.20 mmol), dichloromethane (28 mL), DMAP (50 mg, 0.42 mmol), imidazole (0.71 g, 10.5 mmol), and tertbutyldimethylsilyl chloride (0.76 g, 5.04 mmol). The reaction mixture was stirred at room temperature for 6 h, was then quenched with saturated aqueous sodium bicarbonate and extracted with DCM. The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated. The crude material was purified by column chromatography on silica gel, eluting with 0-80% 3:1 EtOAc / EtOH (with 2% triethylamine) in heptane, to yield 4-((27?,45)-2-(( / ert-butyldimethylsilyl)oxy)-6-azaspiro[3.5]nonan-6-yl)-2,7-dichloro-8-fluoropyrido[4,3-<7| pyrimidine (1.40 g, 2.97 mmol, 71% yield), m / z (ESI): 470.9 (M+H)+.

[00337] Step 3. 4-((25,45)-2-((tert-Butyldiniethylsilyl)oxy)-6-azaspiro[3.5|nonan-6-yl)-7-chloro-2-(((5)-1,2-dimethylpyrrolidin-2-yl)methoxy)-8-fluoropyrido[4,3-rf]pyrimidine. A 40 mL vial was charged with [(25)-1.2-dimethylpyrrolidin-2-yl]methanol (0.41 g. 3.20 mmol, Pharmablock Inc.) and tetrahydrofuran (17 mL). The reaction mixture was cooled to 0 °C and sodium hydride (60 wt% in mineral oil, 0.19 g, 4.70 mmol) was added, and the suspension was stirred for 10 minutes at 0 °C. 4-((2R,4S)-2-((Zert-Butyldimethylsilyl)oxy)-6-azaspiro[3.5]nonan-6-yl)-2,7-dichloro-8-fluoropyrido[4,3-<7]pyrimidine (1.00 g, 2.21 mmol) was added and the reaction mixture was stirred at room temperature for 2 h. The reaction mixture was slowly quenched via the addition of saturated aqueous ammonium chloride solution, and the aqueous layer was extracted with DCM. The combined organic layers were washed with brine solution, dried over sodium sulfate, filtered, and concentrated. The crude material was purified by column chromatography on silica gel. eluting with 0-60% 3:1 EtOAc / EtOH (with 2% triethylamine) in heptane, to yield 4-((25,4S)-2-((tert-butyldimethylsilyl)oxy)-6-azaspiro [3.5 ]nonan-6-yl)-7-chloro-2-(((.S)-l,2-dimethylpyrrolidin-2-yl)methoxy )-8-fluoropyrido[4,3-J|pyrimidine (0.87 g, 1.50 mmol, 72% yield). mZz(ESI): 563.9 (M+H)+.

[00338] Step 4. (25,45)-6-(7-Chloro-2-(((5)-l,2-dimethylpyrrolidin-2-yl)methoxy)-8-fluoropyrido[4,3-rf]pyrimidin-4-yl)-6-azaspiro[3.5]nonan-2-ol. A 40-mL vial was charged 4-((25,45)-2-((Zert-butyldimethylsilyl)oxy)-6-azaspiro[3.5]nonan-6-yl)-7-chloro-2-(((5)-l,2-dimethylpyrrolidin-2-yl)methoxy)-8-fluoropyrido[4.3-<7|pyrimidine (1.07 g. 1.90 mmol) and tetrahydrofuran (23 mL). Tetramethylammonium fluoride (1 M in THF, 2.8 mL, 2.8 mmol) was added, and the reaction mixture was stirred at room temperature for 1.5 h. The reaction mixture was partitioned between ethyl acetate and half-saturated aqueous sodium bicarbonate. The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure, and the crude material was used in the next step without any purification, m / z (ESI): 449.9 (M+H)+. Intermediate RR: 5-(2-((tert-Butyldiphenylsilyl)oxy)ethyl)-6-chloro-l-(tetrahydro-2H-pyran-2-yl)-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l / f-indazole. OTBDPS

[00339] The title compound was prepared in an analogous fashion to Intermediate K using 2-(4- bromo-6-chloro-l-(tetrahydro-2H-pyran-2-yl)-lH-indazol-5-yl)ethan-l-ol (Intermediate E) and tert-butyl(chloro)diphenylsilane (CAS#: 58479-61-1, Aldrich) and imidazole in DCM and THF in Step 1. m / z (ESI): 645.3 / 647.3 (M+H)+. ]H NMR (400 MHz, CDCI3) 5 ppm 8.33 (s, 1 H), 7.68 (s, 1 H), 7.587.66 (m, 4 H), 7.30-7.40 (m, 6 H), 5.62-5.66 (m, 1 H), 3.86-3.99 (m, 1 H), 3.82-3.84 (m. 2 H), 3.72- 3.74 (m, 1 H), 3.54-3.58 (m, 2 H), 2.46-2.55 (m, 1 H), 2.08-2.16 (m, 1 H), 1.98-2.06 (m, 1 H), 1.621.80 (m, 3 H), 1.37 (s, 12 H), 1.03 (s, 9 H). Intermediate SS: (2 / ?,45')-6-(7-Chloro-8-fluoro-2-(((2 / ?,7a / ?)-2-fluorotetrahydro-l / f-pyrrolizin- 7a(5 / f)-yl)methoxy)pyrido[4,3-rf]pyrimidin-4-yl)-6-azaspiro[3.5]nonan-2-ol.

[00340] To a solution of (2R,45)-6-(2.7-dichloro-8-fluoropyrido[4,3-< / ]pyrimidin-4-yl)-6-azaspiro[3.5]nonan-2-ol (Step 1 in Intermediate QQ, 0.39 g, 1.10 mmol) in 1,4-dioxane (3.5 mL) was added ((2A.7aA)-2-fluorotetrahydro-lH-pyrrolizin-7a(5 / / )-yl)methanol (0.35 g. 2.20 mmol) and DIPEA (3.5 mL. 20 mmol). Then the mixture was stirred at 120 °C for 12 h under a N2 atmosphere. The crude reaction mixture was combined with 9 other baches (0.4 g) and concentrated under reduced pressure. The residue was purified by prep-HPLC using a C18 column, eluting with a gradient of 2045% of CH3CN in H2O (10 mM NH4HCO3). to provide (2A,45)-6-(7-chloro-8-fluoro-2-(((27?.7aA)-2-fluoro tetrahydro- IW-pyrrohzin-7a(5H)-y])mcthoxy)pyrido[4.3-<: / |pyrimidin-4-yl)-6-azaspiro[3.5]nonan-2-ol (2.50 g, 5.20 mmol. 46% yield), m / z (ESI): 502.2 (M+Na)+. 1H NMR (400 MHz, DMSO-ds) 8 ppm 8.88 (s. 1 H), 5.26 - 5.44 (m, 1 H), 4.93 (d, J=6.4 Hz, 1 H), 4.10 - 4.18 (m, 2 H), 4.03 - 4.09 (m, 1 H), 3.86 (d, J=3.2 Hz, 2 H), 3.74-3.79 (m. 2 H), 3.23 - 3.30 (m. 1 H), 2.91 - 2.99 (m, 1 H), 2.74 - 2.90 (in, 1 H), 2.52-2.59 (m, 1 H), 2.24 - 2.35 (m, 1 H), 1.99 - 2.05 (m, 2 H). 1.78 -1.93 (m. 4 H), 1.63 - 1.71 (m. 5 H), 1.54 - 1.60 (m, 2 H). Intermediate TT: 5-(2-((tert-Butyldiphenylsilyl)oxy)ethyl)-l-(tetrahydro-2 / f-pyran-2-yl)-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-indazole. H2, Pd / C THF Step 1 OTBDPS N-Nx THP Intermediate TT

[00341] To a mixture of Pd / C (6.0 g, 10% on charcoal, 6.2 mmol) in tetrahydrofuran (100 mL) was added 5-(2-(( / ert-butyldiphenylsilyl)oxj)ethyl)-6-chloro-l-(tetrahydro-277-pyran-2-yl)-4-(4,4,5,5-tetramethyl-1.3.2-dio.\aborolan-2-yl)-1 / / -indazole (Intermediate RR, 4.0 g, 6.2 mmol) under an argon atmosphere. The suspension was degassed and purged with H2 and then stirred under H2 (50 psi) at 50 °C for 12 h. After cooling to room temperature, tire crude reaction mixture was combined with another batch (same scale), filtered through a pad of Celite, and rinsed with tetrahydrofuran. The filtrate was concentrated under reduced pressure and the residue was purified by prep-HPLC on a C18 column, eluting with a gradient of 80-100% CH3CN in H2O (10 mM NH4HCO3), to provide 5-(2-((rerLbutyldiphenylsilyl)oxy)ethyl)-l-(tetrahydro-2H-pyran-2-yl)-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-y 1)-1H-indazole (2.0 g, 26% yield), m / z (ESI): 611.4 (M+H)1. !H NMR (400 MHz. CDCh) 8 ppm 8.42 (s, 1H),7.50-7.60 (m, 5H). 7.27-7.35 (m. 7H), 5.70-5.75 (in. 1H), 3.95-4.05 (m, 1H), 3.80-3.90 (m. 2H), 3.65-3.80 (m, 1H), 3.25-3.35 (m, 2H). 2.50-2.60 (m, 1H). 2.10-2.20 (m. 1H), 2.00-2.10 (m, 1H). 1.60-1.80 (m. 3H), 1.32 (s. 12H). 1.02 (s. 9H). Intermediate UU: (27 / ,45)-6-(7-Chloro-2-(((2 / / ,7iLS)-2-fluor()tetrahydro-l / 7-pyrrolizin-7a(5 / 7)-yl)methoxy)-8-methylpyrido[4,3-rf]pyrimidin-4-yl)-6-azaspiro[3.5]nonan-2-oL Intermediate UU

[00342] Step 1: (2R,45)-6-(2,7-Dichloro-8-methylpyrido[4,3-< / |pyrimidin-4-yl)-6-azaspiro[3.5]nonan-2-ol. To a solution of 2,4,7-trichloro-8-mcthylpyrido[4,3-<7|pyrimidinc (3.0 g, 12 mmol) in tetrahydrofuran (20 mL) at 0 °C was added DIPEA (6.3 mL, 36 mmol) followed by a solution of (2 / / .45)-6-azaspiro|3.5 |nonan-2-ol hydrochloride (2.15 g, 12.1 mmol) in tetrahydrofuran (50 mL). The resulting mixture was stirred at 0 °C for 2 h, was then partitioned between water and EtOAc. The organic layer was washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel, eluting with a gradient of 5-100% ethyl acetate in petroleum ether, to give (27 / ,45)-6-(2,7-dichloro-8-methylpyrido[4,3-i / |pyrimidin-4-yl)-6-azaspiro[3.5]nonan-2-ol (3.5 g, 9.9 mmol, 82% yield). m / z (ESI): 353.4 (M+H)+.

[00343] Step 2: (2R,4S)-6-(7-Chloro-2-(((2R,7aS)-2-fluorotetrahydro-l / / -pyrrolizin-7a(5 / / )-yl)methoxy)-8-methylpyrido[4,3-rf]pyrimidin-4-yl)-6-azaspiro[3.5]nonan-2-ol A mixture of ((27 / ,7a5)-2-fluorotetrahydro-17 / -pyrrolizin-7a(577)-yl)methanol (1.19 g, 7.47 mmol), (27 / ,45)-6-(2,7-dichloro-8-methylpyrido[4,3-<7|pyrimidin-4-yl)-6-azaspiro[3.5]nonan-2-ol (2.2 g, 6.2 mmol), DIPEA (11 mL, 63 mmol) and 4 A MS (5 g) in 1,4-dioxane (11 mL) was stirred at 120 °C for 12 h. After cooling to room temperature, the reaction mixture was concentrated under reduced pressure. The residue was purified by prep-HPLC on a C18 column, eluting with a gradient of 30-65% CH3CN in H2O (10 mM NH4HCO3), to provide (2R,4S)-6-(7-chloro-2-(((2R,7aS)-2-fluorotetrahydro-l / 7-pyrrolizin-7a(5.H)-yl)methoxy)-8-methylpyrido[4,3-7|pyrimidin-4-yl)-6-azaspiro[3.5]nonan-2-ol (2.0 g. 4.2 mmol, 67% yield), m / z (ESI): 498.3 (M+Na)+. !H NMR (400 MHz. CDCI3) 5 ppm 8.81 (s, 1H), 5.19-5.39 (m, 1H). 4.26-4.37 (m, 2H), 4.19 (d, 7=10.49 Hz, 1H), 3.86 (s, 2H). 3.76 (d,7=5.36 Hz, 2H), 3.22-3.33 (m. 2H), 3.18 (s, 1H), 2.92-3.03 (m, 1H), 2.58 (s, 3H), 2.27-2.33 (m, 1H), 2.12-2.26 (m, 5H), 1.88-2.01 (m. 4H), 1.75-1.84 (m, 4H), 1.26 (t, 7=7.15 Hz, 1H). Intermediate VV: tert-Butyl 8-((tert-butyldiphenylsilyl)oxy)-2-hydroxy-6-azaspiro[3.5]nonane-6- carboxylate. OH 1N HCI THF Step 2 BOC2O Et3N, DCM Step 3 NaBH4 MeOH Step 4 ‘BuPhgSiCI imidazole DCM Step 1 O-SL Ph Ph Intermediate W

[00344] Step 1. 8-((tert-Butyldiphenylsilyl)oxy)-2,2-dimethoxy-6-azaspiro [3.5] nonane. A mixture of dimethoxy-6-azaspiro[3.5]nonan-8-ol (3.40 g, 16.9 mmol, Enamine), imidazole (4.60 g, 67.6 mmol), and tert-butylchlorodiphenylsilane (8.8 mL, 34 mmol) were stirred in dichloromethane (84 mL) at room temperature for 16 h. The crude mixture was purified by column chromatography on silica gel, eluting with a gradient of 0-50% EtOAc in heptane, to yield butyldiphenylsilyl)oxy)-2,2-dimethoxy-6-azaspiro[3.5]nonane (7.0 g. 15.9 mmol, 94% yield). m / z (ESI): 440.0 (M+l)+.

[00345] Step 2. 8-((terLButyldiphenylsilyl)oxy)-6-azaspiro[3.5|nonan-2-one hydrochloride. In a 150-mL RBF was charged with 8-((terLbutyldiphenylsilyl)oxy)-2,2-dimethoxy-6-azaspiro[3.5]nonane (4.31 g, 9.80 mmol) and tetrahydrofuran (65 mL). Hydrochloric acid (1 M in THF, 10.6 mL, 10.6 mmol) was added dropwise and the mixture was stirred at 50 °C for 20 h. After cooling to room temperature, the reaction mixture was diluted with water and extracted with ethyl acetate. The combined organic phase was dried over sodium sulfate, filtered, and concentrated to give 8-(( / 677-butyldiphenylsilyl)oxy)-6-azaspiro[3.5]nonan-2-one hydrochloride (3.74 g, 8.70 mmol, 89% yield). m / z (ESI): 394.2 (M+l)+.

[00346] Step 3. tert-Butyl 8-((tert-butyldiphenylsilyl)oxy)-2-oxo-6-azaspiro[3.5]nonane-6-carboxylate. In a 250 mL round-bottom flask was charged with 8-((tert-butyldiphenylsilyl)oxy)-6-azaspiro[3.5]nonan-2-one hydrochloride (3.67 g, 8.53 mmol) and di-tert-butyl dicarbonate (2.79 g, 12.8 mmol) in dichloromethane (43 mL). Triethylamine (3.6 mL. 25.6 mmol) was added dropwise, and the reaction mixture was stirred at room temperature for 1 h. Water was added to quench the reaction and the layers were separated. The aqueous layer was extracted with DCM and the combined organics were dried (Na2SO4) and concentrated. The crude material was purified by column chromatography on silica gel, eluting with a gradient of 0^10% EtOAc in hexane, to provide tertbutyl 8-((tert-butyldiphenylsilyl)oxy)-2-oxo-6-azaspiro[3.5]nonane-6-carboxylate (4.05 g. 8.20 mmol, 96% yield), mz (ESI): 515.9 (M+Na)1.

[00347] Step 4. tert-Butyl 8-((tert-butyldiphenylsilyl)oxy)-2-hydroxy-6-azaspiro[3.5]nonane-6-carboxylate. To the solution of tert-butyl 8-((tert-butyldiphenylsilyl)oxy)-2-oxo-6-azaspiro[3.5]nonane-6-carbo.xylate (3.87 g, 7.83 mmol) in methanol (39 mL) cooled in a 0 °C ice bath was added sodium borohydride (0.44 g, 11.8 mmol) in portions. The reaction mixture was stirred at 0 °C for 1 h, then diluted with water and extracted with ethyl acetate. The combined organics were dried, filtered, and concentrated. The crude material was purified by column chromatography on silica gel. eluting with a gradient of 0-50% ethyl acetate in heptane, to give tert-butyl 8-((tert-butyldiphenylsilyl)oxy)-2-hydroxy-6-azaspiro[3.5]nonane-6-carboxylate (3.63 g, 7.32 mmol, 93% yield), m / z (ESI): 518.9 (M+Na)+. Intermediate WW: 7-Chloro-8-fluoro-2-(((27?,7«A)-2-fluorotetrahydro-17 / -pyrrolizin-7a(5Z / )-yl)methoxy)-4-(2,2,2-trifluoroethoxy)pyrido[4,3-d]pyrimidine. Intermediate WW

[00348] Step 1. 2,7-Dichloro-8-fluoro-4-(2,2,2-trifluoroethoxy)pyrido[4,3-< / ]pyrimidine. To a solution of 2,4,7-trichloro-8-fluoropyrido[4,3-<7|pyrimidine (50.0 g. 198 mmol, LabNetwork) in tetrahydrofuran (750 mL) cooled to -60 °C was added 2,2,2-trifluoroethan-l-ol (18.82 g, 188 mmol), followed by / -BuOK (1 M in THF, 188 mL, 188 mmol) dropwise. The mixture was stirred at -60 °C for 2 h. The reaction mixture was quenched by addition of ELO (1-L) at room temperature and extracted with EtOAc. The combined organic layers were dried over Na2SO4, filtered, and concentrated. The residue was washed with petroleum ether (50 mL), then filtered. The filter cake was concentrated under reduced pressure to give 2,7-dichloro-8-fluoro-4-(2.2,2- trifluoroethoxy)pyrido[4,3-rf|pyrimidine (50.0 g, 158 mmol, 84%yield). 'HNMR (400 MHz, CDCI3) 5 ppm 9.18 (s, 1 H), 5.06-5.12 (m, 2 H).

[00349] Step 2. 7-Chloro-8-fhioro-2-(((27?,7aS)-2-fluorotetrahydro-lH-pyrrolizin-7a(5Z7)-yl)methoxy)-4-(2,2,2-trifluoroethoxy)pyrido[4,3-< / ]pyrimidine. To a solution of 2,7-dichloro-8-fluoro-4-(2,2,2-trifluoroethoxy)pyrido[4,3-<7|pyrimidine (28 g, 89 mmol) in 1,4-dioxane (280 mL) was added ((27?,7aS)-2-fluorotetrahydro-lH-pyrrolizin-7a(577)-yl)methanol (16.9 g, 106 mmol) and DIPEA (46.4 mL, 266 mmol) in sequence then the mixture was stirred at 80 °C for 10 h. The reaction mixture was concentrated under reduced pressure and the residue was diluted with water and extracted with EtOAc. The combined organic layers were dried over Na2SO4, filtered, and concentrated. The residue was purified by column chromatography on silica gel, eluting with a gradient of 5-100% EtOAc in petroleum ether, to provide 7-chloro-8-fluoro-2-(((27?,7aS)-2-fluorotetrahydro-1 / / -pyrrolizin-7a(57f)-yl)methoxy )-4-(2,2,2-trifluoroethoxy )pyrido[4,3-rf| pyrimidine (28.0 g, 63.8 mmol, 72% yield), m / z (ESI): 439.1 / 441.1 (M+H)+. Intermediate XX: tert-Butyl 2-(but-3-en-l-yl)-2-((trimethylsilyl)oxy)-6-azaspiro[3.5]nonane-6-carboxylate. imidazole, DCM Step 2 Step 1 Intermediate XX

[00350] Step 1. tert-Butyl 2-(but-3-en-l-yl)-2-hydroxy-6-azaspiro[3.5]nonane-6-carboxylate. To a solution of tert-butyl 2-oxo-6-azaspiro[3.5]nonane-6-carboxylate (10.0 g, 41.8 mmol) in tetrahydrofuran (100 mL) was added but-3-en-l-ylmagnesium bromide (1 M in THF, 84 mL. 84 mmol) at 0 °C under nitrogen. The reaction mixture was stirred at room temperature for 2 h. The reaction mixture was combined with another 10 g batch and quenched by addition of sat. NHiCI. then extracted with EtOAc. The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to give tert-butyl 2-(but-3-en-l-yl)-2-hydroxy-6-azaspiro[3.5]nonane-6-carboxylate (total 12 g. 49% yield).

[00351] Step 2. tert-Butyl 2-(but-3-en-l-yl)-2-((trimethylsilyl)oxy)-6-azaspiro[3.5]nonane-6-carboxylate. To a solution of tert-butyl 2-(but-3-en-l-yl)-2-hydroxy-6-azaspiro[3.5]nonane-6-carboxylate (6.0 g, 20.3 mmol) in dichloromethane (120 mL) was added imidazole (6.91 g. 102 mmol) and TMSC1 (13 mL. 102 mmol) in sequence. The reaction mixture was stirred at room temperature for 2 h, then was diluted with water and extracted with EtOAc. The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel, eluting with a gradient of 2-100% ethyl acetate in petroleum ether, to give tert-butyl 2-(but-3-en-l-yl)-2-((trimethylsilyl)oxy)-6-azaspiro[3.5]nonane-6-carboxylate (4.26 g, 11.6 mmol, 57 % yield). 'HNMR (400 MHz, CDCI3) 8 ppm 5.79 - 5.97 (in, 1 H), 4.91 - 5.08 (m, 2 H), 3.25 - 3.39 (m, 4 H), 2.16 - 2.26 (m, 2 H). 1.97 - 2.07 (m, 2 H), 1.78 - 1.86 (m, 2 H), 1.59 - 1.75 (m. 4 H), 1.47 (d, / =5.6 Hz, 11 H), 0.12 - 0.18 (m, 9 H). Intermediate YY: 7-(5-Allyl-6-chloro-l-(tetrahydro-2H-pyran-2-yl)-lH-indazol-4-yl)-8-fluoro-2-(((2 / ?,7aA')-2-fluorotctrahydro-1 / / -pyrrolizin-7a(5 / / )-yl)methoxy)-4-(2,2,2-trifluoroethoxy)pyrido[4,3-d]pyrimidine. Intermediate YY

[00352] Step 1. 5-Allyl-4-bromo-6-chloro-l-(tetrahydro-2 / / -pyran-2-yl)-lH-indazole. To a solution of 4-bromo-6-chloro-5-iodo-l-(tetrahydro-2H-pyran-2-yl)-l / f-indazole (50.0 g. 113 mmol) in toluene (500 mL) was added allyltributylstannane (41.3 g. 125 mmol) and LiCl (24.0 g, 566 mmol) in sequence. The reaction mixture was degassed and purged with nitrogen. Pd(PPh3)4 (13.1 g, 11.3 mmol) was added and the reaction mixture was stirred at 110 °C for 12 h. After cooling to room temperature, the reaction was combined with another 50 g batch and filtered. The filtrate was quenched by addition of water, and then extracted with EtOAc. The combined organic layers were dried over Na2SO4. filtered and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel, eluting with a gradient of 2-100% ethyl acetate in petroleum ether, to give 5-allyl-4-bromo-6-chloro-l-(tetrahydro-2H-pyran-2-yl)-1 Ef-indazole (60.0 g, 169 mmol, 75% yield), m / z (ESI): 356.9 / 354.9 (M+H)+.

[00353] Step 2. 5-Allyl-6-chloro-l-(tetrahydro-2H-pyran-2-yl)-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-17 / -indazole. To a solution of 5-allyl-4-bromo-6-chloro-l-(tetrahydro-2H-pyran-2-yl)-l / f-indazole (30 g, 84 mmol) in 1,4-dioxane (600 mL) and water (75 mL) was added 4,4,4',4'.5,5,5',5'-octamethyl-2,2'-bi(L3,2-dioxaborolane) (107 g, 422 mmol), Cs2CO3 (82.4 g, 253 mmol) and Pd(dppf)Cl2 (6.17 g. 8.44 mmol) imder N2. The mixture was heated at 120 °C for 1 h under N2. After cooling to room temperature, the reaction mixture was combined with another 30 g batch and diluted with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by reversed phase MPLC to give 5-allyl-6-chloro-l-(tetrahydro-2H-pyran-2-yl)-4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)-17 / -indazole (29 g, 72 mmol, 43% yield), m / z (ESI): 403.2 / 405.2 (M+H)+.

[00354] Step 3. 7-(5-Allyl-6-chloro-l-(tetrahvdro-2W-pyran-2-yl)-l / f-indazol-4-yl)-8-fluoro-2-(((27?,7a5)-2-fluorotetrahydro-lH-pyrrolizin-7a(5H)-yl)methoxy)-4-(2,2,2-trifluoroethoxy)pyrido[4,3-rf|pyrimidine. To a solution of 7-chloro-8-fluoro-2-(((2 / ?,7a5)-2-fluorotetrahydro-17 / -pyrrolizin-7a(5J7)-yl)methoxy)-4-(2,2,2-trifluoroethoxy)pyrido[4,3-6 / ] pyrimidine (Intermediate WW, 15.0 g, 34.2 mmol) in THF (150 mL) and water (15 mL) was added 5-allyl-6-chloro-1 -(tetrahydro-2H-pyran-2-y 1)-4-(4.4,5,5-tetramethyl-l, 3,2-dioxaborolan-2-yl)-lH-indazole (16.5 g, 41.0 mmol), K3PO4 (21.7 g, 103 mmol) and CataCXium A Pd G3 (CAS No. 1651823-59-4) (3.73 g, 5.13 mmol) under nitrogen. The reaction mixture was stirred at 80 °C for 10 h, was then diluted with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel, eluting with a gradient of 2-100% ethyl acetate in petroleum ether, to give 7-(5-allyl-6-chloro-l-(tetrahydro-277-pyran-2-yl)-lH-indazol-4-yl)-8-fluoro-2-(((2R.7a5)-2-fluorotetrahydro-lFf-pyrrolizin-7a(577)-yl)methoxy)-4-(2,2,2-trifluoroethoxy)pyrido[4,3-J|pyrimidine (11.5 g, 17.0 mmol. 50% yield), m / z (ESI): 679.2 / 681.2 (M+H)+. 'HNMR (400 MHz, CDC / 3)5ppm 9.25 (d. J=3.6Hz, 1 H), 7.77 (d,J= 15.2 Hz, 1 H). 7.47 (d. J = 4.0Hz, 1 H), 5.645.71 (m, 2H). 5.13 -5.36 (m, 1 H). 5.00 (q. J= 8.0 Hz, 2 H), 4.81 (d. J=9.6Hz, 1 H), 4.65 (d, J = 17.2 Hz, 1 H). 4.23 - 4.40 (m, 2 H). 3.88 - 4.03 (m, 1 H). 3.64 - 3.77 (m, 1 H), 3.50 - 3.60 (m, 1 H), 3.38 -3.47 (m, 1 H). 3.20 -3.30 (m, 1 H). 3.11 -3.18(m, 1 H). 2.88-2.98 (m, 1 H), 2.36 - 2.53 (m, 1 H). 2.13 - 2.27 (m. 2 H). 2.00 - 2.10 (m, 3 H). 1.80-1.95 (m, 3 H), 1.59 - 1.71 (m. 4 H). 19FNMR (376 MHz, CDCls) 5 ppm -73.292 (s, 5 F). Intermediate ZZ: (25, 47?)-6-(tert-Butoxycarbonyl)-2-hydroxy-6-azaspiro[3.4]octane-2-carboxylic acid.

[00355] The title compound was synthesized analogous to Intermediate JJ using tert-butyl 2-oxo-6-azaspiro[3.4]octane-6-carboxylate (Pharmablock, Inc.) in Step 1. m / z (ESI): 294.1 (M+Na)+. Intermediate AAA: 2-(3-(4-Bromo-6-chloro-l-(tetrahydro-2Z / -pyran-2-yl)-17f-indazol-5-yl)propyl) 6-(tert-butyl) 2,6-diazaspiro[3.5]nonane-2,6-dicarboxylate. Intermediate A Boc GDI 2-Me-THF Intermediate AAA

[00356] To a stirred solution of 3-(4-bromo-6-chloro-l-(tetrahydro-2H-pyran-2-yl)-lH-indazol-5-yl)propan-l-ol (Intermediate A, 1.5 g, 4.0 mmol) in 2-methyltetrahydrofuran (7 mL) was added 1,1'-carbonyldiimidazole (0.72 g, 4.4 mmol). The reaction mixture was stirred at room temperature for 30 minutes. Then, tert-butyl 2,6-diazaspiro[3.5]nonane-6-carboxylate (1.6 g. 7.2 mmol) was added and the reaction mixture was heated at 80 °C for 18 h. The mixture was cooled to room temperature and diluted with saturated aqueous NH4C1 solution. The aqueous layer was extracted with EtOAc, and the combined organic extracts were dried over MgSO i. filtered, and concentrated. The crude material was purified by column chromatography on silica gel, eluting with a gradient of 0-100% EtOAc in hexane, to provide 2-(3-(4-bromo-6-chloro-l-(tetrahydro-2H-pyran-2-yl)-lH-indazol-5-yl)propyl) 6-( / ert-butyl) 2,6-diazaspiro[3.5]nonane-2.6-dicarboxylate (2.2 g. 3.5 mmol. 86% yield), m / z (ESI): 625.2 (M+H)+. Intermediate BBB: tert-Butyl (2s,47?)-2-((((17?,2S)-2-(6-chloro-l-(tetrahydro-2H-pyran-2-yl)-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l / 7-indazol-5-yl)cyclopropyl)methoxy)methyl)-2-hydroxy-6-azaspiro[3.5]nonane-6-carboxylate Intermediate D                                     N—N,                                  N—N, THP                            THP Intermediate BBB

[00357] Step 1: tert-Butyl (2s,4 / ?)-2-((((l / ?,2.S)-2-(4-bromo-6-chloro-l-(tetrahydro-2 / / -pyran-2-yl)-17 / -indazol-5-yl)cyclopropyl)methoxy)methyl)-2-hydroxy-6-azaspiro[3.5]nonane-6- carboxylate, Intermediate BBB.l. To a mixture of Intermediate D (5.0 g, 13 mmol) and Intermediate B (3.3 g, 13 mmol) in PhMe (115 mL) was added Y(T1O)3 (1.8 g, 3.2 mmol) under N2 at room temperature, and the reaction mixture was stirred at 50 °C for 2 h. The reaction mixture was quenched by addition of sat. aq. NH4C1 (100 mL) and extracted with EtOAc (3 x 80 mL). The combined organic layers were washed with brine (2 x 50 mL), dried overNa2SO4, filtered and concentrated. The resulting residue was purified by reversed phase chromatography, eluting with a gradient of 35-65% ACN in H2O (O.^NEfiELO), to obtain Intermediate BBB.l (4.5 g, 7.0 mmol, 54% yield), m / z (ESI): 638.4 (M+H)+.

[00358] Step 2: tert-Butyl (2v.4 / ?)-2-((((1 / ?.2.S)-2-(6-chloro-l-(tetrahydro-2 / / -pyran-2-yl)-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-177-indazol-5-yl)cyclopropyl)methoxy)methyl)-2-hydroxy-6-azaspiro[3.5]nonane-6-carboxylate, Intermediate BBB. To a mixture of Intermediate BBB.l (2.0 g, 3.1 mmol), B2PHI2 (4.0 g, 15.6 mmol), CS2CO3 (3.1 g, 9.4 mmol) in 1,4-dioxane (10 mL) and water (1 mL) was added Pd(dppf)C12 (0.2 g, 0.3 mmol). The reaction mixture was sparged with nitrogen and stirred at 80 °C for 2 h. The reaction mixture was diluted with H2O (30 mL) and extracted with EtOAc (3 x 30 mL). The combined organic layers were washed with brine (20 mL), dried over NaiSO,. filtered and concentrated. The resulting residue was purified by column chromatography, eluting with a gradient of 20:1 to 0:1 of pet. ether in EtOAc, to obtain Intermediate BBB (1.5 g, 2.2 mmol. 67% yield), m'z (ESI): 686.5 (M+H)+.

[00359] Compounds in Table 23 were prepared following a procedure analogous to the one described above for Intermediate BBB, using appropriate starting materials. All starting materials are commercially available or are described in the Intermediates section above. Table 23. Additional Intermediates Prepared in Analogous Manner to Intennediate BBB. Intermedi ate Structure Name Reagents Method Changes ccc OH F Hl Boc tert-butyl (2x.4r)-2-((2-(2-fluoro-8-(4,4,5,5-tetramethyl-1.3.2-dioxaborolan-2-yl)naphthalen-l-yl)ethoxy)methyl)-2-hydroxy-6- azaspiro [3.5] nonane -6-carboxylate 2-(2-fluoro-8-iodonaphthalen-1 -yl)ethan-l-ol DDD OH cis, L c     pinB. A.F N                H J Boc / n-nthp tert-butyl (2^,4^)-2-((((lAS,2S^)-2-(6-fluoro-1 -(tetrahvdro-2H-pvran-2-yl)-4-(4,4,5,5- ' tetramethyl-1,3,2- dioxaborolan-2 -y 1) -1H-indazol-5- yl)cyclopropyl)methoxy) inethyl)-2-hydroxy-6-azaspiro [3.5] nonane -6-carboxylate r«c-((17?,25)-2-(4-bromo-6-fluoro-1 -(tetrahydro-2H-pyran-2-yl)-17 / -indazol-5-yl)cyclopropyl)me thanol EEE OH / vV               cis, rac L 5       pmEL      ,CI N     Y Y Boc tert-butyl (2s,4R)-2-((((lAS,2S7?)-2-(2-chloro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)cyclopropyl)m ethoxy )methyl)-2-hydroxy-6- azaspiro [3.5] nonane -6-carboxylate rac-((lR, 25)-2-(2-bromo-6-chlorophenyl)cycl opropyl)methanol III OH ^Ox / ~~7\x0\c-'<\] cis, rac L J      PinB-^x^ / Cl N      Y y Boc V / n-nthp tert-butyl 2-(((( IS, 2R)-2-(6-chloro- 1 -(tetrahydro-2H-pyran-2-yl)-4-(4,4,5,5 -tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-indazol-5- yl)cyclopropyl)methoxy) methyl)-2 -hydroxy -5-oxa-8- azaspiro [3.5] nonane -8-carboxylate ((lS,2 / ?)-2-(4-bromo-6-chloro-l-(tetrahydro-2H-pyran-2-yl)-17f-indazol-5-yl)cyclopropyl)me thanol Step 2: Pd(OAc)2 was used in lieu of Pd(dppf)Cl2, EtOAc was used in lieu of dioxane and H2O Table 24. Analytical data for Examples Cmpd.# MS Wz(ESI): (M+H)+ nmr ccc 592.4 (M+Na)+ N / A DDD 670.5 N / A Cmpd.# MS m / z (ESI): (M+H)+ 2H NMR EEE 584.3 (M+Na)+ *H NMR (400 MHz, CDCh) 5 ppm 7.38 (d, J=7.2 Hz, 1 H), 7.29 (m, 1 H), 7.04 - 7.09 (m, 1 H). 3.16 - 3.25 (m, 3 H), 3.00 - 3.15 (m, 5 H), 2.75 - 2.94 (m. 1 H), 2.28 - 2.45 (m. 1 H), 1.70 - 1.88 (m, 3 H), 1.48 - 1.64 (m, 7 H), 1.34 - 1.37 (m, 9 H). 1.17 - 1.20 (m, 12 H), 0.76 - 0.85 (m, 1 H). III 688.2 !H NMR (400 MHz, CDCl3) 5 ppm 8.20 - 8.12 (m, 1H), 7.72 - 7.66 m, 1H), 5.71-5.63 (m, 1H), 4.07-3.97 (m, 1H), 3.83 - 3.70 (m, 1H), 3.583.42 (m, 5H), 3.39 - 3.31 (m, 3H), 3.28 - 3.13 (m, 3H), 2.62 - 2.41 (m, 3H), 2.20-2.08 (m. 3H), 1.98-1.93 (m. 3H), 1.78- 1.69 (in. 2H), 1.46 (brd, J= 17.6 Hz, 25H), 1.31 - 1.27 (m, 3H). Intermediate FFF: 4-(tert-Butoxy)-7-chloro-2-((3,3-difluoro-l-azabicyclo [3.2.0] heptan-5-yl)methoxy)-8-fIuoropyrido [4,3-< / | pyrimidine. Of-Bu Intermediate FFF

[00360] Step 1: 4-(tert-Butoxy)-2,7-dichloro-8-fluoropyrido[4,3-rf]pyrimidine, Intermediate FFF.l. To a stirred mixture of 2,4,7-trichloro-8-fluoropyrido[4,3-r / |pyrimidine (1.5 g, 6.0 mmol, LabNetwork Inc.) in TFA (12 mL) at -78 °C under N2 was added sodium tert-butoxide (2 M in THF, 3.55 g, 3.9 mL, 7.8 mmol, Oakwood Products. Inc.), and the resulting mixture was stirred at -78 °C for 10 minutes. The reaction mixture was diluted with sat. aq. NH4C1 (15 mL) at -78 °C and allowed to warm to room temperature. The biphasic mixture was extracted with EtOAc (3 x 20 mL), and the combined organic extracts were washed with brine, dried over Na2SO4, filtered, and concentrated to provide Intermediate FFF.l (1.5 g, 5.2 mmol, 87%, yield), m / z (ESI): 234.0 (M-tBu+H)+. ’H NMR (400 MHz, CDCl3) 5 ppm 9.07 - 8.99 (m, 1H), 1.84- 1.79 (m, 9H). 19F NMR (376 MHz, CDCl3) 6 ppm -132.21 - -132.60 (m, IF).

[00361] Step 2: 4-(ta7-Butoxy)-7-chloro-2-((3,3-difluoro-l-azabicyclo[3.2.0]heptan-5-yl)methoxy)-8-fIuoropyrido[4,3-< / |pyrimidine, Intermediate FFF. To a stirred mixture of (3,3-difluoro-l-azabicyclo[3.2.0]heptan-5-yl)methanol (0.37 g, 2.24 mmol, Pharmablock) in THF (5.5 mL) at 0 °C under N2 was added lithium bis(trimethylsilyl)amide solution in THF (1 M in THF, 2.1 mL, , 2.1 mmol, Sigma-Aldrich) and the resulting mixture stirred at 0 °C for 10 minutes. To this solution was added Intermediate FFF.l (0.50 g, 1.7 mmol) in THF (2.75 mL), and the resulting mixture was stirred at room temperature for 3 h. The reaction mixture was diluted with sat. aq. NH4C1 (10 mL) and extracted with EtOAc (3x10 mL). The combined organic extracts were washed with brine, dried over Na2SO4, fdtered, and concentrated to give a residue which was purified by chromatography, eluting with a gradient of 0-50% EtOH / EtOAc (1:3, 2% TEA) in heptane, to provide Intermediate FFF (0.57 g, 1.4 mmol, 80% yield), m'z (ESI): 417.0 (M+H)+. ]H NMR (400 MHz, CDCI3) Sppm 8.97-8.83 (m, 1H), 4.62 - 4.48 (m, 2H), 3.84 - 3.67 (m. 1H), 3.49 - 3.05 (m. 3H), 2.65 - 2.52 (m, 3H), 2.51 - 2.39 (m, 1H), 1.83 - 1.77 (m, 9H). 19F NMR (376 MHz, CDCI3) 5 ppm -90.36 (d. J= 234.9 Hz, IF), -99.81 (d. J =234.9 Hz, IF).-135.29 (s, IF). Intermediate GGG: tert-Butyl (2s,4r)-2-((3-(6-(bis(4-methoxybenzyl)amino)-2-bromo-4-cbloropyridin-3-yl)propoxy)methy])-2-bydroxy-6-azaspiro[3.5]nonane-6-carboxylate Pd(dppf)CI2, K2CO3 THF / H2O, 100 °C, 8 h PMB PMB NaOAc, THF / H2O 70 °C, 12 h PMB PMB Step 1 TBAF, DCM 50 °C, 8 h Step 2 PMB PMB Step 4 Intermediate GGG Step 3

[00362] Step 1: (£)-6-Bromo-5-(3-((tert-butyIdimethylsilyl)oxy)prop-l-en-l-yl)-4-chloro-iV,A-bis(4-methoxybenzyl)pyridin-2-amine, Intermediate GGG.l. To a solution of 6-bromo-4-chloro-5-iodo-AN-bis(4-methox}’benzyl)pyridin-2-amine (3.0 g, 5.2 mmol, CAS: 3064753-60-9) and (E)-tert-butyldimethyl((3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)allyl)oxy)silane (2 g, 6.8 mmol. CAS: 114653-19-9) in THF (30 mL) and water (3 mL) was added K2CO3 (3.1 g, 26.1 mmol) and Pd(dppl)C12 (0.4 g, 0.5 mmol), and die mixture was stirred at 100 °C for 8 h. The reaction mixture was diluted with H2O (200 mL) and extracted with EtOAc (2 x 100 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated. The resulting residue was purified by column chromatography on silica gel. eluting with a gradient of 50:1 to 20:1 pet. ether in EtOAc, to obtain Intermediate GGG.l (4.0 g, 6.5 mmol, 41% yield), m / z (ESI): 617.2 (M+H)+.

[00363] Step 2: 6-Bromo-5-(3-((tert-butyldimethylsilyl)oxy)propyl)-4-chloro-A,A-bis(4-methoxybenzyl)pyridin-2-amine, Intermediate GGG.2. To a solution of Intermediate GGG.l (4.0 g, 6.5 mmol) in THF (40 mL) and water (4 mL) was added NaOAc (3.2 g, 38.8 mmol) and 4-methylbenzenesulfonohydrazide (7.23 g, 38.8 mmol), and the mixture was stirred at 70 °C for 12 h. The reaction mixture was diluted with H2O (80 mL) and extracted with EtOAc (2 x 40 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated. The resulting residue was purified by column chromatography on silica gel, eluting with a gradient of 50:1 to 20:1 pet. ether in EtOAc, to obtain Intermediate GGG.2 (3.0 g, 4.8 mmol, 75% yield), m / z (ESI): 621.2 (M+H)+.

[00364] Step 3: 3-(6-(bis(4-Methoxybenzyl)amino)-2-bromo-4-chloropyridin-3-yl)propan-l-ol, Intermediate GGG.3. To a solution of Intermediate GGG.2 (2.8 g, 4.5 mmol) in DCM (28 mL) was added TBAF (1 M in THF, 13.5 mL, 13.5 mmol) and the mixture was stirred at 50 °C for 8 h. The reaction mixture was diluted with H2O (50 mL) and extracted with DCM (2 x 25 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated. The resulting residue was purified by column chromatography on silica gel, eluting with a gradient of 10:1 to 1:1 pet. ether in EtOAc, to obtain Intermediate GGG.3 (1.7 g, 3.3 mmol, 70% yield), m / z (ESI): 507.2 (M+H)+. 1H NMR (400 MHz, CDCI3) 5 ppm 7.15 (d, 7=8.4 Hz, 4 H). 6.86 (d. 7=8.4 Hz. 4 H), 6.39 (s, 1 H), 5.31 (s, 1 H). 4.61 (s, 4 H), 3.81 (s, 6 H), 3.71 - 3.76 (m, 2 H), 2.82 - 2.92 (m, 2 H), 1.80 - 1.91 (m, 2 H).

[00365] Step 4: tert-Butyl (2s,4r)-2-((3-(6-(bis(4-methoxybenzyl)amino)-2-bromo-4-chloropyridin-3-yl)propoxy)methyl)-2-hydroxy-6-azaspiro[3.5]nonane-6-carboxylate, Intermediate GGG. To a solution of Intermediate GGG.3 (1.3 g, 5.0 mmol) in PhMe (34 mL) was added Y(TIO)3 (0.4 g, 0.8 mmol), and the mixture was stirred at 50 °C for 12 h. The reaction mixture was diluted with H2O (50 mL) and extracted with EtOAc (2 x 25 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated. The resulting residue was purified by reversed phase medium pressure LC, eluting with a gradient of 60-90% ACN in H2O (0.1% NH3 H2O), to obtain Intermediate GGG (0.90 g. 1.19 mmol, 35% yield), m / z (ESI): 760.2 (M+H)+. Intermediate HHH: tert-Butyl (25,45)-2-((((17?,25)-2-(6-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-trityl-2 / 7-indazol-5-yl)cyclopropyl)methoxy)methyl)-l-oxa-6-azaspiro[3.5]nonane-6-carboxylate. OH Boc m-CPBA CH2CI2 Step 1 KOt-Bu, THF Step 2 TrN-N 1) / ^xN°2 ( T ^-^SOsCI KOt-Bu, THF 2) SFC Step 3 Pd(OAc)2, (4-OMeC6H4)3P B2pin2, Cs2CO3 EtOAc Step 4 Intermediate HHH

[00366] Step 1: tert-Butyl (35)-3-hydroxy-3-(oxiran-2-ylmethyl)piperidine-l-carboxylatc, Intermediate HHH.l. To a stirred mixture of tert-butyl (S)-3-ally 1-3-hydroxy piperidine-1 -carboxylate (1.75 g, 7.3 mmol, Pharmablock, Inc.) in DCM (48.3 mL) at 0 °C, was added 3-chlorobenzene-1-carbopero xoic acid (5.0 g, 22 mmol, Sigma-Aldrich), and the mixture was stirred at room temperature for 16 h. The reaction was cooled to 0 °C and quenched with a solution of Na2S2O3, then diluted with aq. NaHCOs. The aqueous layer was extracted with DCM, washed with aq. NaHCOs (3x), dried over Na2SO i and concentrated to provide Intermediate HHH.l (1.7 g, 6.5 mmol, 89% yield), which was used in subsequent steps without further purification, m / z (ESI): 280.0 (M+Na)+.

[00367] Step 2: tert-Butyl (35)-3-(3-(((1 / ?.2.S)-2-(4-bromo-6-chloro 2 trityl 2 / / indazol 5 yl)cyclopropyl)methoxy)-2-hydroxypropyl)-3-hydroxypiperidine-l-carboxylate, Intermediate HHH.2. To a stirred mixture of Intermediate AA (1.78 g, 3.3 mmol) in TFA (12 mL) at 0 °C under nitrogen, was added KOtBu (0.40 g, 3.5 mmol, Sigma Aldrich), and the mixture stirred at 0 °C for 10 minutes. Then, a solution of Intermediate HHH.l (0.70 g, 2.7 mmol) in TFA (6.00 mL) was added, and the resulting mixture was stirred at 50 °C for 2 h. The reaction was concentrated and purified by column chromatography on silica gel. eluting with a gradient of 0-100% EtOAc in heptane, to provide Intermediate HHH.2 (0.98 g, 1.2 mmol, 45% yield), m / z (ESI): 822.0 (M+Na)+.

[00368] Step 3: tert-Butyl (25',45)-2-((((17?,25)-2-(4-bromo-6-chloro-2-trityl-2 / 7-indazol-5-yl)cyclopropyl)methoxy)methyl)-l-oxa-6-azaspiro[3.5]nonane-6-carboxylate, Intermediate HHH.3. To a stirred mixture of Intermediate HHH.2 (1.4 g, 1.7 mmol) in THF (17 mL) at 0 °C under N2 was added KOtBu (0.4 g, 3.8 mmol, Sigma Aldrich), and the resulting mixture was stirred at 0 °C for 30 minutes. Then, 2-nitrobenzenesulfonyl chloride (0.5 g, 2.4 mmol, Combi-Blocks Inc.) was added, and the reaction wanned to room temperature over 16 h. The reaction mixture was diluted with H2O, extracted with EtOAc, dried over Na2SO4 and concentrated. The resulting residue was purified by column chromatography on silica gel, eluting with a gradient of 0-70% EtOAc in heptane. Peak 1: Zert-Butyl (27?,4S)-2-((((lA,2S)-2-(4-bromo-6-chloro-2-trityl-2 / 7-indazol-5-yl)cyclopropyl)methoxy)methyl)-l-oxa-6-azaspiro[3.5]nonane-6-carboxylate (0.35 g, 0.40 mmol, 26% yield), m / z (ESI): 804.0 (M+Na)+. Peak 2: ze / 7-Butyl (2S,4S)-2-((((17?,25)-2-(4-bromo-6-chloro-2-trityl-2 / f-indazol-5-yl)cyclopropyl)methoxy)methyl)-l-oxa-6-azaspiro[3.5]nonane-6-carboxylate (Intermediate HHH.3, 0.3 g, 0.3 mmol. 19% yield), m 'z (ESI): 804.0 (M+Na)+.

[00369] Step 4: tert-Butyl (25',45)-2-((((17?,25)-2-(6-chloro-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-2-trityl-277-indazol-5-yl)cyclopropyl)methoxy)methyl)-l-oxa-6- azaspiro[3.5]nonane-6-carboxylate. To a stirred and degassed mixture of Pd(OAc)2 (20 mg, 0.07 mmol, Sigma-Aldrich), tris(4-methoxyphenyl)phosphine (50 mg, 0.13 mmol, Combi-Blocks), CS2CO3 (0.2 g, 0.5 mmol, Ambeed, Inc.), Intermediate HHH.3 (0.26 g, 0.33 mmol) in EtOAc (1.7 mL) under N2 was added B2Pin2 (0.1 g, 0.4 mmol, Combi-Blocks Inc.), and the resulting mixture was stirred at 80 °C for 10 h. The reaction mixture was fdtered and concentrated. The resulting residue was purified by column chromatography on silica gel, eluting with a gradient of 0-80% EtOAc in heptane, to provide Intermediate HHH (0.1 g. 0.1 mmol, 43% yield), m / z (ESI) 852.2 (M+Na)+. Intermediate JJJ: tert-Butyl 2-(5-(3-(4-bromo-6-chloro-l-(tetrahydro-2H-pyran-2-yl)-lH- indazol-5-yl)propyl)-l,3,4-oxadiazol-2-yl)-2-((tert-butyldimethylsilyl)oxy)-6- azaspiro 13.51 nonane-6-carboxylate OH OTBS Intermediate JJJ

[00370] Step 1: 4-(4-Bromo-6-chloro-l-(tetrahydro-277-pyran-2-yl)-177-indazol-5-yl)butanoic acid, Intermediate JJJ.l. To a stirred mixture of methyl 4-(4-bromo-6-chloro-l-(tetrahydro-2H-pyran-2-yl)-lH-indazol-5-yl)butanoate (2.1 g, 5.0 mmol) in THF (13 mL) in H2O (13 mL) at 55 °C under ambient atmosphere was added lithium hydroxide, monohydrate (0.4 g, 10 mmol, Sigma-Aldrich), and the resulting mixture was stirred at 55 °C for 2 h. The reaction was concentrated, diluted with EtOAc, and acidified (pH ~ 2-3) by addition of HC1 solution (0.5 M). The aqueous phase was extracted with EtOAc, dried over Na2SO4 and concentrated to provide Intermediate JJJ.l (2 g, 5 mmol, 99% yield), m / z (ESI): 401.0 (M+H)+.

[00371] Step 2: 4-(4-Bromo-6-chloro-l-(tctrahydro-2J7-pyran-2-yl)-17T-indazol-5-yl)butanehydrazide., Intermediate JJJ.2 To a stirred mixture of Intermediate JJJ.l (2 g, 5 mmol) and DIPEA (2 mL, 11 mmol, Sigma-Aldrich) in DMF (3.3 mL) / ACN(13.3 mL) at room temperature under N2 was added HATU (2.3 g, 6.0 mmol, Combi-Blocks Inc.), and the resulting mixture was stirred at room temperature for 30 minutes. To this mixture, a solution of hydrazine, anhydrous (0.6 mL, 20 mmol, Sigma-Aldrich) and DIPEA (1.9 mL, 11 mmol, Sigma-Aldrich) in DMF (3.3 mL) / ACN (13.3 mL) was added, and the reaction was stirred at room temperature for 1 h. The reaction mixture was diluted with H2O (150 mL), filtered, washed with H2O and dried to provide Intermediate JJJ.2 (1.5 g. 3.7 mmol, 74% yield), m / z (ESI): 415.0 (M+H)T

[00372] Step 3: tert-Butyl 2-(2-(4-(4-bromo-6-chloro-l-(tetrahydro-2H-pyran-2-yl)-lH-indazol-5-yl)butanoyl)hydrazine-l-carbonyl)-2-hydroxy-6-azaspiro[3.5]nonane-6-carboxylate. Intermediate JJJ.3. To a stirred mixture of DIPEA (2.6 mL, 14.8 mmol, Sigma-Aldrich Corporation),4-(4-bromo-6-chloro-1 -itctrahy dro-2H-py ran-2-y I)-1 H-indazol-5 -y l)butanehy drazide (1.54 g, 3.70 mmol) and 6-(tert-butoxycarbonyl)-2-hydroxy-6-azaspiro[3.5]nonane-2-carboxylic acid (1.27 g, 4.45 mmol) in N,A-dimethylformamide (20.5 mL) / dimethyl sulfoxide (4.1 mL) at room temperature under ambient atmosphere, was added HATU (1.62 g, 4.26 mmol, Combi-Blocks Inc.). The resulting mixture was stirred at room temperature for 1 h. The reaction mixture was diluted with brine (30 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic extracts were washed with brine, dried over sodium sulfate, filtered, and concentrated. The crude material was purified by reversed phase chromatography, eluting with a gradient of 5-100% acetonitrile (0.1% formic acid) in water (0.1% formic acid) to afford tert-butyl 2-(2-(4-(4-bromo-6-chloro-l-(tetrahydro-2H-pyran-2-yl)-lA-indazol-5-yl)butanoyl)hydrazine-l-carbonyl)-2-hydroxy-6-azaspiro[3.5]nonane-6-carboxylate (2.35 g, 3.44 mmol. 93% yield), m / z (ESI): 682.0 (M+H)+. *H NMR (400 MHz, CDCh) 5 ppm 8.88 - 9.11 (m, 1 H). 7.96 (s. 2 H), 7.61 - 7.69 (m. 1 H), 5.58 - 5.70 (m. 1 H), 3.95 - 4.07 (m. 1 H), 3.74 - 3.85 (m, 1 H), 3.43 - 3.52 (m, 3 H), 3.34 (br d, 7=5.0 Hz, 3 H), 3.10 - 3.21 (m, 2 H), 2.48 -2.77 (m. 3 H), 2.37 - 2.46 (m. 3 H), 2.08 - 2.30 (m. 3 H), 1.87 - 2.03 (m. 2 H), 1.69 - 1.83 (m. 6 H), 1.47 (d, .7=2.9 Hz, 9 H)

[00373] Step 4: tert-Butyl 2-(2-(4-(4-bromo-6-chloro-l-(tetrahydro-2 / / -pvran-2-yl)-l / f-indazol-5-yl)butanoyl)hydrazine-l-carbonyl)-2-((tert-butyldimethylsilyl)oxy)-6-azaspiro[3.5]nonane-6-carboxylate, Intermediate JJJ.4. To a stirred mixture of Intermediate JJJ.3 (2.4 g, 3.4 mmol) and 2.6-lutidine (1.1 g, 1.2 mL, 10.3 mmol, Sigma-Aldrich) in DCM (22.94 mL) at 0 °C under N2 was added TBS triflate (1.2 mL, 5.2 mmol, Sigma-Aldrich Corporation), and the resulting mixture wanned to room temperature and stirred for 3 h. The reaction mixture was diluted with sat. aq. Na2CO3 (10 mL) and extracted with DCM (3 x 10 mL). The combined organic extracts were washed with brine, dried over Na2SO4, filtered, and concentrated. The resulting residue was purified by column chromatography on silica gel, eluting with a gradient of 0-40% EtOH / EtOAc (1:3) in heptane, to provide Intermediate JJJ.4 (2.6 g, 3.3 mmol, 95% yield), m / z (ESI): 818.0 (M+Na)1.

[00374] Step 5: tert-Butyl 2-(5-(3-(4-bromo-6-chloro-l-(tetrahydro-2 / T-pyran-2-yl)-l / T-indazol-5-yl)propyl)-l,3,4-oxadiazol-2-yl)-2-((terCbutyldimethylsilyl)oxy)-6-azaspiro[3.5]nonane-6-carboxylate, Intermediate JJJ. To a stirred mixture of Intermediate JJJ.4 (2.6 g, 3.3 mmol) in Me-THF (22 mL) at room temperature under N2 was added Burgess reagent (4.7 g, 19.6 mmol, Combi-Blocks Inc.), and the resulting mixture was stirred at 80 °C for 4 h. The reaction mixture was concentrated and purified by column chromatography on silica gel. eluting with a gradient of 0-80% EtOAc in heptane, to provide Intermediate JJJ (0.9 g, 1.1 mmol, 35% yield), m / z (ESI): 778.2 (M+H)1. Intermediate LLL: tert-Butyl (2s,4r)-2-((3-(6-chloro-l-(tetrahydro-2H-pyran-2-yl)-4-(4,4,5,5-tctramcthvl-l,3,2-dioxaborolan-2-vl)-l / / -indazol-5-yl)propoxy)methyl)-2-hydroxy-6-azaspiro[3.5]nonane-6-carboxylate. n-nthp Pd(OAc)2, (4-OMeO6H4)3P B2pin2, CS2CO3 EtOAc Step 2 OH n-nthp Intermediate LLL Intermediate A

[00375] Step 1: tert-Butyl (2s,4r)-2-((3-(4-bromo-6-chloro-l-(tetrahydro-2H-pyran-2-yl)-lH-indazol-5-yl)propoxy)methyl)-2-hydroxy-6-azaspiro [3.5] nonane-6-carboxylate, Intermediate LLL.l. To a stirred mixture of Intermediate A (0.40 g, 1.1 mmol) and Y(TfO)3 (0.14 g. 0.27 mmol, Combi-Blocks Inc.) in PhMe (5 mL) at room temperature under N2 was added Intermediate B (0.41 g, 1.6 mmol) and the resulting mixture stirred at 40 °C for 16 h. The reaction mixture was diluted with H2O (10 mL) and extracted with EtOAc (3x10 mL). The combined organic extracts were washed with brine, dried over Na2SO4, filtered, and concentrated to give a residue which was purified by column chromatography on silica gel, eluting with a gradient of 0-80% EtOAc in heptane, to provide Intermediate LLL.l (0.37 g, 0.6 mmol, 55% yield), m / z (ESI): 648.0 (M+Na)+. ’H NMR (400 MHz, CDCI3) 5 ppm 8.05 - 7.87 (111, 1H), 7.72 - 7.57 (m, 1H), 5.73 - 5.54 (m, 1H), 4.07 - 3.94 (m, 1H), 3.83 - 3.68 (m, 1H), 3.68 - 3.56 (m, 2H), 3.56 - 3.42 (m, 2H), 3.38 - 3.21 (m, 4H), 3.20 - 3.06 (m, 2H), 2.94-2.79 (m, 1H), 2.60-2.41 (m, 1H), 2.22- 1.84 (m, 7H), 1.80- 1.73 (m, 3H), 1.70-1.64 (m, 3H), 1.54- 1.42 (m, 11H).

[00376] Step 2: tert-Butyl (2s,4r)-2-((3-(6-chloro-l-(tetrahydro-2H-pyran-2-yl)-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l / 7-indazol-5-yl)propoxy)methyl)-2-hydroxy-6-azaspiro[3.5]nonane-6-carboxylate, Intermediate LLL. To a stirred mixture of Intermediate LLL.l (0.37 g, 0.6 mmol), B2Piii2 (0.30 g, 1.2 mmol, Combi-Blocks Inc.) and CS2CO3 (0.58 g, 1.8 mmol, Ambeed, Inc.) in EtOAc (3 mL) at room temperature under N2 was added Pd(OAc)2 (18 mg, 0.1 mmol, Sigma-Aldrich Corporation) and tris(4-methoxyphenyl)phosphine (27 mg, 0.1 mmol, Combi-Blocks Inc.). The resulting mixture was sparged with N2 for 15 minutes and stirred at 80 °C for 1 h 15 minutes. The reaction mixture was filtered and concentrated. The resulting residue was purified by column chromatography on silica gel, eluting with a gradient of 0-80% EtOAc in heptane, to provide Intermediate LLL (0.29 g, 0.4 mmol, 74% yield), m / z (ESI): 696.2 (M+Na)+. ’H NMR (400 MHz, CDCh) 8 ppm 8.40 - 8.30 (in. 1H), 7.80 - 7.71 (m. 1H), 5.74 - 5.59 (m. 1H), 4.07 - 3.95 (m, 1H), 3.80 - 3.69 (m, 1H), 3.66 - 3.54 (m, 2H), 3.52 - 3.41 (m, 2H), 3.36 - 3.28 (m, 2H). 3.27 -3.24 (m, 2H), 3.24 - 3.15 (m, 2H), 3.03 - 2.82 (m. 1H), 2.64 - 2.42 (m. 1H), 2.22 - 2.12 (m. 2H), 2.08 - 1.99 (m, 3H). 1.95 - 1.82 (m, 3H). 1.82 - 1.73 (m, 4H). 1.71 - 1.65 (m, 3H), 1.55 - 1.44 (m, 12H). 1.42-1.41 (m, 9H). Intermediate MMM: tert-Butyl (2s,4r)-2-((((Z)-3-(6-chloro-l-(tetrahydro-2 / / -pyran-2-yl)-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-indazol-5-yl)allyl)oxy)methyl)-2-hydroxy-6-azaspiro[3.5]nonane-6-carboxylate. / -Pr2NEt Step 1 HO—'   SnBu3 CataCXium A Pd G3 Y(OTf)2, PhMe Step 2 OH n-nthp Pd(OAc)2, (4-OMeC6H4)3P B2pin2, Cs2CO3 EtOAc Step 3 OH n-nthp Intermediate MMM

[00377] Step 1: (Z)-3-(4-Bromo-6-chloro-l-(tetrahydro-2.H-pyran-2-yl)-177-indazol-5-yl)prop-2-en-l-ol, Intermediate MMM.1. To a mixture of (Z)-2-propen-3-(tributylstannyl)-l-ol (2.3 g, 6.6 mmol, AA BLOCKS LLC), 4-bromo-6-chloro-5 -iodo-l-(tetrahydro-2H-pyran-2-y 1)-1 / / -indazole (2.34 g, 5.30 mmol,CAS: 74141-13-2), and CataCXium A Pd G3 (CAS No. 1651823-59-4)(0.2 g, 0.3 mmol, Ambeed, Inc.) was added DIPEA (11 mL). The mixture was sparged with N2, and stirred at 100 °C for 1 h. The reaction mixture was diluted with 10% aq. LiCl (10 mL) and EtOAc (15 mL). The organic layer was washed with 10% aq. LiCl (10 mL), dried with Na2SO4, filtered, and concentrated. The resulting residue was purified via chromatography , eluting with a gradient of 0-40% EtOAc in heptane, to provide Intermediate MMM.1 (0.97 g, 2.6 mmol, 49% yield), m / z (ESI): 370.8 (M+H)+.

[00378] Step 2: tert-Butyl (2s,4r)-2-((((Z)-3-(4-bromo-6-chloro-l-(tetrahydro-2H-pyran-2-yl)-l / 7-indazol-5-yl)allyl)oxy)methyl)-2-hydroxy-6-azaspiro[3.5]nonane-6-carboxylate, Intermediate MMM.2. To a solution of Intermediate MMM.1 (0.52 g, 1.4 mmol) in PhMe (9.3 mL), was added Y(TfO)3 (0.19 g, 0.30 mmol, Combi-Blocks Inc.) and Intermediate B (0.53 g, 2.1 mmol). The reaction was stirred at 40 °C for 22 h. The reaction mixture was then concentrated and purified via RP-HPLC, using a gradient of 10-100% MeCN (0.1% formic acid) in water (0.1% formic acid), to provide Intermediate MMM.2 (0.38 g, 0.6 mmol, 43% yield), m / z (ESI): 646 (M+Na)+.

[00379] Step 3: tert-Butyl (2s,4r)-2-((((Z)-3-(6-chloro-l-(tetrahydro-2Zf-pyran-2-yl)-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l / 7-indazol-5-yl)allyl)oxy)methyl)-2-hydroxy-6-azaspiro[3.5]nonane-6-carboxylate, Intermediate MMM. To Intermediate MMM.2 (0.38 g, 0.6 mmol) was added CS2CO3 (0.30 g, 0.9 mmol, Combi-Blocks Inc.), B2Pin2 (0.18 g, 0.7 mmol, Combi-Blocks Inc.), Pd(OAc)2 (6.8 mg, 0.03 mmol, AK Scientific, Inc.) and tris(4-methoxyphenyl)phosphine (21 mg, 0.1 mmol, Combi-Blocks Inc) in EtOAc (1.2 mL). The mixture was sparged with N2 for 5 minutes and stirred at 80 °C for 2.5 h. The reaction was cooled to room temperature, filtered, and concentrated. The resulting residue was purified by column chromatography on silica gel, eluting with a gradient of 0-40% EtOAc in heptane, to provide Intermediate MMM (0.16 g, 0.20 mmol, 40% yield), m / z (ESI): 671.2 (M+H)+. Intermediate NNN: 7-Chloro-8-fluoro 4-(methoxymethoxy)-2-methylpyrido[4,3-< / ]pyrimidine. MOM-Br, / -Pr2NEt CH2CI2 Step 2 OMOM F Intermediate NNN

[00380] Step 1: 7-Chloro-8-fluoro-2-methylpyrido[4,3-< / ]pyrimidin-4-ol, Intermediate NNN.l. To a stirred mixture of 4,7-dichloro-8-fluoro-2-methylpyrido[4,3-r / |pyrimidine (0.5 g, 2.2 mmol. PharmaBlock) in BuOH (6 mL) at room temperature under ambient atmosphere was added HC1 (2 N, 7.1 g. 6 mL. 12 mmol, Thermo Fisher Scientific) and the resulting mixture was stirred at 100 °C for 1 h. The reaction was cooled to room temperature then diluted with EtOAc and sat. aq. Na2HCO3. The aqueous phase was extracted with EtOAc. dried over Na2SO4, and concentrated to give Intermediate NNN.l (0.50 g, 2.2 mmol. 100% yield), m / z (ESI): 214.2 (M+H)+.

[00381] Step 2: 7-Chloro-8-fluoro 4-(methoxymethoxy)-2-methylpyrido[4,3-<Z]pyrimidine, Intermediate NNN. To a stirred mixture of Intermediate NNN.l (0.4 g, 2 mmol) and DIPEA (1.8 mL, 10.1 mmol, Sigma-Aldrich) in DCM (13.4 mL) at 0 °C under N2 was added bromomethyl methyl ether (0.3 mL. 3 mmol, Sigma-Aldrich), the reaction allowed to warm to room temperature and stirred for 3 h. The reaction mixture was diluted with sat. aq. Na2HCO3 (20 mL) and extracted with DCM (3 x 15 mL). The combined organic extracts were washed with brine, dried over Na2SO4. filtered, and concentrated. The resulting residue was purified by column chromatography on silica gel, eluting with a gradient of 0-100% EtOH / EtOAc (1:3, 2% TEA) in heptane, to provide Intermediate NNN (0.4 g. 1.7 mmol. 83% yield), m / z (ESI): 258.0 (M+H)+. Intermediate OOO: 4-(tert-Butoxy)-7-chloro-2-(((27?,7aN)-2-fluorotetrahydro-lH-pyrrolizin-7a(5 / 7)-yl)methoxy)-5-methylpyrido[4,3-< / ]pyrimidine. ci Me NaOt-Bu THF, -78 °C Step 1 Of-Bu Me Ot-Bu Intermediate OOO

[00382] Step 1: 4-( / c'H-Butoxy)-2,7-dichloro-5-methylpyrido[4,3-< / |pyrimidine, Intermediate 000.1. To a stirred mixture of 2,4,7-trichloro-5-methylpyrido[4,3-<7|pyrimidine (3.0 g, 12.1 mmol, CAS: 2454396-72-4) in THF (15 mL) at -78 °C under N2, was added sodium tert-butoxide (2 M in THF, 6.6 mL, 13.3 mmol, Oakwood Products. Inc ), and the resulting mixture was stirred at -78 °C for 3 h. The reaction mixture was diluted with sat. aq. NH4CI and extracted with EtOAc. The combined organic extracts were washed with brine, dried over Na2S0 i. filtered, and concentrated to give a residue which was purified by column chromatography on silica gel, eluting with a gradient of 0-80% EtOH / EtOAc (1:3, 2% TEA) in heptane, to provide Intermediate OOO.l (0.3 g, 1.1 mmol, 10% yield). m,z (ESI): 286.2 (M+H)+. !H NMR (400 MHz, CDCI3) 5 ppm 7.54 (s, 1H), 3.01 (s, 3H), 1.80 (s, 9H).

[00383] Step 2: 4-( / ert-Butoxy)-7-chloro-2-(((27?,7a5)-2-fluorotetrahydro-lLLpyrrolizin-7a(5Ef)-yl)niethoxy)-5-methylpyrido[4,3-d|pyrimidine, Intermediate 000. To a stirred mixture of ((2r,7ay)-2-fluorohexahydro-l / 7-pyrrolizin-7a-yl)methanol (0.4 g, 2.5 mmol, Phannablock, Inc.) in THF (5 mL) at room temperature under N2 was added lithium bis(trimethylsilyl)amide solution in THF (1 M in THF. 3.3 mL, 3.3 mmol, Sigma-Aldrich Corporation), and the resulting mixture was stirred at room temperature for 10 minutes. Then a solution of Intermediate OOO.l (0.3 g, 1.1 mmol) in THF (4 mL) was added, and the resulting mixture was stirred at room temperature for 16 h. The reaction mixture was concentrated under reduced pressure. The resulting residue was purified by column chromatography on silica gel. eluting with a gradient of 0-70% EtOH / EtOAc (1:3. 2% TEA) in heptane, to provide Intermediate 000 (0.4 g, 0.9 mmol. 81% yield), mz (ESI): 409.3 (M+H)+.1 H NMR (400 MHz, CDCl3) 5 ppm 7.37 (s, 1H). 5.42-5.15 (m, 1H). 4.26-4.15 (m, 2H). 3.31 - 3.22 (m, 2H), 3.21 - 3.14 (m, 1H), 3.00 (td, J= 9.2, 5.7 Hz. 1H), 2.94 (s, 3H), 2.30 - 2.06 (m, 3H), 2.01 -1.83 (m. 3H), 1.77 (s. 9H). SECTION 2: Synthesis of Example Compounds

[00384] Provided in this section is the synthesis of examples described herein. It would be understood that compounds described herein (such as compounds of Formula (I), Formula (I-B). Fonnula (II), Formula (H-B), Formula (III), Formula (III-B), Formula (IV), Formula (IV-B), Fonnula (V), Formula (V-B), Formula (VI) or Formula (VLB), or compounds listed in Table 1, Table 2 or compounds of Embodiments 1-214, or a pharmaceutically acceptable salt of any of the foregoing) whose preparation is not specifically described in this section could be prepared in an analogous manner. Example 1.010: (ll?,37?)-10-Chloro-32-fluoro-24-(((21?,7a5)-2-fluorotetrahydro-lH-pyrrolo[ 1,2-a] pyrrol-7a(5 / / )-yl)methoxy)-5-oxa-l 3,14,19,23,25,27- hexaazaheptacyclo [25.3.1.1-1,3-.1-18,22-.0-9,17-.0-12,16~.0~21,26~]tritriaconta- 9,ll,14,16,18(32),19,...

Claims

1. A compound of Formula (I):(I)or a pharmaceutically acceptable salt thereof, wherein;X is -CH2- or -O-Z is C-H, C-halogen, C-CN, C-C1-4 alkyl, C-C1-4 haloalkyl, C-C1-4 alkoxy, C-C1.4 haloalkoxy, C-C3-7 cycloalkyl or N;Q is CH, C-halogen, C-C1-4 alky l, C-C1-4 haloalky l or N;B is a C3-7 cycloalkyl or 3-7 membered hctcrocycloalkyl;n is 0, 1 or 2;m is 0, 1 or 2;p is 0, 1 or 2;q is 0, 1 or 2;each Rx independently is hydroxyl, halogen, oxo, cyano, -N(RZ)2, C1-4 alky l, C1.4 deuteroalkyl, C1.4 alkoxy, C1-4 haloalkyl, Cm haloalkoxy, C1-4 hydroxyalkylene, 5-7 membered heteroaryl, -S(O)2-Ci-4alkyl, -S(O)2N(RZ)2, -C(O)RZ, -C(O)ORZ, -C(O)N(RZ)2. -C1-4 alkylene-C(O)-Ci. 4alkyl, -C1-4 alkylene-C(O)N(Rz)2, Cm alkylene-S(O)2-Ci-4alkyl, or -S-Ci-4alkyl;L2 is a bond. Ci-e alkylene, -O-Ci-e alkylene. -S-C1-6 alkylene, NRZ, O or S, wherein each Cie alkylene, -O-Ci-e alky lene and -S-C1-6 alkylene chain is substituted with 0-2 occurrences of R2;R1 is hydrogen, hydroxyl, Ce-io aryl, 5-10 membered heteroaryl, C3-8 cycloalkyl or 4-15 membered heterocycloalkyl, wherein each aryl, heteroaryl, cycloalkyl or heterocycloalkyl is substituted with 0-3 occurrences of R5;each R2 independently is halogen, deuterium, hydroxyl or C1.4 alkyl;wherein two geminal R2 groups, together with the atom to which they are attached form a spiro-Ca-? cycloalkyl group substituted with 0-2 occurrences of Rw; or wherein two adjacent R2 groups, together with the atoms to which they are attached form a fused-C3-7 cycloalkyl group substituted with 0-2 occurrences of R'v;R4 is hydrogen, hydroxyl, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, C2-4 alkenyl, C2-4 alkynyl. Ck- cycloalkyl or cyano:each R" independently is halogen, cyano, oxo, -T-Ry, hydroxyl, -N(RZ)2, C1-4 alkyl. Cm haloalkyl, C1-4 alkoxy or -O-C2-4 alkynyl;each R6a> R6band R6c independently is hydrogen, halogen, hydroxyl, cyano. -N(RZ)2. -C(O)RZ, -C(O)ORZ, C1.4 alkyl, C1.4 alkoxy. C1.4 haloalkyl, C1.4 haloalkoxy. C2-4 alkynyl or C3-6 cycloalkyl or R6a and R6b. together with the atom to which they are attached form a fused C3 7 cycloalkyl;R6d is hydrogen, -C(O)-Ci.g alkyl or -C(O)-OCi-8 alkyl;each Rw independently is C1-4 alkyl, C1-4 alkoxy, -C(O)-Ci-4 alkyl, -C(O)-O-Ci-4 alkyl, halogen, hydroxyl or C1.4 haloalkyl;T is C1-4 alkylene, -S(O)2-, -C(O)-, -C1-4 alkylene-C(O)-, C1-4 alkylene-S(0)2- or -S-;Ry is halogen, C1-4 alkyl, C1-4 haloalkyl, hydroxyl, cyano or -N(RZ)2; andeach Rz independently is hydrogen or C1-4 alkyl.

2. The compound of claim 1, wherein the compound is a compound of Formula (I-B):(RW)qL1Rln' 'VR6a(I-B)R6bd6c*\\K N-NHor a pharmaceutically acceptable salt thereof, wherein;X is -CH2- or -O-Z is C-H, C-halogen, C-CN, C-C1-4 alkyl, C-C1-4 haloalkyl, C-C1.4 alkoxy, C-C1.4 haloalkoxy, C-C3-7 cycloalkyl or N;Q is CH. C-halogen, C-C1-4 alkyl, C-C1.4 haloalkyl or N;B is a C3-7 cycloalkyl or 3-7 membered heterocycloalkyl;n is 0, 1 or 2;m is 0, 1 or 2;p is 0, 1 or 2;q is 0, 1 or 2;each Rx independently is hydroxyl, halogen, oxo, cyano, -N(RZ)2, C1-4 alkyl. Cm deuteroalkyl, Cm alkoxy, Cm haloalkyl, Cm haloalkoxy, Cm hydroxyalkylene, 5-7 membered heteroaryl, -S(O)2-Ci-4alkyl, -S(O)2N(RZ)2, -C(O)RZ, -C(O)ORZ, -C(O)N(RZ)2. -Cm alkylene-C(O)-Ci. 4alkyl, -Cm alkylene-C(O)N(Rz)2, Cm alkylene-S(O)2-Ci-4alkyl, or -S-CMalkyl;L2 is a bond. Cm alkylene, -O-Cm alkylene. -S-Cm alkylene, NRZ, O or S, wherein each Cie alkylene, -O-Cm alky lene and -S-Cm alkylene chain is substituted with 0-2 occurrences of R2;,O.L1 isOO0'0 O'O O'R1 is hydrogen, hydroxyl, Ce-io aryl, 5-10 membered heteroaryl, C3-8 cycloalkyl or 4-15 membered heterocycloalkyl, wherein each aryl, heteroaryl, cycloalkyl or heterocycloalkyl is substituted with 0-3 occurrences of R\each R2 independently is halogen, deuterium, hydroxyl or Cm alkyl;wherein two geminal R2 groups, together with the atom to which they7 are attached form a spiro-C , - cycloalkyl group substituted with 0-2 occurrences of Rw; or wherein two adjacent R2 groups, together with the atoms to which they are attached form a fused-C , - cycloalky l group substituted with 0-2 occurrences of Rw; R4 is hydrogen, hydroxyl, halogen, C1.4 alkyl, C1.4 alkoxy, Ci-4 haloalkyl, C2-4 alkenyl, C2-4 alky nyl, C3-7 cycloalkyl or cyano;each R5 independently is halogen, cyano, oxo, -T-Ry. hydroxyl, -N(RZ)2. C1.4 alkyl. C1.4 haloalkyl, C1-4 alkoxy or -O-C2-4 alkynyl;each R6aR6bandR6c independently is hydrogen, halogen, hydroxy l, cyano, -N(RZ)2, -C(O)RZ, -C(O)ORZ, Cm alky l, C1-4 alkoxy , C1-4 haloalky l, C1-4 haloalkoxy , C2-4 alky ny l or C3-6 cycloalky l or R6a and R6b, together with the atom to which they are attached form a fused C3-7 cycloalkyl;T is Cm alkylene, -S(O)2-, -C(O)-, -C1-4 alkylene-C(O)-, C1-4 alkylene-S(O)2- or -S-;each Rw independently is Cm alky l, Cm alkoxy, halogen, hydroxyl or Cm haloalkyl;Ry is halogen, Cm alkyl, Cm haloalkyl, hydroxyl, cyano or -N(RZ)2; and each Rz independently is hydrogen or Cm alkyl.

3. The compound or salt of claim 2, wherein the compound is a compound of Formula(H-B)(II-B)or a pharmaceutically acceptable salt of said compound, wherein X, Z, p. n, Rx, L2. L1. R1. R2, R4, R5, R6a, R6b, R6c, Rw, T, Ry and Rz are as defined for Formula (I-B).

4. The compound or salt of claim 2, wherein the compound is a compound of Formula(III-B)RW(III-B)or a pharmaceutically acceptable salt of said compound, wherein X, Z, p, n, Rx, L2, L1, R1, R2, R4, R5, R6a, R6b, R6c, Rw, T, Ry and Rz are as defined for Formula (I-B).

5. The compound or salt of claim 2, wherein the compound is a compound of Formula(IV-B)(IV-B)or a pharmaceutically acceptable salt of said compound, wherein X, Z, p. n, Rx, L1. R4. R6a, R6b, R6c. R". T, Ry and Rz are as defined for Formula (I-B).

6. The compound or salt of claim 2, wherein the compound is a compound of Formula (V-B):RW(V-B)or a pharmaceutically acceptable salt of said compound, wherein Z, L1, R4, R6a, R6b, R6c, Rw, T, Ry and Rz are as defined for Formula (I-B).

7. The compound or salt of claim 2, wherein the compound is a compound of Formula(Vl-B)RW(VI-B)or a pharmaceutically acceptable salt of said compound, wherein L1, R6a. R6b, R6c, Rw, T. Ry and Rz are as defined for Formula (I-B).

8. The compound or salt of any of claims 1-2, wherein Z is N and Q is CH.

9. The compound or salt of any of claims 1 -2, wherein Z is N and Q is N.

10. The compound or salt of any of claims 1-9, wherein L2 is -O-methylene or -O-ethylene substituted with 0-2 occurrences of R211. The compound or salt of any of claims 1-10, wherein L2 is -O-methylene substituted with 0 occurrences of R212. The compound or salt of claim 11, wherein R1 is 7a-(hexahydro-lH-pyrrolizinyl), 2-azetidinyl or 2-pyrrolidinyl substituted with 0-3 occurrences of R5.

13. The compound or salt of claim 12, wherein R1 is 7a-(hexahydro-lH-pyrrolizinyl), 2-azetidinyl or 2-pyrrolidinyl substituted with one occurrence of R5.

14. The compound or salt of claim 13, wherein R5 is fluorine or methyl.

15. The compound or salt of claim 12, wherein R1 is 2-pyrrolidinyl substituted with twooccurrences of R5.

16. The compound or salt of claim 15, wherein R5 is independently fluorine, ethyl or methyl.

17. The compound or salt of any of claims 1-10, wherein L2 is -O-methylene substituted with 2 occurrences of R218. The compound or salt of claim 17, wherein both R2 are deuterium.

19. The compound or salt of claim 18, wherein R1 is 7a-(hexahydro-lH-pyrrolizinyl) substituted with one occurrence of R5.

20. The compound or salt of claim 19, wherein R5 is halogen.

21. The compound or salt of any of claims 1-10. wherein L2 is -O-w-propylene substituted with two occurrences of R2.

22. The compound or salt of claim 21, wherein two geminal R2 groups, together with the atom to which they are attached form a spiro-cyclopropyl substituted with two occurrences of Rw.

23. The compound or salt of claim 22, wherein both Rw are halogen.

24. The compound or salt of claim 23, wherein R1 is -N(RZ)2 and both Rz are methyl.26.The compound or salt of claim 25, wherein -L2-R1 is27.The compound or salt of claim 26, wherein -L2-R1 is28. The compound or salt of claim 26, wherein -L^R1 is29. The compound or salt of any of claims 1-28. wherein X is O.

30. The compound or salt of claim 29. wherein —1—             is32. The compound or salt of any of claims 1-28, wherein X is -CH2-.

36. The compound or salt of any of claims 1-35, wherein R4 is hydrogen, hydroxyl, halogen, Ci-4 alkyl or Ci-4 alkoxy.

37. The compound or salt of claim 36, wherein R4 is fluorine.

38. The compound or salt of any of claims 1-37, wherein R6a, R6b andR6c are each independently hydrogen, halogen, Ci-4 alkyl, Ci-4 alkoxy or Ci-4 haloalkyl.

39. The compound or salt of claim 38, wherein R6b and R6c are each hydrogen and R6a is chlorine.

40. The compound or salt of claim 38, wherein R6b and R6c are each hydrogen and R6a is methyl.

41. The compound or salt of any of claims 1-40, wherein R6d is hydrogen or -C(O)-Ci-s alkyl.

42. The compound or salt of claim 41, wherein R6d is hydrogen.

43. The compound or salt of claim 1, wherein the compound is:Compound1.0011.002Compound1.003Compound1.0101.012Compound1.0331.0351.0361.0371.0391.0411.0421.0431.044CompoundCompoundCompound1.0521.0541.0551.059OW°An W1 n-nh1.0621.0651.0661.067CompoundCompoundCompound1.0681.0691.0701.0711.0731.077CompoundCompoundCompoundOH1.081OHn-nh1.0821.083OH1.084OH1.088OH1.091OH1.086OH1.089OH1.0871.09044. The compound or salt of claim 43, wherein the compound is:CompoundCompoundCompound1.0011.002OH1.003OH1.0101.0331.035OH1.0831.084N-nh1.0821.08945. The compound or salt of claim 44. wherein the compound is:CompoundCompoundCompound1.0021.0101.03346. The compound or salt of claim 45, wherein the compound is:

47. A pharmaceutical composition comprising the compound or salt according to any one of claims 1-46 and a pharmaceutically acceptable excipient.

48. A compound or salt according to any one of claims 1-46 or the pharmaceutical composition according to claim 47 for use as a medicament.

49. A compound or salt according to any one of claims 1-46 or the pharmaceutical composition according to claim 47 for use in treating cancer.

50. A compound or salt according to any one of claims 1-46 or the pharmaceutical composition according to claim 47 for use in treating cancer, wherein one or more cells of the cancer express a KRAS G12D. G12V, G12A, G12S, G12R. G13D, Q61H, Q61L, Q61R or G12C mutant protein.

51. The compound, salt or pharmaceutical composition for use of claim 49 or 50, wherein the cancer is pancreatic cancer, colorectal cancer, non-small cell lung cancer, small bowel cancer, appendiceal cancer, cancer of unknown primary, endometrial cancer, mixed cancer types, hepatobiliary cancer, small cell lung cancer, cervical cancer, germ cell cancer, ovarian cancer, gastrointestinal neuroendocrine cancer, bladder cancer, myelodysplastic / myeloproliferative neoplasms, head and neck cancer, esophagogastric cancer, soft tissue sarcoma, mesothelioma, thyroid cancer, leukemia, or melanoma.

52. A use of the compound or salt according to any one of claims 1-46 or the pharmaceutical composition according to claim 47 in the preparation of a medicament for treating cancer.

53. A use of the compound or salt according to any one of claims 1 -46 or the pharmaceutical composition according to claim 47 in the preparation of a medicament for treating cancer, wherein one or more cells of the cancer express a KRAS G12D, G12V, G12A, G12S, G12R, G13D, Q61H, Q61L, Q61R or G12C mutant protein.

54. The use according to claim 52 or 53, wherein the cancer is non-small cell lung cancer, small bowel cancer, appendiceal cancer, colorectal cancer, cancer of unknown primary, endometrial cancer, mixed cancer types, pancreatic cancer, hepatobiliary cancer, small cell lung cancer, cervical cancer, germ cell cancer, ovarian cancer, gastrointestinal neuroendocrine cancer, bladder cancer, myelodysplastic / myeloproliferative neoplasms, head and neck cancer, esophagogastric cancer, soft tissue sarcoma, mesothelioma, thyroid cancer, leukemia, or melanoma.

55. A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound or salt according to any one of claims 1-46 or a pharmaceutical composition according to claim 47.

56. A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound or salt according to any one of to any one of claims 1-46 or a pharmaceutical composition according to claim 47, wherein one or more cells of the cancer express a KRAS G12D, G12V, G12A, G12S, G12R, G13D, Q61H, Q61L, Q61R or G12C mutant protein.

57. The method according to claim 55 or 56, wherein the cancer is non-small cell lung cancer, small bowel cancer, appendiceal cancer, colorectal cancer, cancer of unknow n primary, endometrial cancer, mixed cancer types, pancreatic cancer, hepatobiliary7 cancer, small cell lung cancer, cervical cancer, germ cell cancer, ovarian cancer, gastrointestinal neuroendocrine cancer, bladder cancer, myelodysplastic / myeloproliferative neoplasms, head and neck cancer, esophagogastric cancer, soft tissue sarcoma, mesothelioma, thyroid cancer, leukemia, or melanoma.

58. The method according to claim 55 or 56, wherein the cancer is non-small cell lung cancer, colorectal cancer, pancreatic cancer, appendiceal cancer, endometrial cancer, esophageal cancer, cancer of unknow n primary, ampullary cancer, gastric cancer, small bow el cancer, sinonasal cancer, bile duct cancer, or melanoma.

59. The method according to claim 58, wherein the cancer is non-small cell lung cancer.

60. The method according to claim 58, wherein the cancer is colorectal cancer.

61. The method according to claim 58, wherein the cancer is pancreatic cancer.

62. The method according to anyone of claims 55-61, wherein the subject has a cancer that was determined to have one or more cells expressing the KRAS G12D. G12V, G12A, G12S, G12R, G13D, Q61H, Q61L, Q61R or G12C mutant protein prior to administration of the compound, salt or composition.